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The discovery of a novel marine natural product hemicalide (1), with promising anticancer 
activity, has sparked interest in elucidating its full three-dimensional structure. Studies into the 
total synthesis and stereochemical assignment of the complex polyketide structure of hemicalide 
are described in this dissertation. Overall, this synthesis-enabled stereochemical assignment has 
established the relative configuration of 11 stereocentres out of a total of 21. All the requisite 
stereocentres have been configured with excellent diastereoselectivity and this work establishes a 
solid foundation for ongoing efforts towards the total synthesis of hemicalide. 
 
In the first chapter, previous synthetic efforts by the Ardisson-Cossy team are outlined, including 
their initial proposed assignment for the C1-C28 region of hemicalide. This is followed by a 
discussion of the computational studies undertaken in our group which casts doubt on the 
suggested 3D structure. Chapter two describes the synthesis of three key hemicalide fragments 
corresponding to the C1-C6 (A), C7-C15 (B) and C16-C28 (C) regions. Modifications from 
previous work have been made where appropriate to enable an expedient gram-scale synthesis of 
these fragments. The experimental results in this chapter support earlier computational DP4 NMR 
predictions about the most probable C18-19 relative stereochemistry. 
 
The next chapter investigates fragment coupling strategies to furnish two possible diastereomeric 
candidates for a C1-C28 truncate (D) in conjunction with work carried out in parallel by Lam. 
Further elaboration enabled detailed NMR chemical shift comparisons to conclude the relative 
stereochemistry between the C7-C15 and the C16-C28 regions. These experiments also gave 
further insight on the nature of the C1 carboxyl group. Unlike the earlier fragments, the C26-C35 
region has no assigned stereochemistry. The flexible conformational nature of this section has 
frustrated computational studies so synthetic studies have been undertaken. In the final chapter of 
this dissertation, a library of fragments (E) was synthesised to help assign the configuration of 
this section. 
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For compounds related to hemicalide 1 (Figure 1), the carbon skeleton numbering is based on the 
numbering scheme as assigned in the original isolation literature.1  
 
Figure 1: Numbering scheme of Hemicalide 
 
The syn and anti convention for assigning relative stereochemistry is used throughout, as first 
defined by Masamune2 (Figure 2). A syn relationship is defined by any two substituents both 
pointing to the same side of the plane of the paper when the main chain is drawn in a zig-zag 
conformation as demonstrated with A and C. If the two substituents are on opposite sides of the 
plane of the paper, then they are defined as anti as demonstrated with B and D. 
 
Figure 2: syn and anti relationships 
 
The two metal enolates P and Q are referred to as the Z- and E-enolates respectively, according to 
the accepted IUPAC conventions. The metal-oxygen substituent is designated in all cases as 
having the highest priority (Figure 3). 
 




























































Å  Ångstrom 
Ac  Acetyl 
Ar  Aromatic 
aq.  Aqueous 
BAIB  (Diacetoxyiodo)benzene 
bipy  Bipyridyl 
Bn  Benzyl 
Bz  Benzoyl 
brsm  Based on recovered starting material 
Bu  n-butyl 
cat.  Catalytic 
Cp  Cyclopentadienyl 
COSY  1H–1H correlation spectroscopy 
CuTC  Copper thiophenecarboxylate 
CSA  Camphorsulfonic acid 
Cy  Cyclohexyl 
DCC  N,N’-Dicyclohexylcarbodiimide 
DDQ  2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DIAD  Diisopropyl azodicarboxylate 
DIBAL Diisobutylaluminium hydride 
DIPCl  B-chlorodiisopinocamphenylborane 
DIPEA Diisopropylethylamine or Hünig's base 
DMAP  4-dimethylaminopyridine 
DMB  2,3-Dimethoxybenzyl 
DME  1,2-Dimethoxyethane 
DMF  N,N’-Dimethylformamide 
DMP  Dess–Martin periodinane 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dppf  1,1’-Bis(diphenylphosphino)ferrocene 
d.r.  Diastereomeric ratio 
DTBMP 2,6-Di-tert-butyl-4-methylpyridine 
e.e.  Enantiomeric excess 





eq.  Equivalents 
Et  Ethyl 
FT-IR  Fourier Transform-Infrared spectroscopy 
g  Gram(s) 
HMBC Heteronuclear Multiple Bond Correlation spectroscopy 
HMDS  Hexamethyldisilazine 
HSQC  Heteronuclear Single Quantum Coherence spectroscopy 
HPLC  High Performance Liquid Chromatography 
HWE  Horner–Wadsworth–Emmons 
h  Hour(s) 
Hz  Hertz 
i-  Iso 
IC50  Half maximal inhibitory concentration 
Ipc  Isopinocamphenyl 
J  1H–1H coupling constant 
L  Unspecified ligand 
LDA  Lithium diisopropylamide 
M  Unspecified metal; Molar 
Me  Methyl 
min  Minute(s) 
mg  Milligram(s) 
mmol  Millimole(s) 
mL  Millilitre(s) 
mol  Mole(s) 
MS  Molecular sieves 
Ms  Mesyl (methanesulfonyl) 
MTPA  α-Methoxy-α-(trifluoromethyl)phenylacetate 
n-  Normal 
NBS  N-Bromosuccinimide 
NIS  N-Iodosuccinimide 
nM  Nanomolar 
NMO  N-Methylmorpholine N-oxide 
NMP  N-Methyl-2-pyrrolidone 
NMR  Nuclear Magnetic Resonance spectroscopy 
NOESY Nuclear Overhauser Effect spectroscopy 




P  Unspecified protecting group 
PE 30-40 Petroleum Ether, bp 30-40 °C or pentanes 
PE 40-60 Petroleum Ether, bp 40-60 °C or hexanes 
Ph  Phenyl 
pin  Pinacolate 
PMB  Para-methoxybenzyl 
PMBTCA Para-methoxybenzyl trichloroacetamide 
PT  1-Phenyl-1H-tetrazol-5-yl 
py  Pyridine 
R  Unspecified substituent 
RCM  Ring Closing Metathesis 
Rf  Retention factor 
ROESY Rotating-frame Nuclear Overhauser Effect spectroscopy 
rt  Room temperature 
t-  Tert- 
TASF  Tris(dimethylamino)sulfonium difluorotrimethylsilicate 
TBS  Tert-butyldimethylsilyl 
TEMPO (2,2,6,6-Tetramethylpiperidin-1-yl)oxy 
TES  Triethylsilyl 
THF  Tetrahydrofuran 
TLC  Thin layer chromatography 
TMDS  Tetramethyldisiloxane 
TMS  Tetramethylsilane or trimethylsilyl 
TMSE  (Trimethylsilyl)ethyl 
Tf  Triflyl (trifluoromethanesulfonyl) 
Ts  Tosyl (para-toluenesulfonyl) 
μl  Microlitre(s) 
μmol  Micromolar(s) 
  





CHAPTER ONE: INTRODUCTION 
 
1.1 Introduction to Marine Natural Products as Anticancer Therapeutics 
 
Natural products are a rich source of bioactive molecules that can be investigated in the search for 
new drugs and therapies. Historical examples are well exemplified by the extraction of morphine 
from Papaver somniferum poppies in 1803 and the isolation of the first antibiotic penicillin from 
the fungus Penicillium notatum by Fleming in 1929.3 Currently, more than half of the drugs on 
the market are of natural origin. This reflects the advantages of using natural products as a lead 
structure, namely their high biological target specificity and binding efficiency.4 
 
Alternative drug discovery programs commonly utilise high throughput screening in conjunction 
with combinatorial chemistry to accelerate the screening of synthetic compounds. Nonetheless, 
such approaches have not been as successful as natural product discovery in identifying bioactive 
compounds for further studies.5 Advancements in analytical and spectroscopic techniques have 
also enabled the elucidation of multiple novel compounds even in complex mixtures such as 
crude extracts from natural sources.6 In the cases of natural products that are derived from 
microbial origins, a better understanding of the genomic composition of the source organism has 
also opened up the possibility of manipulating the relevant gene clusters to obtain new 
compounds.5 This has led to a renaissance of natural products discovery in the search for new 
drug candidates. 
 
For many years, pharmacognosy has been focused on natural products derived from terrestrial 
environments. However, attention has more recently turned towards studying marine organisms 
as a rich, unexplored reservoir for discovering new chemical leads in medicine.7 As many as 10 
million unique species inhabit these aquatic environments, making the deep sea one of the most 
biodiverse habitats on Earth, rivaling other species-rich colonies like rainforests.8 
 
Several hundred metres below the surface, deep sea organisms have to survive under extreme 
conditions such as low light intensity, low temperatures, low oxygen levels and intensely high 
pressures.8 The marine organisms that produce the most promising and potent lead compounds 
tend to be sessile organisms with no apparent physical defence mechanisms as they are believed 
to have evolved chemical defences instead.9 There is often debate as to whether it is the marine 
organism themselves or their symbiotic microorganisms that produce the bioactive natural 




products in question.10 These compounds are usually highly potent as they would be greatly 
diluted by seawater once discharged by the organism and this potency makes them valuable 
targets for further clinical studies, particularly as anticancer agents for chemotherapy.9 In 
particular, marine sponges, where microbes may constitute up to 60% of the biomass, are popular 
targets for harvesting secondary metabolites to study. Most of these bioactive compounds are 
only produced in tiny amounts as secondary metabolites and this fact places a limit on their 
usefulness for mass harvesting.11 Total synthesis could provide a sustainable, alternative supply 
source within practical limits and would also allow access to novel structural analogues of the 
original compound.12 
 
The first commercial success story of a marine natural product reaching Food and Drug 
Administration (FDA) approval is cytarabine (Cytosar-U®)13 2 (Figure 4), now an anticancer 
drug. Metabolites from the marine sponge Tethya crypta were used as lead compounds from 
which the synthetic analogue cytarabine was developed. More recent examples can be found in 
trabectedin (Yondelis®)13 3, isolated from the tunicate Ecteinascidia turbinata, and eribulin 
mesylate (Halaven®)13 4, a synthetic analogue of halichondrin B produced by the sponge 
Halichodria okadai. Of particular note is that trabectedin 3 is the original natural product without 
any modifications during any phase of its development.5 Despite the success of these natural 
products, the vast majority does not pass clinical trials as they do not outperform an industry 
standard or might exhibit toxic side effects.5 
 
Figure 4: Examples of marine natural products that have obtained FDA approval 
 
While marine natural products with therapeutic uses include treatments for pain management, 
antivirals and hypertriglyceridemia, the overwhelming majority of them have been selected for 
their anticancer properties.5 This reflects the commercial value of anticancer treatments as cancer 
represents one of the leading causes of death in developed nations. In addition, several anticancer 
drugs have shown synergistic interactions when administered together.5 This opens up further 















































The events in the cell cycle are highly regulated and many anomalies can cause the cell cycle to 
arrest, eventually signaling the cell for programmed cell death, or apoptosis.14 Anticancer 
compounds take advantage of the high rate of cellular division in cancerous cells compared to 
normal cells, killing them at a faster rate than healthy cells.14 Common biological targets of 
anticancer drugs include DNA and topoisomerases but most importantly microtubules, formed of 
α- and β-tubulin polymers. All known antimitotic compounds specifically bind to β-tubulin in the 
microtubule polymer but not α-tubulin.15 
 
Microtubules are important to cell division by forming the mitotic spindle where chromosomes 
attach themselves in preparation for migration towards the new daughter cell nuclei.15 Movement 
of the microtubules arises from its dynamic behavior of polymerisation, leading to growth, and 
depolymerisation, resulting in shortening.  Well-established antimitotic compounds are known to 
interfere with microtubule dynamics by either inhibiting tubulin polymerisation or 
depolymerisation. Drugs that bind to the vinca domain, named after the Vinca alkaloids such as 
vinblastine 5 and vincristine 6 (Figure 5), destabilise tubulin growth.15 Another well-
characterised binding site is the taxoid domain, a target for taxanes derived from the Taxus yew 
trees most prominently featuring paclitaxel 7 and docetaxel 8.15 It has been shown that epothilone 
A 9 and discodermolide 10 operate through a similar microtubule-stabilising mechanism as the 
taxanes.15 
 
While many successful antimitotic drugs have been developed based on the Vinca alkaloid or 
taxane scaffold, an emerging threat in the form of cancer cell resistance renders many of these 
compounds ineffective during treatment.16 Resistant cancer cells overexpress the MDR1 gene 
responsible for the production of P-gp, an efflux pump that removes hydrophobic compounds 
from the cell, a common characteristic of the Vinca alkaloids and the taxanes. Alternatively, some 
malignant cells overexpress βIII-tubulin, an isotype of β-tubulin, which inherently enhances 
dynamic instability of microtubules and counteracts the stabilising action of taxanes. Solutions to 
these problems have included designing second- and third-generation taxanes to escape 
recognition by P-gp. Additionally, new drug candidates such as peluroside A 11 and laulimalide 
12 have been identified as drugs that target βIII-tubulin and are awaiting clinical trials (Figure 
5).16 

















































































































1.2 Methods for Structural Elucidation 
 
1.2.1 The Role of Total Synthesis in Structural Determination 
 
Advancements in purification and analytical techniques, in particular NMR spectroscopy, have 
enabled detailed structural determination on microgram quantities of novel compounds. Despite 
this, more than 300 structural revisions to natural products have been made since 1990.17 
Ultimately, total synthesis remains a powerful tool in providing incontrovertible proof of the true 
structure of a compound. 
 
For example, while the relative and absolute stereochemistry of spongosoritin A18 13 was not 
assigned during isolation, it was assumed that it would have a (6R, 8R) configuration by analogy 
with des-hydroxygracilioether C 14, gracilioether B 15 and gracilioether C 16, all isolated from 
relatives of the same Plakortis genus of marine sponges (Figure 6). However, the recent 
discovery of other secondary metabolites such as 17 and 18 have cast doubt on the assumption 
that the family of natural products share a common biosynthetic pathway. Perkins’ synthesis of 
both diastereomers 13 and 19 and subsequent NMR comparison made it clear for the first time 
that the true structure was indeed (6R, 8R) as suspected.18 
 
Figure 6: Proposed structure of spongosoritin A and other related compounds 
 
In the case of callipeltoside A 20, the relative stereochemistry of the trans cyclopropane ring with 
respect to the rest of the molecule could be not be determined initially. Synthetic efforts towards 
the two possible diastereomers by Paterson19 and Trost20 indicated that both putative structures 20 



































rotation and the circular dichroism spectrum provided the final proof for the relative and absolute 
configuration of the compound. This problem would eventually be revisited in the form of 
phorbaside A 22, bearing significant structural similarity to callipeltoside A. Intriguingly, the 
proposed structure featured the antipodal cyclopropane moiety on the basis of semiquantitative 
circular dichroism studies. The Paterson21 approach to synthesise the two possible diastereomers 
22 and 23 was once again met with inconclusive results from NMR correlations. Validation of the 
proposed structure 22 was obtained from correlation of circular dichroism and optical rotation 
data. 
 
Figure 7: Proposed structures of callipeltoside A and phorbaside A and their epi- counterparts 
 
1.2.2 NMR-based Prediction Methods for Structural Determination 
 
Although total synthesis is a powerful tool for validating the proposed structure for complex 
organic molecules, it is a time-consuming and resource-intensive process.  Consequently, the use 
of ab initio NMR calculations for virtual molecules has attracted much attention in recent years. 
Pioneered by Bifulco22, this approach has led to the structural reassignment of several natural 
products such as hexacyclinol23,24 and maitotoxin.25 
 
By comparing the predicted chemical shifts against the experimental values, one candidate 
structure, if not a handful, should emerge as a good match with the natural product. This will 
greatly reduce the number of structures under consideration to expedite further synthetic efforts if 
required. The quantification of the fit for each possible structure is best characterised by the DP4 
probability, developed by Smith and Goodman.26 The level of success of DP4 has been shown to 

























































The DP4 probability is an extension of the earlier CP3 parameter27, also developed by Smith and 
Goodman. This is useful for assigning two sets of experimental data to two possible structures, 
typically found when performing a stereoselective reaction that yields a major and minor product. 
DP4 is used when there is only one set of experimental values to be matched against multiple 
putative structures. This method was applied to the structural determination of leiodermatolide 24 
where the DP4 results identified partial fragments 25 and 26 with the same relative 
stereochemistry as proposed by the isolation team (Figure 8).28 This marked the first time the 
structure of a complex polyketide was analysed with the DP4 protocol. 
 
Figure 8: Proposed structure of leiodermatolide and the virtual fragments used in DP4 analysis  
 
A standard NMR-based prediction process begins with a conformational search on all the 
candidate molecules under examination and identifying all low-energy conformers, typically 
within 10 kJ mol-1 of the global minina. Density Functional Theory (DFT) Gauge Including 
Atomic Orbital (GIAO) calculations are then performed on these conformers and weighted 
according to a Boltzmann distribution to yield a combined calculated chemical shift for each 
atom. Linear regression may be applied at this stage to remove any systematic errors by applying 
an appropriate scaling factor. The error associated with each resonance is then computed.26 
 
DP4 analysis assumes that the errors between the calculated and experimental data obey a t-
distribution. The probability of encountering each error in a given structure can be computed 
accordingly and the product of these probabilities represents the overall absolute probability. 
Bayes’ theorem can be used to convert the absolute probabilities into relative probabilities to 
identify the most likely candidate. Taking into account both 1H and 13C data provides an even 
more accurate prediction with DP4 analysis.26 Since enantiomers display identical NMR spectra, 
DP4 cannot be used to assign absolute stereochemistry but only relative stereochemistry. 
 
The synergy between computational and synthetic efforts towards structural determination is best 
showcased by baulamycin A 27 (Figure 9). Attempts to reach a total synthesis of this natural 
product by Goswami29 and Aggarwal30 were frustrated by the discovery that spectroscopic data 























concluded that the initial stereochemical assignment was incorrect, Aggarwal set out to determine 
the correct configuration of baulamycin out of 128 possible stereoisomers.30 The flexible nature 
of the carbon backbone greatly complicated computational efforts in studying baulamycin as the 
experimental NMR parameters are derived from a weighted average of multiple low-energy 
conformers of the molecule. However, restricting the analysis to just four possible diastereomers 
in the C11-C1’ region made the calculations more feasible. By comparing the 1H–1H coupling 
constants and ROESY measurements, the relative stereochemistry in this region was reassigned 
to anti–anti–syn. Unfortunately, this approach did not lead to any conclusive result when applied 
to the C4-C8 region. An expedient synthesis of the remaining four possible diastereomers was 
enabled by the assembly-line synthesis methodology31 developed in the Aggarwal group. This 
was achieved by using chiral building blocks with predetermined e.e. to produce the four 
diastereomers as a mixture with carefully chosen ratios. Analysis of the signal intensities in the 
13C NMR then allowed identification of each diastereomer. Standard NMR correlation parameters 
revealed an unambiguous reassignment of this region to syn–syn. Having corrected the relative 
stereochemistry of baulamycin, the absolute configuration was determined by comparing optical 
rotation data. The revised structure 28 reveals a correction of five out of seven misassigned 
stereocentres.30 
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baulamycin A (27, proposed structure)
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1.3 Introduction to Hemicalide: Isolation, Characterisation and Biological Activity 
 
Found in the deep waters around the Torres Islands of Vanuatu, hemicalide was isolated from the 
marine sponge Hemimycale sp. by the CNRS-Pierre Fabre Laboratories working together with 
the Institut de Recherche pour le Dévelopment (IRD).1 A fresh sample of Hemimycale sp. (5 kg) 
was lyophilised (650 g) and sequentially macerated with CHCl3 and twice with aqueous EtOH. 
The combined filtrates were concentrated in vacuo to obtain an aqueous syrup, which was 
washed with CH2Cl2 and EtOAc to eliminate inorganic salts. The desalinated extract was 
concentrated in vacuo, taken up in aqueous MeOH and partitioned with hexane; only the 
methanolic extract displayed the desired pharmacological activity. This extract was further 
purified with flash column chromatography (EtOAc and MeOH) and HPLC (H2O and MeCN) to 
afford the active molecule hemicalide (0.5 mg, 0.000077% with respect to lyophilisate).1 
 
High resolution electrospray ionisation time of flight mass spectrometry (HRESITOFMS) 
identified a (M–H)– component with m/z = 1061.6780 which corresponded to a molecular 
formula of C59H97O16.1 The two-dimensional structure (Figure 8) of hemicalide was assigned as 
1 by extensive NMR spectroscopic studies which indicated a 46-carbon atom skeleton comprising 
a conjugated trienic acid (C1-C7), a polyproprionate stereohexad (C8-C13), a conjugated diene 
(C14-C17), an α,β-dihydroxylactone (C19-C23) and an α-hydroxylactone (C37-C41).1 Although 
the methyl ester analogue of hemicalide was described by the isolation team, its characterization 
was not reported. Due to the low isolated yield, no further chemical derivatisation nor 
degradation experiments could be carried out to help assign the absolute configuration of the 21 
stereocentres in hemicalide. 
 























Hemicalide has demonstrated potent antiproliferative activity against a panel of various human 
cancer cell lines with a mean IC50 in the subnanomolar concentrations (Table 1).1 This makes it 
an attractive target for further biological studies in addition to its structurally complexity. 
Cell Line Disease IC50 (nM) 
A549 Non small cell lung cancer 0.82 
BxPC3 Pancreatic cancer 0.47 
LoVo Colon cancer 0.081 
MCF7 Breast cancer 0.011 
Namalwa Burkitt’s lymphoma 1.1 
SK-OV-3 Ovarian cancer 0.33 
 
Table 1: Antiproliferative activity of hemicalide against various cancer cell lines 
 
Attempts to define hemicalide’s mechanism of action on cellular activity have been probed by 
using HeLa tumor cells in immunocytochemistry assays. Within a dosage range of 5-50 nM, cells 
in interphase were found to be devoid of their microtubular cytoskeleton, as labeled by α-tubulin, 
while centrosomes were present and separated, as labeled by γ-tubulin. On the other hand, mitotic 
cells were found to be arrested in prometaphase without microtubules, while the centrosomes 
were also present and separated.1 This evidence suggested that hemicalide destabilises the α/β-
microtubule network through a novel, unexplored mechanism that differs from other well-known 
antimitotic natural products.15 Due to the low isolation yield, further biological studies were not 
possible. 
  





1.4 Stereochemical Assignment of Hemicalide 
 
1.4.1 C1-C15 Polypropionate Stereohexad 
 
When studying the 13C NMR spectrum of hemicalide, Ardisson noticed that the chemical shift 
due to Me12 was unusually low at 7.6 ppm, indicating that C12 belonged to a syn-syn C11-C13 
stereotriad.32 The same phenomenon was not observed for Me10, which suggested that the C9-
C11 stereotriad was anti-anti, syn-anti or anti-syn in its relative relationship. These observations 
reduced the possible number of diastereomers for this region from 32 to six. To assist the 
stereochemical assignments, synthetic efforts towards diastereomers 29A-29F were undertaken to 
compare their NMR spectral data with hemicalide (Figure 11).32 
 
Figure 11: Diastereomers used for Ardisson’s NMR-based comparison studies on the C1-C15 region of 
hemicalide 
 
Initial studies of the 13C NMR signals related to the C1-C7 region for all these diastereomers 
showed substantial differences in chemical shifts which was attributed to the natural product 
being isolated as a carboxylate salt instead of the carboxylic acid. The use of a model system 30 
confirmed that a similar deviation profile in the 13C NMR was observed upon deprotonation to 
afford the sodium salt 31 (Scheme 1). Notably, this salt effect did not affect the aliphatic region 




































Reagents and conditions: (a) NaH, THF, 0 °C 
Scheme 1: Ardisson’s synthesis of a model carboxylate salt to examine a possible ‘salt effect’ 
 
Closer examination of the C8-C13 region in the 13C NMR spectrum then eliminated 
diastereomers 29C-29F as potential candidates due to the large differences in chemical shifts 
(|ΔδC| > 1 ppm) (Figure 11). To further identify a better correlation with hemicalide, the 1H NMR 
spectrum of diastereomers 29A and 29B were compared and this study suggested that 
diastereomer 29A was the better match to hemicalide (|ΔδH| < 0.1 ppm).32 
 
Independently, DP4 analysis was undertaken by Smith26 in the Goodman group based on all 32 
possible diastereomers 32A-32AF (Figure 12). The results concur that diastereomer 32A has the 
highest probability (85.2%) of having the same relative stereochemistry as the corresponding 
region of hemicalide with the next most likely structure 32J being assigned a 13.4% probability. 
However, 32J does not exhibit the expected syn/anti stereotriad pattern, thus increasing the 















Figure 12: Diastereomers used for Smith’s DP4 analysis on the C1-C15 region of hemicalide and their 
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1.4.2 C17-C25 α,β-Dihydroxy-δ-lactone 
 
Investigations into elucidating the relative stereochemistry for the C17-C25 region of hemicalide 
were also carried out by Ardisson (Figure 13).33 NOESY analysis established correlations 
between H22 and H24, Me24 as well as to one H20 proton. The latter H20 proton also showed a 
3J19,20 coupling constant of 11.5 Hz with H19, indicating a trans relationship. These results 
indicated that both C21 and C22 hydroxyl groups were cis to each other but trans to the C19 
chain. These observations reduced the possible number of diastereomers for this region from 16 
to four. As with previous work on the C1-C15 fragment, all four diastereomers of model 
fragments with hemicalide 33A to 33D were synthesised to compare their NMR data with 
hemicalide (Figure 13).33 
 
Comparison studies of the 13C NMR spectra for the four diastereomers proved, unfortunately, to 
be inconclusive as all four had similar deviation profiles. On inspection of the 1H NMR spectra 
instead, the signals corresponding to H20, H24 and H25 of hemicalide were observed as part of a 
broad 22H methylene multiplet and the H18 signal was a broad multiplet that did not lead to 
meaningful conclusions.1 Ardisson asserted that any signal due to H22 would be less sensitive to 
structural changes in the lactone than H19 so a comparison of the chemical shift of this signal 
eliminated diastereomers 33C and 33D (Figure 13) as suitable candidates bearing the natural 
stereochemistry. Indeed, the chemical shifts for H19 in the spectra of all four diastereomers were 
very different from that in hemicalide, presumably due to the presence of an ether oxygen at C17 
as opposed to an olefin. Closer inspection of the multiplicity of the H19 signal being a ddd 
suggested that 18,19-anti diastereomer 33B was a closer match to hemicalide than the 
corresponding 18,19-syn 33A.33 






Figure 13: Diastereomers used for Ardisson’s NMR-based comparison studies on the C17-C25 region of 
hemicalide 
 
On closer inspection, however, this interpretation was considered by us to be inconclusive. 
Notably, the corresponding H37 signal of hemicalide in a similar δ-lactone ring appears as a ddd 
(J = 11.0, 7.5, 3.9 Hz) where a 36,37-syn relationship has been determined (vide infra). Likewise, 
a similar system in a rhizoxin D intermediate 34 (Figure 14) developed by the Leahy group34 also 
shows a ddd multiplicity (J = 12.1, 3.6, 2.9 Hz) for the oxymethine proton in a syn relationship. 
More importantly, later work by the Ardisson group35 during the synthesis of the C18-C24 δ-
lactone yielded intermediate 35 where the multiplicity had now changed to a dt (J = 11.3 Hz, 3.9 
Hz), casting doubt on the validity of the initial stereochemical assignment. 
 
Figure 14: Comparison of other similar δ-lactone systems to 12 
 
DP4 calculations were also performed by MacGregor36 for this region with all 16 possible 
diastereomers (Figure 15) to independently assign the stereochemistry of a C16-C27 virtual 
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probability (99.0%) of matching the stereochemistry of hemicalide. Diastereomer 36N, 
corresponding to the structure proposed by Ardisson, was assigned a 1.0% probability with the 
DP4 analysis. We reason that having the olefin group at C17 renders model systems 36A-36P 
structurally more similar to hemicalide and enables a more realistic comparison. 
 
Figure 15: Diastereomers used for MacGregor’s DP4-based comparison studies on the C18-C25 region 
















































































1.4.3 C25-C34 Polyacetate Stereotriad 
 
To date, there has been no published research on elucidating the stereochemistry within the C25-
C34 region, neither synthetic efforts nor modeling. The reported 1H NMR spectrum listing 
signals for this region is of little use as most signals (H25, H26, H28, H30, H32, H33) are within 
a broad 22H methylene multiplet (δH 2.02-1.02 ppm) and the remaining key signals (H27, H29, 
H31) are broad multiplets without resolved coupling information.1 Likewise, there are no 
particular 13C NMR signals of interest, with the exception of the unusual upfield shift of C30 (δC 
32.2 ppm).1 
 
DP4 calculations carried out by MacGregor in this region of hemicalide on diastereomers 37A-
37H (Figure 11) have yet to propose any particular stereoisomer with high confidence.37 The 
conformationally flexible nature of this region has made the computational modelling more 
challenging. 
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1.4.4 C35-C46 α-Hydroxy-δ-lactone 
 
As with the C18-C24 α,β-dihydroxylactone, Ardisson used NOESY analysis to help assign the 
stereochemistry within the C35-C46 α-hydroxylactone.38 Correlations were found between H37, 
H40 and Me42, implying a cis relationship between H37 and H40 but a trans relationship 
between H37 and H42. This study reduced the number of possible diastereomers from 32 to eight. 
While synthetic efforts towards all eight diastereomers were ongoing, it soon became apparent 
that epimers at C45 displayed almost identical NMR data, rendering it impossible to confidently 
assign the configuration at this remote stereocentre. For the purposes of preliminary structure 
determination, the absolute configuration at C45 was arbitrarily assigned as (45R) and the number 
of diastereomers to be considered was further reduced to four (Figure 17).38 
 
Figure 17: Diastereomers used for Ardisson’s NMR-based comparison studies on the C35-C46 region of 
hemicalide 
 
Comparisons with the corresponding region of hemicalide were made between diastereomers 
38A, 38B and 38C, but not with 38D (Figure 9), presumably because the deviations in its NMR 
spectrum were too significant. For selected representative carbons (C36, Me36, C37, C38, C39, 
C42, Me42, C43), diastereomer 38A showed the best agreement (|ΔδC| < 0.5 ppm) with the 
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and 38B showed similar chemical shifts for C36, Me36 and C37, while those for diastereomers 
38A and 38C showed similar chemical shifts for C39, C42, Me42 and C43.38 This observation 
indicated that an epimeric centre at C36 or C42 did not affect the chemical shifts of the opposite 
chain on the lactone, explaining why diastereomer 38D was no longer considered a plausible 
candidate for comparison. 
 
To further support the stereochemical assignment, the 1H NMR spectral data of diastereomers 
38A, 38B and 38C (Figure 17) were also re-examined. Once again, the 36,37-syn diastereomer 
38A emerged as the best fit for hemicalide. The multiplicity of the oxymethine H37 signal was 
also a good match with hemicalide, suggesting that a configurational change at C36 could induce 
significant conformational changes in the lactone.38 
 
Without access to the NOESY data at the time, the 1H NMR spectral data for hemicalide was 
examined where a 3J39,40 coupling constant of 11.3 Hz between H39 and H40 suggested a trans 
relationship and in agreement with Ardisson’s studies. DP4 calculations undertaken by 
MacGregor36 for this region used all 32 possible diastereomers 39A-39AF (Figure 13) of the 
C35-C46 region. While these calculations are not yet complete, it appears that the 36,37-syn 
diastereomer 39A is predicted with confidence and in agreement with Cossy and Ardisson. 
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1.5 Previous Synthetic Work on Hemicalide 
 
1.5.1 C1-C15 Polypropionate Stereohexad 
 
The Ardisson and Cossy groups are working together towards the synthesis of hemicalide and 
have reported their results in a series of papers. 
 
Ardisson’s synthesis32,35 of the C1-C17 stereohexad-containing fragment began from (S)-Roche 
ester (S)-40 which was transformed into aldehyde 41 via TBS protection of the alcohol, DIBAL 
reduction of the ester moiety and then oxidised to aldehyde 21 under Swern conditions.39 This 
was engaged with lactate-derived ketone 4240 in a Paterson boron-mediated aldol reaction to 
afford the 1,2-anti aldol adduct 4341 with high diastereoselectivity (d.r. >20:1). Methylation of 
the aldol adduct 43 was carried out (MeOTf, DTBMP), followed by reduction with LiBH4 and 
oxidative cleavage of the nascent diol with NaIO4 to afford aldehyde 44. This was submitted to 
an Evans aldol reaction42 with oxazolidinone 45 to obtain the 1,2-syn aldol adduct 46 (Scheme 2). 
 
Cleavage of the oxazolidinone auxiliary from product 46 (Scheme 1) occurred smoothly via a 
Weinreb amide43 and the free alcohol was protected as TMS ether 47. Nucleophilic addition of 
the lithiated derivative of vinyl iodide 48 into Weinreb amide44 47 followed by deprotection of 
the TMS ether with Amberlyst-15 resin gave ketone 49. A 1,3-syn reduction of the ketone with 
Zn(BH4)2 via chelation control45 and protection of the resultant diol as a siloxane (t-Bu2Si(OTf)2, 
2,6-lutidine) afforded intermediate 50. Exchange of the vinyl silane for a vinyl iodide (NIS) and 
cleavage of the TBS ether (CSA) afforded alcohol 51. 
 
To complete the fragment synthesis, alcohol 51 was first oxidised to the aldehyde with DMP46 
(Scheme 2) where it was treated with phosphonate 52 in a HWE olefination47 to arrive at the 
fully elaborated C1-C15 fragment 53. Phosphonate 52 was obtained from 2,4-hexadienoic acid 54 
in a sequential Mitsunobu reaction48 (TMSCH2CH2OH, PPh3, DIAD), cross metathesis with allyl 
bromide and the Hoveyda-Grubbs II catalyst49 and an Arbuzov reaction50 (P(OEt)3). 
 





Reagents and conditions: (a) TBSCl, imidazole, DMF, rt; (b) DIBAL, CH2Cl2, –40 °C ® –20 °C, 98% over 
two steps; (c) (COCl)2, DMSO, Et3N, CH2Cl2, –55 °C ® rt, 100% (d) Cy2BCl, Me2NEt, 42, Et2O, –0 °C, 
then 41, –78 °C ® –25 °C, 98%; (e) MeOTf, DTBMP, CH2Cl2, 45 °C, 76%; (f) LiBH4, THF, –78 °C ® rt; (g) 
NaIO4, MeOH, rt, 84% over two steps; (h) Bu2BOTf, Et3N, 45, CH2Cl2, 0 °C, then 44 –78 °C ® 0 °C; (i) 
MeONHMeHCl, AlMe3, CH2Cl2, –20 °C ® rt, 75%; (j) TMSOTf, 2,6-lutidine, CH2Cl2, –30 °C, 93%; (k) 48, 
t-BuLi, Et2O, –90 °C, then 47, –78 °C ® –50 °C, 99%; (l) Amberlyst-15, MeOH, rt, 99%; (m) Zn(BH4)2, 
Et2O, CH2Cl2, –78 °C ® –50 °C, 87%, d.r. 9:1; (n) t-Bu2Si(OTf)2, 2,6-lutidine, DMF, rt, 76%; (o), NIS, THF, 
0 °C, 87%; (p) CSA, MeOH, 0 °C, 87%; (q), DMP, CH2Cl2, rt; (r) LDA, 52, THF, –78 °C, then 51, –78 °C ® 
0 °C, 92% over two steps; (s) TMSCH2CH2OH, PPh3, DIAD, THF, 0 °C ® rt, 83%; (t) CH2=CHCH2Br, 
Hoveyda–Grubbs II catalyst (3 mol%), CH2Cl2, rt, 62%; (u) P(OEt)3, 120 °C, 96% 
Scheme 2: Synthesis of intermediate 53 in Ardisson’s route to the C1-C15 fragment 
 
1.5.2 C16-C25 α,β-Dihydroxy-δ-lactone and Fragment Assembly of a C1-C25 Subunit 
 
Synthetic efforts directed towards the C16-C25 fragment of hemicalide by the Ardisson group14 
employed a Dias allylation51 as the first step (Scheme 3). Allylsilane 55 was prepared from (R)-
Roche ester (R)-40 by benzyl protection, Grignard addition into the ester moiety52 and a Peterson 
olefination53 with Amberlyst-15. Exposure of allylsilane 55 to SnCl4 and the known aldehyde 56 
led to alcohol 57 in high diastereoselectivity (d.r. 19:1). Subsequent acylation with 2-bromoacetyl 
bromide and ozonolysis afforded ketone 58. An alternative, higher-yielding route developed by 





















































































aldehyde 56 in a titanium-mediated aldol reaction54 to form aldol adduct 60 (d.r. 9:1) which was 
acylated with 2-bromoacetyl bromide to give ketone 58 (Scheme 3). 
 
To form the lactone core 61 (Scheme 3), a SmI2-mediated intramolecular Reformatsky reaction55 
was performed on ketone 58 followed by dehydration with SOCl2. Dihydroxylation of enoate 61 
with K2OsO42H2O and NMO furnished diol 62 with high chemoselectivity and 
diastereoselectivity. Protection of diol 62 as bis-TES ethers (TESOTf, 2,6-lutidine) and exchange 
of the vinyl bromide for a vinyl boronic ester afforded product 63. 
 
Reagents and conditions: (a) BnTCA, TfOH, cyclohexane/CH2Cl2, rt, 85%; (b) TMSCH2MgCl, CeCl3, THF, 
–78 °C ® rt, 67%; (c) Amberlyst-15, n-hexane, rt, 90%; (d) SnCl4, 55, CH2Cl2, –78 °C, then 56, –78 °C, 
62%; (e) BrCH2COBr, py, CH2Cl2, 0 °C, 100%, (f) O3, Sudan red III, CH2Cl2, –78 °C, then PPh3, 50%; (g) 
TiCl4, DIPEA, 59, CH2Cl2, –78 °C, then 56, –78 °C, 73%; (h) SmI2, THF, –78 °C ® rt, (i) SOCl2, py, CH2Cl2, 
0 °C, 79% over two steps; (j) K2OsO42H2O (5 mol%), NMO, acetone/H2O, rt, 100% (d.r. >95:5), (k) 
TESOTf, 2,6-lutidine, CH2Cl2, rt, 77%; (l) PdCl2(PPh3)2 (2.4 mol%), PPh3, PhOK, B2pin2, THF, 50 °C, 82% 






















































With both the C1-C15 and C16-C25 fragments 53 and 63 in hand, the Cossy and Ardisson 
groups35 employed a Suzuki coupling56 (Scheme 4) using catalytic Pd(PPh3)4 and TlOEt to afford 
the C1-C25 fragment 64. Cleavage of the TES ethers and the TMSE ester (TASF) and the 
siloxane (HFpy/py) gave the benzyl-protected C1-C25 fragment 65. 
 
Reagents and conditions: (a) Pd(PPh3)4 (1 mol%), TlOEt, THF/H2O, rt, 97%; (b) TASF, DMF, rt; (c) HFpy, 
THF, 0 °C, 40% over two steps 



















































Comparisons between the 1H and 13C NMR spectral data of fragment 65 and hemicalide have 
also been made (Figure 19).35 Due to the salt effect observed in previous correlation studies (See 
Chapter 1.4.1), the C1-C7 region was not considered for the analysis. Overall, there was good 
agreement with the natural product (|ΔδH| < 0.1 ppm and |ΔδC| < 1.5 ppm) for the C8-C24 region. 
However, upon closer inspection, the C18-C24 δ-lactone region is clearly not as good a match for 
the corresponding region in hemicalide than the C8-C13 stereohexad region. Of particular note 
are the resonances for H18 and H19 with Δδ of –0.08 and +0.08 ppm respectively. This raises 
concerns over the stereochemical assignment of the C18-C24 δ-lactone, in particular the 18,19-











































































1.5.3 C35-C46 α-Hydroxy-δ-lactone 
 
The reported synthesis of the remaining C35-C46 fragment by the Cossy and Ardisson groups18 
returned to (S)-Roche ester (S)-40 as the chiral building block (Scheme 5). The hydroxyl group in 
ester (S)-40 was protected with as a PMB ether and transaminated to the Weinreb amide 66. 
Reduction of Weinreb amide 66 using DIBAL afforded an aldehyde which was treated with 
Hafner–Duthaler’s allyltitanium complex 6757 to afford homoallylic alchohol 68. The product 68 
was acylated with acryloyl chloride and ring-closing metathesis took place in the presence of 
Grubbs II catalyst58 to give unsaturated δ-lactone 69. The boronic ester 70 (Scheme 6) was 
obtained from optically pure alcohol 71 via TBS protection (TBSCl, imidazole) and cross 
metathesis catalysed by the Grubbs II catalyst. 
 
To join intermediates 69 and 70, a rhodium-catalysed conjugate addition59 was employed to 
afford product 72 (d.r. 5:1) (Scheme 5). α-Oxidation of the lactone was achieved by enolisation 
with NaHMDS and treatment with Davis’ oxaziridine 7360, leading to alcohol 74 as a single 
diastereomer. The final stereocentre in intermediate 75 was installed via a hydroxyl-directed 
hydrogenation with Crabtree’s catalyst61 with poor diastereoselectivity (d.r. 2:1). The absolute 
configuration of this new methyl-bearing stereocentre was assigned by Vibrational Circular 
Dichroism (VCD) analysis62 as (42R). 
 
Further chain extension to intermediate 76 (Scheme 5) was enabled by sequential TBS protection 
(TBSOTf, 2,6-lutidine) of the free alcohol 75 and oxidative cleavage of the PMB ether (DDQ, pH 
7 buffer). Oxidation of alcohol 76 with DMP46 afforded an aldehyde which was engaged in a 
Julia–Kocienski olefination43 with PT sulfone 77 to give olefin 78 where exposure to HFpy/py 
completed the synthesis of the unprotected C35-C46 model fragment 79. 






Reagents and conditions: (a) PMBTCA, CSA, CH2Cl2, rt; (b) MeONHMeHCl, i-PrMgCl, THF, –40 °C ® –
10 °C, 87% over two steps; (c) DIBAL, THF, –78 °C ® –40 °C; (d) 67, Et2O, –78 °C, 92% over two steps; 
(e) CH2=CHCOCl, DIPEA, CH2Cl2, –78 °C; (f) Grubbs II catalyst (5 mol%), CH2Cl2, reflux, 72% over two 
steps; (g) 70, [Rh(COD)Cl]2 (3 mol%), LiOH, dioxane/H2O, 40 °C, 74%; (h) NaHMDS, THF, –78 °C, then 
73, –78 °C, 72%; (i) Crabtree’s catalyst (8 mol%), H2, CH2Cl2, rt, 72%; (j) TBSOTf, 2,6-lutidine, CH2Cl2, 
0 °C, 92%; (k) DDQ, CH2Cl2/H2O, rt, 99%; (l) DMP, NaHCO3, CH2Cl2, rt; (m) 77, KHMDS, THF, –78 °C ® 
rt, 70% over two steps; (n) HFpy, THF, rt, 95%; (o) TBSCl, imidazole, DMF, rt, 96% (p) isopropenyl 
pinacol boronate, Grubs II catalyst (4 mol%), CH2Cl2, reflux, 55% 
Scheme 5: Cossy’s synthesis of a C32-C46 fragment 79 of hemicalide 
 
We note that 79 is only a model fragment for the C35-C46 region of hemicalide which cannot be 
used for further fragment coupling. However, Cossy and Ardisson do intend to use the Julia–
Kocienski olefination on an earlier intermediate which allows fragment coupling to the remainder 
of the molecule. For selected representative atoms, the 1H and 13C NMR spectral data of 79 is in 

















































































1.5.4 Correction of the 18,19-syn Relationship 
 
Following the Paterson group’s disclosure of the 18,19-syn relationship, the Cossy group63 re-
examined their initial stereochemical assignment by synthesising subunit 80 (Figure 20) in an 
analogous fashion to intermediate 37 (See Chapter 1.5.2). The erroneous 18,19-anti relationship 
was then corrected to 18,19-syn in agreement with our results based on the improved correlations 
of 80 with hemicalide compared to 37. 
 
Figure 20: Diastereomers used for Cossy’s re-examination of the C17-C25 region of hemicalide 
 
Unexpectedly, the change in stereochemistry at C19 led to a diminished performance of the 
SOCl2-mediated dehydration and the subsequent Upjohn dihydroxylation during the synthesis of 
intermediate 80. These were key reactions used to construct the lactone ring and to set the diol 
stereocentres.33 Meanwhile, ongoing synthetic efforts to extend the C1-C25 subunit beyond C25 
were met with disappointing results. The Cossy group took this opportunity to change their 
retrosynthetic plan leading to a C1-C27 subunit instead.63 
 
The revised synthesis began from (S)-citronellol 81 as a chiral building block (Scheme 6). 
Following a TES protection, the olefin was subjected to an ozonolysis with a reductive workup to 
afford alcohol 82. The crude 82 could be telescoped through five more steps via aldehyde 83, 
involving benzyl protection, a Swern oxidation, a Pihko methylenation64, aldehyde reduction and 
benzoylation leading to benzoate 84 in a 64% yield over six steps. 
 
Allylstannane 85 was obtained via a palladium-mediated stannylation with Trost’s conditions 
(Scheme 6).65 This set the stage for an asymmetric allylation of known aldehyde 56 under the 
reagent control of Corey’s bromoborane complex 86.66 Although the adduct 87 was obtained as a 
88:12 mixture of syn and anti epimers, the desired 18,19-syn diastereomer could be isolated in 69% 
yield. A simple esterification then delivered acrylate 88 smoothly as an RCM precursor. The use 
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The Cossy group found that Upjohn conditions were not optimal for the dihydroxylation when 
the enoate features an 18,19-syn relationship instead of 18,19-anti. Like the Paterson group, the 
use of citric acid68 as an additive provided a marked improvement for this reaction (vide infra) 
leading to diol 91 in 70% yield. Following a bis-TES protection, the vinyl bromide was 
exchanged for a vinyl boronate under palladium catalysis to afford intermediate 92 (Scheme 6). 
 
Reagents and conditions: (a) TESCl, Et3N, CH2Cl2, 0 °C ® rt, 100%; (b) O3, CH2Cl2, –78 °C, then NaBH4, 
MeOH, rt; (c) NaH, THF, 0 °C, then BnBr, TBAI, 0 °C ® rt; (d) (COCl)2, DMSO, CH2Cl2, –78 °C ® –45 °C, 
then Et3N, –78 °C ® rt; (e) HCHO (35 wt. % in H2O), pyrrolidine, CH3CH2CO2H, i-PrOH, 45 °C; (f) LiAlH4, 
THF, 0 °C; (g) PhCOCl, Et3N, rt, 64% over six steps; (h) Pd(PPh3)4 (5 mol%), (Bu3Sn)2, Et2AlCl, n-BuLi, 
THF, –78 °C ® rt, 100%; (i) 86, CH2Cl2, rt, then 56, –78 °C, 78% (d.r. 88:12); (j) CH2=CHCOCl, DIPEA, 
CH2Cl2, –78 °C, 91%; (k) 89 (10 mol%), PhMe, 100 °C, 83%; (l) K2OsO42H2O (2 mol%), NMO, citric acid, 
THF/H2O, rt, 70%; (m) TESOTf, 2,6-lutidine, CH2Cl2, 0 °C, 96%; (n) PdCl2(PPh3)2, PPh3, PhOK, B2pin2, 
THF, 50 °C, 66% 
Scheme 6: Cossy’s revised approach to fragment 92 featuring the corrected 18,19-syn relationship 
 
To assemble the full C1-C27 subunit, vinyl boronate 92 was coupled with vinyl iodide 53 in a 
palladium-catalysed Suzuki reaction56 in the presence of aqueous TlOEt (Scheme 7). This 
afforded the product diene 93 in good yield (82%). As with previous deprotection attempts, the 
desilylation was carried out in two steps. The TES ethers at C21 and C22 as well as the TMSE 




































































buffered HFpy. Carboxylic acid 94 was thus obtained in 90% yield, representing one of two 
possible diastereomers for this subunit, featuring a 13,18-anti relationship. To date, the Cossy and 
Ardisson groups have not reported an attempt to synthesise the other 13,18-syn diastereomer.   
 
Reagents and conditions: (a) Pd(PPh3)4 (1 mol%), TlOEt, THF, rt, 82%; (b) TASF, DMF, rt; (c) HFpy/py, 
THF, 0 °C, 90% over two steps 



















































The change from an 18,19-anti to 18,19-syn relationship has a marked effect on the NMR 
correlations of subunit 65 and 94 (Figure 21). This is particularly evident in the δ-lactone section 
spanning C17-C24 where 18,19-syn subunit 94 is a much better fit for the natural product than 
the initially proposed 18,19-anti subunit 65. Previously, the largest errors for 18,19-anti subunit 
65 were |ΔδH| < 0.1 ppm and |ΔδC| < 1.5 ppm; with the 18,19-syn subunit 94, these errors were 
now reduced to |ΔδH| < 0.04 ppm and |ΔδC| < 0.5 ppm. 
 
Despite the improved correlations, the chemical shift deviations in subunit 94 are relatively large 
given that this molecule constitutes just over half of the entire carbon backbone. With no 
rationalisation for the Cossy group synthesising only one of two possible diastereomers of 94, 





































































18,19-anti subunit 65 18,19-syn subunit 94






To date, the Ardisson and Cossy groups have proposed the relative configurational assignment of 
most stereocentres in hemicalide 1 through NMR-based comparison studies of the relevant 
diastereomeric model fragments. These results have identified 29A,32 33B33 and 38A38 as bearing 
the same relative stereochemistry in the corresponding C1-C17, C17-C25 and C32-C46 regions 
of hemicalide (Figure 22). Independently, the Paterson group has also carried out DP4 analysis to 
predict the most probable structure for each fragment.36 The DP4 analysis also identifies model 
fragments with the same stereochemistry as 29A and 38A for the C1-C17 and the C34-C46 
regions, but suggests 36M as a more likely structure than 33B for the C17-C25 fragment instead. 
We are confident of our assignment in 36M as it is structurally more similar to the natural 
product than 33B, making the analysis more reliable. The Cossy group ultimately conceded that 
the C17-C25 fragment 80 should bear a 18,19-syn relationship rather than 18,19-anti. 
 
Figure 22: Summary of the stereochemical assignment for the C1-C17, C17-C25 and C32-C46 regions of 
hemicalide as determined by the Ardisson, Cossy and Paterson groups 
 
The Cossy and Ardisson groups have undertaken synthetic efforts towards the assembly of a C1-
C25 unit35 65 (Scheme 4) as well as a revised C1-C27 unit63 93 of hemicalide (Scheme 7) by 
utilizing a Suzuki coupling for fragment coupling. Comparison studies of the C1-C25 fragment 
65 with hemicalide have revealed potential stereochemical assignment issues in the C18-C24 δ-
lactone region, especially the C18-C19 anti relationship. Further examination of the revised 

























































a model fragment of the C32-C46 region 79 has also been described38 (Scheme 5) but further 
modifications are required to make it useful for fragment coupling. 
  




CHAPTER TWO: SYNTHESIS OF THE C1-C15 AND  
C16-C28 FRAGMENTS 
 
2.1 Initial Objectives and Synthetic Plan 
 
Hemicalide 1 is a synthetic target of interest as it features several polypropionate and polyacetate 
motifs which can be readily assembled with the use of asymmetric boron aldol reaction protocols 
developed in our group. As outlined in Scheme 8, three key disconnection sites have been 
identified as suitable fragment union strategies. It was envisioned to use a late stage boron aldol 
reaction to form the C28-C29 bond. This gives rise to two key fragments of equal complexity, 
namely a C1-C28 subunit 95 where the relationship between the two stereoclusters still needs to 
be rigorously established. The remaining C29-C46 subunit 96 can be further disconnected with an 
sp2-sp3 Suzuki coupling56 to construct the C33-C34 bond to give the C29-C33 and C34-C46 
subunits 97 and 98 respectively. 
 
Although the assignment of the relative stereochemistry of hemicalide within the C1-C17 region 
and the C18-C24 region has been independently proposed by the DP4 method and synthesis of 
model systems, the relationship between the two stereoclusters is currently unknown. Hence, it 
was desirable to selectively synthesise both diastereomers 99 and 100 in order to compare all 
NMR spectral data against that reported1 for hemicalide to determine which is more likely to 
represent the natural stereochemistry of the full polyketide. This approach has been successfully 
employed by our group during the total synthesis of spirastrellolide A.69 
 
Compounds 99 and 100 bear a methyl ketone at C28 which provides a handle for a 
diastereoselective boron aldol coupling to allow for future extension towards the full natural 
product. A Stille coupling70 would be used to join the C1-C15 fragment 101 to the C16-C28 
dihydroxylactone fragment 102 with the flexibility for a late-stage iodine-tin exchange on either 
fragment as required. Both enantiomers 101 and ent-101 would be synthesised separately and 
individually coupled to intermediate 102 in order to generate the two diastereomers 99 and 100 
respectively. The work discussed in this chapter describes the synthesis of 101, ent-101 and 102 
while coworker Nelson Lam71 synthesised ent-102 concurrently.  This work builds on the route 
which was previously developed by Callum MacGregor37 with the aim of further optimising the 
synthesis of the key building blocks. 






Scheme 8: Key disconnections and coupling strategy for the diastereomeric C1-C28 fragments 99 and 
100 
 
2.2 Synthesis of the C1-C15 Fragment 101 
 
2.2.1 Retrosynthesis and Strategy 
 
Intermediate 101 features several functionalities and stereochemical relationships that are useful 
in planning a synthesis (Scheme 9). The triene region could be made via a HWE olefination47 
between aldehyde 103 and phosphonate 104 in order to achieve the requisite (E)-geometry. The 
1,4-syn relationship between C8 and C11 could be constructed by a boron-mediated aldol 
reaction72 between aldehyde 105 and ethyl ketone 106. Ketone 106 itself is obtained from the 
























































































in aldehyde 105 could be installed via an Evans aldol reaction42 between aldehyde 107 and 
oxazolidinone 108. 
 
Scheme 9: Retrosynthetic analysis of the C1-C15 fragment 101 
 
2.2.2 Synthesis of the C11-C15 Aldehyde 105 
 
Oxazolidinone 45 could be prepared following Evans’ protocol74 (Scheme 10). Reduction of L-
phenylalanine 108 with LiAlH4 gave aminoalcohol 109 which was cyclised with diethyl 
carbonate under basic conditions to give auxiliary 110. Acylation of the auxiliary was achieved 
by deprotonating with n-BuLi followed by trapping with propionyl chloride to give oxazolidinone 
45 in 50% over three steps. 
 
Reagents and conditions: (a) LiAlH4, Et2O, 0 °C ® rt, 75%; (b) CO(OEt)2, 100 °C, 78%; (c) n-BuLi, THF, –
78 °C; CH3CH2COCl, 85% 
Scheme 10: Synthesis of Evans auxiliary derivative 108 
 
The known aldehyde 107 was prepared in a four step sequence from diethyl methylmalonate 111 
(Scheme 11). This had also previously been employed in our group’s total synthesis of 
leiodermatolide.75 Malonate ester was alkylated (NaH, CHI3) to give intermediate 112, which 
upon treatment with KOH in EtOH at elevated temperatures was converted into carboxylic acid 
113 via the intermediate dicarboxylate.76 This hydrolysis-decarboxylation-elimination sequence 






























































Reagents and conditions: (a) NaH, THF, rt ® reflux; CHI3; (b) KOH, EtOH, reflux, 58% over two steps; (c) 
LiAlH4, Et2O, 0 °C ® rt, 79% (d) MnO2, CH2Cl2, rt, 88% (e) CuBr, bipy, DMAP, TEMPO, O2 balloon, MeCN, 
rt, 91% 
Scheme 11: Synthesis of aldehyde 107 from diethyl methylmalonate 111 
 
Carboxylic acid 113 was reduced to alcohol 114 (LiAlH4, 77%) which was oxidised to aldehyde 
107 (Scheme 10).76 On a small scale, this oxidation was possible by using MnO2 as the oxidant. 
However, as the scale of reaction was increased (>20 mmol), this procedure became operationally 
unfeasible as the reaction was still sluggish despite the use of superstoichiometric equivalents 
(10-20 eq.) of MnO2. A more practical alternative for this transformation was to use a catalytic 
copper-TEMPO system77 where molecular oxygen was employed as the terminal oxidant. While 
the original optimised conditions called for Cu(OTf) and NMI, these could be substituted with 
CuBr and DMAP respectively and the reaction proceeded cleanly with good yield (91%) in just 
under 5 h. 
 
A mechanism for the copper-TEMPO mediated oxidation has been proposed by Stahl (Scheme 
12).78 The catalyst 115 is activated by O2 to form 116 which dimerises to the peroxo-bridged 
binuclear Cu(II) species 117. This is sequentially reduced to complex 118 followed by the active 
mononuclear Cu(II) species 119. Following ligand exchange of the substrate for hydroxide in 
intermediate 120, hydride abstraction by TEMPO then generates the aldehyde product together 
with turnover of the catalytic system. Notably, H2O2 is generated as a by-product that 
disproportionates into H2O and O2 under the reaction conditions. This proposal is consistent with 
Stahl’s observation that the stoichiometry of O2 consumed to alcohol substrate is 1:2.78 
 
Due to its volatility and instability, aldehyde 107 was always freshly prepared and subjected to 
further reaction immediately without storage or further purification. While the presence of 
TEMPO could be detected by 1H NMR spectroscopy in the crude 107, this did not appear to have 

























Scheme 12: Proposed mechanism for the oxidation of 114 to 107 
 
 
Reagents and conditions: (a) 45, Bu2BOTf, DIPEA, CH2Cl2, –78 °C, then 107, –78 °C ® –20 °C, 80% 
(d.r. >20:1) 
Scheme 13: Evans aldol reaction of 107 and 108 to form aldol adduct 121 
 
Aldehyde 107 was treated with the boron enolate of propionyl-oxazolidinone 45 under the 
conditions developed by Evans (Scheme 13).42 Enolisation of ketone 45 was conducted at –78 °C 
with Bu2BOTf and DIPEA. To ensure complete enolisation, the reaction mixture was briefly 
warmed to –10 °C but cooled back to –78 °C before introducing aldehyde 107. The reaction 
mixture was then transferred to a freezer overnight. Cleavage of any residual boronate ester from 
the aldol adduct could be achieved by repeatedly azeotroping the crude material with MeOH to 
























































































Chelation of the boron Lewis acid between the carbonyl and the oxazolidinone presents two 
competing transition states, TS-I and TS-II, in which the methyl group on the propionyl arm of 
the oxazolidinone is either pointing away or towards the bulky auxiliary (Scheme 14). The 
preferred transition state for deprotonation minimises developing allylic (A1,3) strain, thus TS-I 
leads to the favoured (Z)-enolate 122. The excellent stereocontrol in the aldol reaction can be 
attributed to the clean generation of the (Z)-enolate 122 in >100:1 selectivity. 
 
Scheme 14: Selective (Z)-enolization of oxazolidinone 45 
 
Reaction of the (Z)-enolate 122 with aldehyde 107 would be expected to occur via the highly 
ordered, six-membered chair-like transition state (Scheme 15).79 To minimse 1,3-diaxial 
interactions, the main chain of the aldehyde would adopt a pseudo-equatorial position. The high 
levels of diastereoselectivity of this aldol reaction is determined by the chiral auxiliary adopting a 
low energy conformation within the transition state that opposes the enolate C–O dipole. Thus, 
two possible transition states, TS-III and TS-IV, are in competition where the benzyl group 
either points away from or into the other substituents on the chair. In practice, this steric 
interaction is minimised in transition state TS-III and leads to aldol adduct 121 as the major 











minimise steric  
















































Scheme 15: Diastereoselective transition states for the aldol reaction of 107 and 122 
 
The expected syn relative stereochemistry in product 121 was confirmed by 1H NMR 
spectroscopic analysis. β-hydroxyketones are known to adopt a chair-like conformation due to a 
stabilising intramolecular hydrogen bonding interaction between the carbonyl lone pair and the β-
hydroxyl group (Figure 23).80 The measured vicinal coupling constant between H12 and H13 
(3J12,13 = 3 Hz) in 121 is highly indicative of a 1,2-syn relationship due to the gauche arrangement 
of the protons.   
 
Figure 23: Comparison of chair-like conformers of 1,2-syn and 1,2-anti aldol adducts 
 
A comparison of all NMR spectroscopic data was in full agreement with the previously 
synthesised37 enantiomeric aldol adduct ent-121, where the absolute configuration at C13 was 
assigned via Mosher ester analysis.81–83  
 
Further elaboration of aldol adduct 121 into aldehyde 105 was first explored with the route 
developed by MacGregor. Intermediate 121 was treated with AlMe3 and MeN(H)OMeHCl to 
cleave and recover the oxazolidinone auxiliary 110 (83% recovery) together with formation of 
Weinreb amide43 125 (93%) (Scheme 16). Here, it was crucial that the β-hydroxyl group was free 


















































































3JH,H = 7-10 Hz
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chelated complex between the two carbonyls, thus selectively activating it towards nucleophilic 
substitution. The hydroxyl group of Weinreb amide 125 was then later protected as a TES ether 
126 (TESCl, imidazole) in good yield (94%). Intermediate 126 was reduced using DIBAL44 (70%) 
to ensure that no over-reduction occurred. This reaction was found to be somewhat capricious as 
some degree of epimerisation at C12 was sometimes observed (20:1 to 6:1) in this work. Efforts 
to control the stoichiometry of DIBAL employed and to lower the reaction temperature were met 
with no improvement. 
 
Reagents and conditions: (a) MeN(H)OMeHCl, AlMe3, THF, 0 °C ® rt, then 121, 0 °C ® rt, 93%; (b) 
TESCl, imidazole, CH2Cl2, 94%; (c) DIBAL, PhMe, –78 °C ® –30 °C, 70% 
Scheme 16: First synthetic route towards aldehyde 105 from intermediate 121 
 
To overcome the problem associated with epimerisation of aldehyde 105, an alternative synthetic 
pathway was proposed (Scheme 17). In this sequence, aldol adduct 121 was first protected as the 
TES ether 127 (TESCl, imidazole, 92%) and the product reduced to alcohol 128 with LiBH4 
(80%). The reduction step occurred predominantly at the imide carbonyl and not the 
oxazolidinone to allow for recovery of the auxiliary 110 (78%). Alcohol 129 was oxidised to 
aldehyde 105 by a Swern oxidation39 cleanly in excellent yield (99%) without any loss of 
stereochemical purity. In addition to an improvement in yield (61% and 73% over three steps 
respectively), the latter was preferred because it was essential to deliver aldehyde 105 as a single 
stereoisomer for the subsequent boron-mediated aldol reaction. 
 
Reagents and conditions; (a) TESCl, imidazole, CH2Cl2, 92%; (b) LiBH4, Et2O, –78 °C ® 0 °C, 80%; (c) 
(COCl)2, DMSO, Et3N, CH2Cl2, –78 °C ® –20 °C, 99% 
Scheme 17: Alternative synthetic route towards aldehyde 105 from intermediate 121 
 
Before moving on to examining the next step, it is worth highlighting that while the Evans aldol 
reaction delivered intermediate 121 in good yield and d.r., the success of the reaction was 






























































developed by Crimmins was investigated as an alternative for this reaction.84 The original 
conditions employed by Crimmins require the use of TiCl4 and two equivalents of (–)-sparteine, 
where the amine is functioning as both a base and a ligand for titanium. However, this protocol 
was restricted to chiral auxiliaries containing oxazolidinethiones and thiazolidinethiones. In 
addition, cost considerations due to (–)-sparteine have limited the utility of this protocol. Further 
work by Crimmins showed that a mixture of DIPEA and NMP was an effective substitute for (–)-
sparteine in their capacity as a base and ligand respectively.85 This improved protocol also 
expanded its substrate scope to include oxazolidinones. Crimmins reported a range of aldehydes 
that engaged successfully with propionyl-oxazolidinone 45 with mostly excellent yields and d.r. 
(Scheme 18).85 
 
Reagents and conditions; (a) 45, TiCl4, DIPEA, NMP, CH2Cl2, 0 °C, then RCHO, various yields 
Scheme 18: Examples of Evans aldol reactions performed by Crimmins with the modified protocol 
 
Applying these conditions to substrates 107 and 45 gave aldol adduct 121 with an improved yield 
of 88% but poorer stereoselectivity of d.r. 10:1 (Scheme 19). Unlike the Evans conditions, an 
appreciable quantity of the diastereomer 124 was detected in the crude product. While 121 and 
124 were initially inseparable, they were readily separated following protection as their TES 
ethers (TESCl, imidazole). It was critical that clean separation was achieved at this stage, or else 
128 and ent-128 would be obtained upon reductive cleavage of the auxiliary (LiBH4), thus 
eroding the e.e. of 128. 
 
Reagents and conditions; (a) 45, TiCl4, DIPEA, NMP, CH2Cl2, 0 °C, then 107, 88% (d.r. 10:1) 
Scheme 19: Evans aldol reaction of 107 and 45 to form aldol adduct 121 with Crimmins’ conditions 
 
Arguments for rationalising the selective (Z)-enolisation of 45 with TiCl4 to form titanium 
enolate 129 are analogous to the case with Bu2BOTf. The proposed transition states that account 
for the Crimmins reaction also bear resemblance to the Evans ones (Scheme 20). In the preferred 
transition state TS-V, NMP has coordinated to titanium. This allows the auxiliary to adopt a 
conformation that opposes the enolate C–O dipole and minimises steric clash by placing the 












R = i-Pr, yield 99%, d.r. 97:3
R = n-C5H11, yield 75%, d.r. 93:7
R = Ph, yield 97%, d.r. 94:6

































to a competing transition state TS-VI where the auxiliary binds to the titanium metal. This 
represents a failure of NMP to completely coordinate to titanium. 
 
Scheme 20: Diastereoselective transition states for the aldol reaction of 107 and 129 under Crimmins’ 
conditions 
 
2.2.3 Synthesis of the C7-C15 Stereohexad 
 
Following standard group protocols, the ethyl ketone 106 was readily synthesised from 
commercially available Roche ester (R)-40 in three steps (Scheme 21) as precedented in our 
work for aplyronine A.73 The hydroxyl group of Roche ester (R)-40 was protected with 
PMBTCA under acid catalysis to afford PMB ether 130 in 85% yield. Ester 130 was transformed 
into Weinreb amide 131 under standard conditions (MeON(H)MeHCl, i-PrMgCl, 88%) and the 
product was reacted with EtMgBr to afford ethyl ketone 106 in 94% yield. 
 
Reagents and conditions: (a) PMBTCA, PPTS, CH2Cl2, 0 °C ® rt, 85%; (b) MeN(H)OMeHCl, i-PrMgCl, 
THF, –20 °C, 88%; (c) EtMgBr, Et2O, –78 °C ® –10 °C, 94% 

























































































Reagents and conditions: (a) 106, Cy2BCl, Et3N, Et2O, 0 °C, then 105, –78 °C ® –20 °C, 70% (d.r. >20:1) 
Scheme 22: Boron-mediated aldol reaction of 105 and 106 to form aldol adduct 132 
 
A boron-mediated aldol reaction (Scheme 22) between ketone 106 and aldehyde 105 could now 
be carried out. This would require the generation of the (E)-enolate of ketone 106 which could be 
achieved by using Cy2BCl and Et3N. By binding to either of the carbonyl lone pairs in ketone 106, 
two competing transition states, TS-VII and TS-VIII, may arise (Scheme 23). It has been 
proposed by Goodman using molecular orbital calculations86 that TS-VIII is favoured due to a 
minimisation of steric clash between the bulky boron groups and the large group of the ketone 
and activation of the acidic C–H proton by hydrogen-bonding from the Cl atom. Using a small 
base like Et3N enables facile deprotonation despite the crowded reactive centre. The 
computational methods support the observation that (E)-enolate 134 is formed in excellent 
selectivity. 
 
Scheme 23: Selective (E)-enolisation of ketone 106 
 
The six-membered transition state to account for the diastereoselectivity in the aldol reaction 
itself is calculated to be boat-like in conformation, allowing for a stabilising formyl hydrogen 
bond interaction between the electron rich oxygen atom of the PMB ether and the activated 
aldehyde formyl proton in the axial position (Scheme 24).46 The preferred transition state for the 
reaction is that which minimises allylic (A1,3) strain along C8-C10 as well as observing Felkin–
Anh control from the α-chiral aldehyde.87 In this case, the Felkin product also minimises syn-























































of ketone 106 and aldehyde 105 led to aldol adduct 132 as the major product featuring a 1,2-anti-
1,4-syn relationship in high diastereoselectivty (>20:1) and in good yield (70%) (Scheme 24). 
 
Scheme 24: Diastereomeric transition states for the aldol reaction of 105 and 134 
 
As before, the relative stereochemistry between C10 and C11 in aldol product 132 was confirmed 
by inspection of the vicinal coupling constant in the 1H NMR spectrum.80 In this instance, the 
large 3J10,11 value of 9 Hz confirmed the 1,2-anti relationship. All spectroscopic data was in full 
agreement with the data previously reported by MacGregor37 of the enantiomeric aldol adduct 
ent-132 where the absolute configuration at C11 was assigned by Mosher ester analysis,81–83 thus 
confirming the expected stereochemistry of 132 as drawn. 
 
Next, the hydroxyl group of aldol product 132 was protected as the TES ether 136 with TESOTf 
and 2,6-lutidine in good yield (82%) (Scheme 25). To install the final stereocentre in the 
stereohexad, the ketone moiety at C9 of intermediate 136 was reduced with DIBAL at low 
temperature (–40 °C) to give the (9S) configuration of alcohol 137 (80%). Pleasingly, this 
























































































Reagents and conditions: (a) TESOTf, 2,6-lutidine, CH2Cl2, –78 °C, 91%; (b) DIBAL, CH2Cl2, –78 °C ® –
40 °C, 84% (d.r. >20:1); (c) Me3OBF4, Proton Sponge®, 4Å MS, CH2Cl2, rt, 71%. 
Scheme 25: Synthesis of methyl ether 141 from aldol adduct 132 
 
The high level of diastereoselectivity of the reduction of ketone 136 was proposed to proceed via 
a chelated transition state (Scheme 26).89 Hydride delivery would occur by axial attack going 
through a chair-like transition state rather than a twist-boat-like one. TS-XI is the lower energy 
transition state by avoiding steric hindrance from the methyl group and the incoming nucleophile, 
leading to alcohol 137 as the product rather than 138. 
 
Scheme 26: Diastereomeric transition states for the reduction of 136 
 
To confirm the stereochemical outcome of the reduction step, both (S) and (R)-MTPA ester 
derivatives 139 and 140 were prepared from the corresponding MTPA acids under Steglich 
conditions (DCC, DMAP) (Scheme 27).90 
 
Reagents and conditions: (a) (S)-MTPA, DCC, DMAP, CH2Cl2, rt, 60%; (b) (R)-MTPA, DCC, DMAP, 
CH2Cl2, rt, 84% 











141P = H 132

































































MTPA derivatives of secondary alcohols adopt a preferred conformation in which the carbinyl 
proton, MTPA ester carbonyl and MTPA trifluoromethyl group lie in the same plane (Figure 
24(a)). As a result, the protons of the (R)-MTPA ester that lie on the same side of the plane as the 
phenyl group (Ha, Hb, Hc) are diamagnetically shielded, resulting in upfield chemical shifts 
relative to the same proton signals in the corresponding (S)-MTPA ester (Ha, Hb, Hc), which are 
on the same side of the plane as the methoxy group. Thus, unambiguous assignments of proton 
signals with Δδ > 0 (Δδ = δS – δR) belong to protons on the right-hand side of the MTPA plane 
from the perspective of the MTPA trifluromethyl group (Figure 24(b)); by contrast, protons with 
Δδ < 0 belong to protons on the left-hand side of the plane.81–83 Following this model, the 
configuration at C9 was unambiguously determined to be (9S). 
 
Figure 24: Mosher ester analysis  
 
Proton δH (S)-MTPA 139 δH (R)-MTPA 140 Δδ = δS – δR 
H12 1.94 1.92 +0.02 
Me12 0.81 0.76 +0.05 
H11 3.65 3.61 +0.04 
H10 2.20 2.18 +0.02 
Me10 1.06 0.89 +0.17 
H8 2.56 2.58 –0.02 
Me8 0.82 0.85 –0.03 
H7a 3.10 3.14 –0.04 
H7b 3.07 3.14 –0.07 
ArCH2a 4.37 4.40 –0.03 
ArCH2b 4.34 4.35 –0.01 
  
Table 2: List of chemical shifts in MTPA esters 139 and 140 for Mosher ester analysis of 137 
 
The planned intermediate 141 was completed by methylation of the newly formed hydroxyl 
group of alcohol 137 using Meerwein’s salt (72%). The use of Proton Sponge® and activated 


























observed (Scheme 25). This side reaction was also reported by MacGregor37 during preliminary 
investigations into this transformation. 
 
  





2.2.4 Synthesis of the C1-C15 Fragment via HWE Olefination 
 
At this point, attention was turned towards synthesising the C1-C6 phosphonate 104 in 
preparation for the eventual HWE reaction.47 Treating sorbic acid 54 with thionyl chloride in 
methanol furnished methyl sorbate 142 in essentially quantitative yield. The allylic carbon was 
then brominated with NBS in refluxing benzene (Scheme 28). The previously reported route 
towards 143 gave a low yield of 24% for this reaction so further investigations were carried out to 
optimise this step. The primary cause for the low yield was the presence of multiple by-products 
that could not be removed by chromatography. It was assumed that some of the by-products 
might be geometric isomers of 143, but any attempt at isomerisation via conjugate addition-
elimination (DMAP) or radical-assisted π-bond rotation (I2) did not lead to any changes in the 
product composition. Other possible by-products include further bromination of 143 although this 
was not thoroughly examined.  By quenching the reaction before the onset of by-product 
formation (2 h), the yield of 143 could be increased to 37% with the option for recovering 
unreacted methyl sorbate 142. Although the bromination step gave a modest yield, the low cost of 
the starting material and reagents enabled multi-gram quantities of 143 to be routinely 
synthesised. Gratifyingly, the subsequent Arbuzov reaction50 where bromide 143 was heated in 
excess triethyl phosphite gave phosphonate 104 in excellent yield (94%). 
 
 
Reagents and conditions: SOCl2, MeOH, reflux, 95%; (b) NBS, (BzO)2, PhH, reflux, 37%; (c) P(OEt)3, 
120 °C, 94% 
Scheme 28: Synthesis of phosphonate 104 
 
With the methyl ether 141 in hand, the stage was set to access a single enantiomer of the C1-C15 
fragment 101. This involved oxidative deprotection of the PMB ether to give primary alcohol 144 
(DDQ, pH 7 buffer) and oxidation to aldehyde 103 (DMP)46 in 99% yield. The crucial HWE 
olefination was conducted by treating aldehyde 103 with the lithium anion of phosphonate 104 to 

























Reagents and conditions: (a) DDQ, pH 7 buffer, CH2Cl2, rt, 77%; (b) DMP, NaHCO3, CH2Cl2, rt, 95%; (c) 
104, LDA, THF, –78 °C, then 103, –78 °C, 70% 
Scheme 29: The final three steps to the C1-C15 fragment 101 
 
The high selectivity for the (E) geometric isomer in the HWE olefination can be understood by 
examining the relative rates of the elementary steps in the reaction mechanism (Figure 25).47 
Initially, the phosphonate anion 145 forms either a syn or anti adduct with the aldehyde rapidly 
and reversibly, where ksyn > kanti, thus 146 is the major intermediate. However, the subsequent 
cyclisation to give a four-membered oxaphosphatane is slower. In this case, ktrans > kcis, so 147 
smoothly transforms into 148 where its only fate is to collapse into the desired (E) product 101. 
Any remaining intermediate 146 equilibrates back to 145 and 147 instead of undergoing 
cyclisation to 149 due to the slow kinetics of this step, hence delivering the desired product 101 
instead of the (Z, E, E) olefin 150. 
 



























P = PMB 141






















































At this point, the synthesis of 101 has been achieved in 11 steps in the longest linear sequence 
with an overall yield of 11.3% (Scheme 30). By using oxazolidinone ent-45 (derived from L-
phenylalanine) and ketone ent-106 (derived from Roche ester (S)-40), the analogous route 
(Scheme 31) could be undertaken to deliver ent-101 in 14.0 yield over 11 steps. 
 
 
Reagents and conditions; (a) 45, Bu2BOTf, DIPEA, CH2Cl2, –78 °C ® –10 °C, then 107, –78 °C, 80% 
(d.r. >20:1); (b) TESCl, imidazole, CH2Cl2, 92%; (c) LiBH4, Et2O, –78 °C ® 0 °C, 80%; (d) (COCl)2, DMSO, 
Et3N, CH2Cl2, –78 °C ® –20 °C, 99%; (e) 106, Cy2BCl, Et3N, Et2O, –78 °C ® 0 °C, then 105, –78 °C, 70% 
(d.r. >20:1) ;(f) TESOTf, 2,6-lutidine, CH2Cl2, –78 °C, 91%; (g) DIBAL, CH2Cl2, –78 °C ® –40 °C, 84% 
(d.r. >20:1); (h) Me3OBF4, Proton Sponge®, 4Å MS, CH2Cl2, rt, 71%; (i) DDQ, pH 7 buffer, CH2Cl2, rt, 77%; 
(j) DMP, NaHCO3, CH2Cl2, rt, 95%; (k) 104, LDA, THF, –78 °C, then 103 –78 °C, 70%. 



































































































Reagents and conditions; (a) ent-45, Bu2BOTf, DIPEA, CH2Cl2, –78 °C ® –10 °C, then 107, –78 °C, 79% 
(d.r. >20:1); (b) TESCl, imidazole, CH2Cl2, 97%; (c) LiBH4, Et2O, –78 °C ® 0 °C, 82%; (d) (COCl)2, DMSO, 
Et3N, CH2Cl2, –78 °C ® –20 °C, 95%; (e) ent-106, Cy2BCl, Et3N, Et2O, –78 °C ® 0 °C, then ent-105, –
78 °C, 74% (d.r. >20:1) ;(f) TESOTf, 2,6-lutidine, CH2Cl2, –78 °C, 97%; (g) DIBAL, CH2Cl2, –78 °C ® –
40 °C, 82% (d.r. >20:1); (h) Me3OBF4, Proton Sponge®, 4Å MS, CH2Cl2, rt, 72%; (i) DDQ, pH 7 buffer, 
CH2Cl2, rt, 80%; (j) DMP, NaHCO3, CH2Cl2, rt, 99%; (k) 104, LDA, THF, –78 °C, then ent-103 –78 °C, 70% 



































































































2.3 Synthesis of the C16-C28 Fragment 102 
 
2.3.1 Retrosynthesis and Strategy 
 
The proposed C16-C28 fragment 102 incorporates the α,β-dihydroxy-δ-lactone of hemicalide and 
terminates in a methyl ketone and vinyl iodide (Scheme 32). The methyl ketone functionality 
would be installed by a Ba(OH)2-mediated HWE olefination91 of a C25 aldehyde followed by 
conjugate reduction of the intermediate enone. The 1,2-diol functionality would be installed by a 
syn-dihydroxylation of the corresponding α,β-unsaturated lactone and would come from vinyl 
iodide 151. 
 
Scheme 32: Retrosynthetic analysis of the C16-C28 fragment 102 
 
The α,β-unsaturated lactone of intermediate 151 could be assembled by an aldol addition of 152 
with ethyl acetate followed by dehydration. Using group methodology, a diastereoselective 1,4-
syn aldol reaction between ketone 153 and aldehyde 154 could be used to install the correct 
configuration at C19 (Scheme 32). Both ketone 153 and aldehyde 154 can be obtained from the 
same enantiomer of Roche ester derivative ent-130. 
 
2.3.2 Synthesis of the Aldol Adduct 152 
 
Following MacGregor’s work, the ester ent-130 was reduced with LiAlH4 to give the primary 
alcohol 155 (90%) which was oxidised to the aldehyde 156 under Swern conditions39 ((COCl)2, 
DMSO; Et3N) (Scheme 33). To avoid the risk of racemisation of aldehyde 156 on storage, it was 
immediately submitted to the Corey–Fuchs reaction92 (CBr4, PPh3) to obtain 1,1-dibromo olefin 
157 in 77% yield over two steps. Treament of olefin 157 with n-BuLi to effect a Fristch–





































Reagents and conditions: (a) LiAlH4, Et2O, 0 °C ® rt, 90%; (b) (COCl)2, DMSO, Et3N, CH2Cl2, –78 °C ® –
20 °C; (c) PPh3, CBr4, CH2Cl2, 0 °C, then 156, –78 °C ® 0 °C, 77% over two steps; (d) n-BuLi, THF, –
78 °C; MeI, –78 °C, 92% 
Scheme 33: Synthesis of alkyne 158 from ester ent-130 
 
The regio- and stereocontrolled transformation of alkyne 158 into vinyl iodide 159 was achieved 
via hydrozirconation with in situ preparation of the Schwartz reagent (Cp2Zr(H)Cl),93 followed 
by trapping of the organozirconium species with I2 in 78% yield (Scheme 34). While the 
Schwartz reagent is commercially available, it is known to be sensitive to light, air and moisture 
upon long-term storage so an in situ generation of this reagent is helpful in addressing these 
issues. Addition of the Schwartz reagent across the alkyne occurs in a syn-stereospecific fashion 
where the zirconium adds to the least hindered end of the alkyne to minimise steric interactions.94 
Using an excess (2 eq.) of the Schwartz reagent has been shown to improve the regioselectivity 
via a reversible second addition to both regioisomers which undergoes free bond rotation and β-
hydride eliminates to form the major (E) regioisomer under thermodynamic control (Figure 
26).94 
 
The vinyl iodide 159 was converted into the sensitive aldehyde 154 by sequential DDQ-mediated 
PMB ether cleavage to give the alcohol 160 in 90% yield and oxidation with DMP46 (Scheme 34). 
Aldehyde 154 was found to be very sensitive and best prepared fresh and used in the subsequent 
aldol reaction with minimal purification. As the vinyl iodide was suspected to contribute to the 
instability of aldehyde 154, it was proposed as an alternative to employ alkyne 158 and install the 
vinyl iodide at a later stage. This was inspired by precedent from Nicolaou’s synthesis of 
apoptolidin95 for a late-stage hydroiodination of an advanced intermediate. Disappointingly, 
























Reagents and conditions: (a) Cp2ZrCl2, DIBAL, THF, 0 °C, then 158, 0 °C ® rt, then I2, –78 °C, 76%; (b) 
DDQ, pH 7 buffer, CH2Cl2, rt, 90%; (c) DMP, NaHCO3, CH2Cl2, rt, 80%; (d) DDQ, pH 7 buffer, CH2Cl2, rt, 
52%; (e) DMP, NaHCO3, CH2Cl2, rt, yield N.C. 
Scheme 34: Synthesis of aldehyde 154 from alkyne 158 
 
 
Figure 26: Mechanism of hydrozirconation of alkyne 158 
 
The 1,4-syn aldol reaction between the methyl ketone 153 and the aldehyde 154 afforded the 
aldol adduct 152 in 68% yield and with the same d.r. of 9:1 in the DMB ether series carried out 
by MacGregor37 (Scheme 35). The initial choice of the DMB analogue of 153 was to facilitate a 
facile, late-stage deprotection due to concerns about the sensitivity of the vinyl iodide functional 
group. However, later work in the PMB ether series confirmed that these precautions were 
unfounded. In addition, the use of the methyl ketone 153 simplified production of this 
intermediate as it could be obtained from a common intermediate in the C1-C15 fragment, 
Weinreb amide ent-131, by reacting with MeMgBr (92%). 
 
Reagents and conditions: (a) MeMgBr, –78 °C ® –10 °C, Et2O, 92%; (b) 153, Cy2BCl, Et3N, Et2O, 0 °C, 
then 154, –78 °C ® –20 °C, 68% (d.r. 9:1); (c) 153, (–)-DIPCl, Et3N, Et2O, 0 °C, then 154, –78 °C ® –
20 °C, 64% (d.r. >20:1) 




























































Compared to the analogous aldol reaction using 106, the use of a methyl ketone instead of an 
ethyl ketone has led to an erosion of d.r. in the product. As with aldol adduct 132, the six-
membered transition state invoked in the aldol reaction of enolate 163 and aldehyde 154 is 
thought to be boat-like in conformation, allowing for a stabilizing formyl hydrogen bond 
interaction between the electron rich oxygen atom of the PMB ether and the activated aldehyde 
formyl proton in the axial position (Scheme 36).72 Two competing transition states, TS-XIII and 
TS-XIV, can arise but their difference in energy is significantly reduced as they have similar 
amounts of allylic strain along C20-C24 due to C20 only bearing H atoms. The absence of a Me 
group at C20 also precludes syn-pentane interactions as a stereocontrol element. Moderate 
diastereoselectivity may be imparted by Felkin–Anh control from the α-chiral aldehyde, leading 
to aldol adduct 152 as the major product (Scheme 36).87 
 
Scheme 36: Diastereomeric transition states for the aldol reaction of 154 and 163 
 
In light of the moderate level of stereocontrol, the use of chiral (–)-Ipc ligands to further reinforce 
the diastereoselectivity was explored in order to improve the d.r. of the aldol reaction. This has 
been precedented in our group’s synthesis of the chivosazoles.96 Gratifyingly, this change in 
conditions to enolisation with (–)-DIPCl and Et3N delivered aldol adduct 152 as a single 
diastereomer with only a slight decrease in yield (Scheme 35). 
 
These results reflect the steric influence of the chiral (–)-Ipc ligands in the aldol reaction as 
analysed by DFT calculations.97 For TS-XV, the axial ligand has a Me group that clashes with the 



































































Together with the Felkin–Anh control87 discussed earlier, the pathway leading to major product 
152 is now significantly lower in energy than the alternative (Scheme 37). 
 
Scheme 37: Diastereomeric transition states for the aldol reaction of 154 and 163 with chiral ligands 
 
The absolute configuration of the aldol adduct 152 was confirmed by Mosher ester analysis.81–83 
Both (S) and (R)-MTPA ester derivatives 165 and 166 were prepared from the corresponding 
MTPA acids under Steglich conditions (DCC, DMAP) (Scheme 38).90 Despite being unable to 
fully assign the proton signals in MTPA ester 165, there were sufficient signals on both sides of 
the carbinyl proton to allow for the anticipated (19R) assignment (Table 3). 
 
Reagents and conditions: (a) (S)-MTPA, DCC, DMAP, CH2Cl2, rt, 63%; (e) (R)-MTPA, DCC, DMAP, 
CH2Cl2, rt, 76% 













































































Proton δH (S)-MTPA 165 δH (R)-MTPA 166 Δδ = δS – δR 
H25a 3.55 3.49 +0.06 
H25b 3.46 3.41 +0.05 
H24 N.A.a 2.88 N.A. 
Me24 0.99 0.94 +0.05 
H20a N.A.a 2.85 N.A. 
H20b N.A.a 2.75 N.A. 
H18 N.A.a 2.76 N.A. 
Me18 0.87 0.92 –0.05 
H17 5.87 5.98 –0.11 
Me16 2.32 2.40 –0.08 
a obscured in a 4H multiplet 
Table 3: List of chemical shifts in MTPA esters 165 and 166 for Mosher ester analysis of 152 
 
2.3.3 Synthesis of Diol 174 
 
The resulting aldol product 152 was protected as the TBS ether 167 in good yield (TBSOTf, 2.6-
lutidine, 88%) and used in the subsequent acetate aldol reaction (Scheme 39). The ketone 167 
was successfully reacted with the lithium enolate of ethyl acetate to afford aldol adduct 168 as a 
5:1 mixture of inseparable diastereomers. Exposure of 168 to HFpy effected deprotection of the 
TBS ether and in situ lactonisation to give intermediate 169. When working on a large scale, the 
use of HFpy could be substituted with TsOH in methanol. Lactone 169 remained an inseparable 
mixture of epimers in the same 5:1 ratio. 
 
Reagents and conditions: (a) TBSOTf, 2,6-lutidine, CH2Cl2, –78 °C, 95%; (b) LDA, EtOAc, THF, –78 °C, 
then 167, 97%; (c) HFpy, THF, 0 °C ® rt, 85%; (d) TsOH, MeOH, rt, 83% 
Scheme 39: Synthesis of lactone 169 from aldol adduct 152 
 
Although the two epimers of lactone 169 could not be cleanly separated, the minor isomer was 
isolated with sufficient purity to conduct nOe studies. Key correlations between Me24 and H20ax 
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Accordingly, the major epimer had to be 169A. The major and minor epimers of aldol adduct 168 
can therefore be assigned as 168A and 168B respectively. Further investigation into the 
stereoinduction was not pursued as the C21 stereocentre would be destroyed in the next step via a 
dehydration reaction. However, the configuration of C21 did in fact appear to have consequences 
for this step (vide infra). 
 
Figure 27: Identification of the major and minor epimers of 168 and 169 
 
In the event, the dehydration reaction was first carried out using conditions employed by 
MacGregor37 (MsCl, Et3N) (Table 4, Entry 1). However, the desired elimination product 151 
was consistently obtained along with significant quantities of an inseparable product-like 
impurity. While the impurity could not be fully characterised, an inspection of its 1H NMR 
spectrum suggested the presence of a tri-substituted olefin so 170 was proposed as the putative 
structure. Attempts to isomerise 170 to the desired product 151 with acid (TsOH, MeOH) or base 
(LDA) did not alter the ratio of 151 to 170. 
 
Various other dehydration conditions were examined in order to minimise the formation of this 
by-product. Turning to Ardisson’s choice of SOCl2 and pyridine33 (Entry 2) did not lead to any 
improvement, nor did other conventional methods such as the Burgess reagent98 (Entries 3-5). 
Pleasingly, mixing lactone 169 with Ac2O and DMAP99 (Entry 6) in refluxing benzene and 
















































Entry Conditions Result 
1 MsCl, Et3N, CH2Cl2, 0 °C ® rt, 5 h 83% yield, 5:1 151:170 
2 SOCl2, py, 0 °C ® rt, 5 h 81% yield, 5:1 151:170 
3 TsCl, py, CH2Cl2, rt ® rt, 18 h Recovered 169 
4 Burgess reagent, THF, rt, 2 h Complex mixture 
5 Ac2O, DBU, CH2Cl2, rt, 5 h Complex mixture 
6 Ac2O, DMAP, py/PhH, reflux, 16 h 88% yield, only 151 
 
Table 4: Conditions examined for the dehydration of 169 to 151 
 
Although the dehydration problem had been resolved, the origin of by-product 170 had yet to be 
understood. A similar impurity was also identified in the work of MacGregor37 who worked with 
the DMB analogue of 169. The combined results of this investigation and MacGregor’s results 
suggested that the amount of impurity 170 in the dehydration reaction correlated positively with 
the d.r. of lactone 169. A closer inspection of the supporting NMR spectra in Ardisson’s work33 
once again revealed the presence of this evasive impurity. This is despite the fact that Ardisson’s 
intermediate 171 was synthesised as a single diastereomer via a highly stereoselective 
Reformatsky reaction involving the chelated transition state TS-XVII (Scheme 40). The idea that 
the dehydration mechanism was stereospecific was thus ruled out with this finding. 
 
Reagents and conditions: (a) SmI2, THF, –78 °C ® rt, yield N.C. 
Scheme 40: Synthesis of Ardisson’s intermediate 171 via a Reformatksy reaction 
 
Various modes of elimination were considered next to shed light on the reaction. Epimer 172, 
with an axially positioned OR leaving group, is well set-up for an E2-like pathway (or E1cb) with 
a greater preference for deprotonation at H22 than H20 due to its lower pKa (Figure 28). This is 
also true for conformer 173A of the corresponding epimer but not for conformer 173B with an 












































or H20, resulting in a mixture of products. In order to encourage an E2-like elimination instead of 
E1-like for both epimers, a poorer leaving group, such as OAc, would be better suited than an 
excellent one like OMs or OSO2Cl. 
 
Figure 28: Proposed rationalisation of the stereochemical dependence of C21 for the dehydration 
 
 
Entry Conditions Result 
1 10 mol% K2OsO42H2O, 6 eq. NMO,  t-BuOH/H2O/THF, 0 °C, variable times 
25-50% 174 
2 5 mol% K2OsO42H2O, 6 eq. NMO,  2 eq. citric acid, t-BuOH/H2O/THF, 0 °C, 18 h 
25% conversion 
3 5 mol% K2OsO42H2O, 1.2 eq. NMO,  2 eq. citric acid, t-BuOH/H2O/THF, rt, 3 h 
50% conversion 
4 5 mol% K2OsO42H2O, 1.2 eq. NMO,  2 eq. citric acid, t-BuOH/H2O/THF, rt, 18 h 
48% 174, 34% 175 
5 2 mol% K2OsO42H2O, 0.6 eq. NMO,  2 eq. citric acid, t-BuOH/H2O/THF, rt, 5 h 
55% 174, 30% 151 
6 KMnO4, Me2CO/H2O, 0 °C ® rt, 5 h Complex mixture 
7 KMnO4, TBAB, CH2Cl2/H2O, 0 °C ® rt, 5 h Complex mixture 
 
Table 5: Conditions examined for the dihydroxylation of 151 to 174 
 
With the pure α,β-unsaturated δ-lactone 151 at hand, the stage was set for a dihydroxylation to 
install the final two stereocentres in this fragment (Table 5). Under standard Upjohn conditions 
(K2OsO42H2O, NMO), the desired diol 174 was obtained along with significant amounts of triol 































































electronic properties with the vinyl iodide, thus compromising the chemoselectivity. In contrast, 
Ardisson did not observe this problem with a vinyl bromide as it is more electron deficient than 
the lactone alkene.33 
 
Modifications to the Upjohn conditions were explored to improve on the existing results. 
Sharpless found that the use of citric acid as an additive can greatly accelerate the 
dihydroxylation of electron deficient alkenes and improve their yield.68 Initially, it appeared that 
adding citric acid to the reaction at 0 °C offered no improvement (Table 5, Entry 2) but 
repeating the reaction at room temperature enabled us to reproduce the maximum conversion of 
50% in a shorter time while using less osmium and NMO (Entry 3). Citric acid did not entirely 
solve the chemoselectivity problem as complete consumption of NMO still led to significant 
quantites of triol 175 (Entry 4). By employing a substoichiometric amount of NMO (Entry 5), 
diol 174 could be reliably obtained in 55% yield while the starting material 151 could also be 
recovered and resubmitted twice more to increase the throughput of the reaction. This result 
could also be reproduced on a gram scale. 
 
Mechanistically, dihydroxylation begins with a [3+2] cycloaddition of OsO4 with the olefin to 
form an osmate ester 176 (Figure 29). Under homogenous Upjohn conditions, oxidation of this 
Os(VI) complex outcompetes hydrolysis, thus interrupting the first catalytic cycle and shunting 
the process towards a second catalytic cycle via intermediates 177 and 178.68 A deleterious 
pathway deactivates the catalyst in the form of dianion 180, arising from deprotonation of bis-
osmate ester 179. This 18-electron complex is remarkably stable and resistant to hydrolysis, thus 
inhibiting product release and lowering catalyst turnover. Electron withdrawing groups on the 
substrate lower the pKa of complex 179, making it more susceptible to deprotonation even in the 
presence of a weak base such as N-methylmorpholine, the by-product of NMO re-oxidation. 
Acidic conditions thus suppress this unwanted side reaction and maintain the turnover of the 
catalyst.68 






Figure 29: Mechanism of dihydroxylation under homogenous Upjohn conditions 
 
In addition to its role as an acid buffer, citric acid can also chelate to osmium. In particular, this 
protects Os(VI) complexes from disproportionation to Os(VIII) and insoluble Os(IV) species 
which can occur under acidic conditions. The free carboxylic acids on the citrate also create a 
hydrophilic environment around osmium which accelerates the rate limiting hydrolysis of the 
osmate ester 182, thus avoiding the undesired secondary cycle. Under these conditions, the 
catalytic cycle can be further simplified (Figure 30).68 
 















































































































Other attempts at addressing the chemoselectivity issue included exploring reagents that were 
selective for electron deficient olefins. KMnO4 was identified as a suitable reagent due to its 
nucleophilic character. There have been several examples100 in the literature that demonstrate the 
chemoselective nature of KMnO4 and may even have marked improvement in yield compared to 
OsO4 (Scheme 41). Unfortunately, the use of KMnO4 with enoate 151 led to complex mixtures 
(Table 5, Entries 6-7).  
 
Scheme 41: Examples of permanganate-mediated dihydroxylations showing chemoselectivity for electron 
deficient olefins 
 
An alternative route for achieving enhanced chemoselectivity was to deprotect the PMB group 
(DDQ) and use the free OH group in 151 to direct the osmium reagent to the nearest olefin. 
Disappointingly, this approach did not lead to any improved selectivity for the lactone alkene 
over the vinyl iodide (Scheme 42). 
 
Reagents and conditions: (a) DDQ, pH 7 buffer, CH2Cl2, rt, 85%; (b) K2OsO42H2O, NMO, citric acid, THF, 
rt, 30% 
Scheme 42: Exploring the possibility of a hydroxyl-directed dihydroxylation of 151 
 
The π-face selectivity of the Upjohn dihydroxylation was accounted for with a model developed 
by Datta (Figure 31(a)).101 The lactone ring adopts a half-chair conformation 186 where the C15-
C18 sidechain shields the top face, hence favouring approach of the osmium reagent from below 
the ring. As the olefin has (E)-geometry, and hence two low energy conformers, the Houk 
model102 predicts that the allylic chiral centre at C24 does not exert any significant stereocontrol 
for the dihydroxylation.103 Through nOe studies, the relative configuration of C21 and C22 was 



















































Figure 31: Stereochemical rationalisation and proof of diol 174 
 
With all the requisite stereocentres installed for this fragment, greater attention was paid to the 
H19 resonance henceforth as this was one of the key signals used by Ardisson in their 
stereochemical assignment of this fragment. For example, H19 was observed to display a ddd 
splitting pattern (J = 11.5, 6.6, 3.7 Hz) in diol 174 that is more similar to natural hemicalide1 1 (J 
= 11.3, 7.5, 3.5 Hz) than Ardisson’s proposed fragment 33B (J = 13.2, 6.1, 3.9 Hz).33 This result 
was also consistent for all downstream intermediates, lending further support for the proposed 
reassignment of the 18,19-anti relationship by Ardisson-Cossy to 18,19-syn (vide infra). 
 
2.3.4 Completion of the C16-C28 Fragment 
 
To complete the C16-C28 fragment synthesis (Scheme 43) diol 174 was protected as a bis-TES 
ether 187 (TESOTf, imidazole) and the PMB group removed under mild oxidative conditions 
(DDQ). Alcohol 188 was then subjected to a Dess–Martin oxidation46 to prepare aldehyde 189 
and used immediately in a HWE reaction91 with β-ketophosphonate 190 using Ba(OH)2 to 
minimise the risk of epimerisation at C24. 
 
Reagents and conditions: (a) TESOTf, 2,6-lutidine, CH2Cl2, 0 °C, 88%; (b) DDQ, pH 7 buffer, CH2Cl2, rt, 
80%; (c) DMP, NaHCO3, CH2Cl2, rt; (d) 190, Ba(OH)2, THF, rt, then 189, THF/H2O, 0 °C ® rt, 80% over 
two steps; (e) Cu(OAc)2H2O, PPh3, TMDS, PhMe, rt, 67% 








































































In this manner, 191 was delivered as a single geometric (E) isomer from the HWE reaction. The 
choice of mild conditions (Ba(OH)2) in this case is particularly suited for the deprotonation of a 
β-ketophosphonate such as 190. Chelation of the metal ion to both the carbonyl and phosphonate 
oxygen atoms lowers the pKa of the methylene protons, thus facilitating anion formation.91 The 
mechanism of the HWE reaction is then analogous to the reaction described for triene 101, thus 
accounting for the high selectivity for the (E) isomer.  
 
Moving forward, the enone 191 was submitted to a Stryker’s reduction104 in order to furnish the 
full C16-C28 fragment 102. The reaction was investigated with several variations on how the 
copper-hydride complex is prepared. Using solid hexameric [PPh3CuH]6 gave the lowest yield, 
ostensibly due to the difficulty in preparing this reagent with the rigorous exclusion of air. An in 
situ formulation of the reagent as a solution105 (Cu(OAc)2, PPh3, TMDS) proved more robust and 
the copper species could be employed catalytically. Under these conditions, turnover of the 
catalytic cycle is achieved by reduction of the cuprate enolate 192 with TMDS to silyl enol ether 
193, thus regenerating the active copper (I) hydride species (Figure 32). 
 
Figure 32: Mechanism of the conjugate reduction of 191 to 102 
 
The conjugate reduction had been shown to proceed with modest yields (53%) and required 
further optimisation as 1H NMR analysis of the crude reaction mixture revealed several by-
products. Purification revealed at least one of the by-products to be 194 as a mixture of epimers at 
C27. This was further verified by showing that both isomers of 194 converged onto a single 
product upon oxidation (DMP46, NaHCO3). This suggests that TMDS is undergoing a competing 
1,2-reduction of enone 191, presumably occurring during the rate limiting catalyst turnover step. 
Employing stoichiometric amounts of copper alongside careful monitoring of the reaction 
improved the yield of ketone 102 to 67%. It is also possible that product 102 has undergone a 
similar 1,2-reduction, thus diminishing its yield, although this reduced product could not be 






























With these results, the synthesis of 102 (Scheme 44) has been achieved in 18 steps in the longest 
linear sequence with an overall yield of 4.4%. By using ketone ent-153 and aldehyde ent-154 
(both derived from Roche ester (R)-40), an analogous route (Scheme 45) was undertaken by Lam 
to deliver ent-102 in a similar yield.71 
  





Reagents and conditions: (a) LiAlH4, Et2O, 0 °C ® rt, 90%; (b) (COCl)2, DMSO, Et3N, CH2Cl2, –78 °C ® –
20 °C;  (c) PPh3, CBr4, CH2Cl2, 0 °C, then 156, –78 °C ® 0 °C, 77% over two steps; (d) n-BuLi, THF, –
78 °C; MeI, –78 °C, 92%; (e) Cp2ZrCl2, DIBAL, THF, 0 °C, then 158, 0 °C ® rt, then I2, –78 °C, 76%; (f) 
DDQ, pH 7 buffer, CH2Cl2, rt, 90%; (g) DMP, NaHCO3, CH2Cl2, rt, (h) 153, (–)-DIPCl, Et3N, Et2O, –78 °C 
® 0 °C, then 154, –78 °C, 70% over two steps; (i) TBSOTf, 2,6-lutidine, CH2Cl2, –78 °C, 95%; (j) LDA, 
EtOAc, THF, –78 °C, 97%; (k) HFpy, THF, 0 °C ® rt, 85%; (l) Ac2O, DMAP, PhH/py, reflux, 88%; (m) 
K2OsO42H2O (2 mol%), NMO, citric acid, t-BuOH/H2O/THF, rt, 5 h, 55%; (n) TESOTf, 2,6-lutidine, CH2Cl2, 
0 °C, 88%; (o) DDQ, pH 7 buffer, CH2Cl2, rt, 80%; (p) DMP, NaHCO3, CH2Cl2, rt; (q) 190, Ba(OH)2, THF, rt, 
then 189, THF/H2O, 0 °C ® rt, 80% over two steps; (r) Cu(OAc)2H2O, PPh3, TMDS, PhMe, rt, 67% 






































































































Reagents and conditions: (a) LiAlH4, Et2O, 0 °C ® rt, 76%; (b) (COCl)2, DMSO, Et3N, CH2Cl2, –78 °C ® –
20 °C; (c) PPh3, CBr4, CH2Cl2, 0 °C, then ent-156, –78 °C ® 0 °C, 80% over two steps; (d) n-BuLi, THF, –
78 °C; MeI, –78 °C, 91%; (e) Cp2ZrCl2, DIBAL, THF, 0 °C, then ent-158, 0 °C ® rt, then I2, –78 °C, 78%; (f) 
DDQ, pH 7 buffer, CH2Cl2, rt, 84%; (g) DMP, NaHCO3, CH2Cl2, rt, (h) ent-153, (–)-DIPCl, Et3N, Et2O, –
78 °C ® 0 °C, then ent-154, –78 °C, 62% over two steps; (i) TBSOTf, 2,6-lutidine, CH2Cl2, –78 °C, 97%; (j) 
LDA, EtOAc, THF, –78 °C, 97%; (k) HFpy, THF, 0 °C ® rt, 89%; (l) Ac2O, DMAP, PhH/py, reflux, 89%; 
(m) K2OsO42H2O (2 mol%), NMO, citric acid, t-BuOH/H2O/THF, rt, 5 h, 40%; (n) TESOTf, 2,6-lutidine, 
CH2Cl2, 0 °C, 88%; (o) DDQ, pH 7 buffer, CH2Cl2, rt, 80%; (p) DMP, NaHCO3, CH2Cl2, rt; (q) 190, Ba(OH)2, 
THF, rt, then ent-189, THF/H2O, 0 °C ® rt, 80% over two steps; (r) Cu(OAc)2H2O, PPh3, TMDS, PhMe, rt, 
70% 










































































































CHAPTER THREE: FRAGMENT UNION AND  
NMR CORRELATIONS  
 
3.1 Stereochemical Studies of the C1-C15 Fragment 
 
Although the synthesis of the C1-C15 fragment 101 had been carried out with excellent 
diastereoselectivity at every step, we wished to investigate how well the spectroscopic data for 
this truncate might fit with the natural product. To this end, the bis-TES protecting groups were 
removed with HFpy/py to give diol 195 in 75% yield for NMR correlation studies (Scheme 46). 
This reaction also served as a model study for the global deprotection later. 
 
Reagents and conditions: (a) HFpy/py, THF, 0 °C ® rt, 75% 
Scheme 46: Deprotection of the C1-C15 fragment 101 
 
Although natural hemicalide contains a carboxylic acid at C1, previous work by Ardisson cast 
doubt on this. A possible ‘salt effect’ was proposed which was responsible for distorting the 
chemical shifts of the C1-C7 trienic signals.32 Ardisson also showed that this perturbation did not 
extend into the aliphatic region hence the C1 methyl ester in diol 195 was not hydrolysed and the 
entire C1-C7 region was also excluded from spectroscopic comparison with natural hemicalide. 
In addition, resonances arising from C14 and C15 were ignored due to their proximity to the 
truncated end as the vinyl iodide functionality bears little resemblance with the natural product. 
 
A comparison of the 13C NMR spectrum of the C1-C15 fragment 195 (Figure 32) was 
inconclusive as most resonances had relatively large deviations and it appeared to have worse 
homology with hemicalide than the Ardisson fragment 65.35 Fortunately, in the 1H NMR 
spectrum, fragment 195 correlated closely with hemicalide and also the Ardisson fragment 65 
though notable exceptions were observed at H11 and H13. The difference at H13 could be 
attributed to the proximity to vinyl iodide in fragment 195, a major structural difference 
compared to the diene present in hemicalide. The deviation in chemical shift at H11 was 
concerning initially, but there was strong confidence in the assigned configuration at this centre 
because of the Mosher ester analysis performed earlier. In addition, the multiplicity of H11 in 























As the spectra are recorded in d4-MeOD, we can likely rule out an internal hydrogen-bonding 
network enabling hemicalide to fold upon itself. This leaves a conformational effect as the most 
plausible reason for the chemical shift deviation of H11. The presence of the α,β-
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The availability of intermediates 101 and 195 provided an opportunity to carry out model studies 
on the methyl ester hydrolysis at the C1 carboxyl terminus (Scheme 47). The use of KOTMS was 
pursued initially as a mild alternative to an alkali metal hydroxide-mediated hydrolysis but 
complex reaction profiles were produced with both 196 and 197. Pleasingly, Ba(OH)28H2O-
mediated hydrolysis delivered clean conversion of the methyl esters 101 and 197 to carboxylic 
acids 198 and 199 respectively as judged by 1H NMR spectroscopic analysis of the crude 
products. 
 
Reagents and conditions: (a) KOTMS, THF, rt; (b) Ba(OH)28H2O, MeOH, rt 
Scheme 47: Model studies of methyl ester hydrolysis in intermediates 101 and 195 
 
3.2 Stereochemical reassignment of the C16-C28 fragment 
 
The stereochemical reassignment of the C16-C28 region of hemicalide was investigated by using 
174 (Scheme 48) as a branchpoint in the synthesis. This also allowed vinyl iodide 174 to be used 
as a model system for studying the Stille coupling70 in our planned synthesis. Earlier work by 
MacGregor37 demonstrated that although vinyl trimethylstannane 200 was accessible via a Wulff-
Stille reaction106 with a 67% yield, it was highly unstable and would decompose faster than it 
could be used in the Stille coupling. As such, vinyl stannane 201 was selected as the coupling 
partner instead. This was prepared from 114 via a lithium-halogen exchange (NaH, t-BuLi) 
followed by trapping with SnBu3Cl (60%). To ensure the hydroxyl group does not quench any 
lithiated species under the reaction conditions, 114 was first deprotonated with NaH. 
 
Reagents and conditions: (a) NaH, 114, THF 0 °C, then t-BuLi, SnBu3Cl, –78 °C, 60% 
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The Stille coupling represents a reliable method of joining two fragments because 
organostannanes exhibit wide functional group tolerance and good reactivity with electrophiles. 
Further advancements to this protocol have been developed over the years, particularly to address 
the rate limiting transmetallation step in the catalytic cycle (Figure 34). The rate acceleration 
observed when copper (I) salts are added is well documented and is attributed to a tin-copper 
exchange to generate a more nucleophilic organocuprate species. However, the positive influence 
of copper is limited by the reversible nature of the tin-copper exchange so a tin scavenger is 
required to drive the equilibrium to completion. Fluoride sources have been proposed as a tin 
scavenger by Baldwin but face severe restrictions in their utility due to their incompatibility with 
silyl protecting groups.107 Fürstner reported that [NBu4][Ph2PO2] was an effective substitute for 
fluoride, enabling the Stille coupling to be conducted under essentially neutral conditions.108 This 
modified protocol was successfully employed in late stage fragment couplings of several natural 
products such as leiodermatolide,75 iejimalide B109 and ouabagenin.110 Pleasingly, these 
conditions were also successful in the cross coupling of vinyl iodide 174 and vinyl stannane 201 
in a 1:1 ratio to give the (E, E) diene 202 in 74% yield (Scheme 49). The stoichiometry in the 
model reaction boded well for the fragment coupling in the full system as it enabled both late-
stage intermediates to be used efficiently without wastage.  
 
Figure 34: Mechanism of the Stille coupling with modifications by Fürstner  
 
 
Reagents and conditions: (a) Pd(PPh3)4, CuTC, [NBu4][Ph2PO2], DMF, 0 °C, 74% 


















































Initial NMR studies of diene 202 were hampered by the fact that the H19 signal was obscured by 
the methylene protons of the PMB protecting group in d4-MeOD. Over concerns that allylic 
oxidation at C13 will outcompete the deprotection at C24, as observed during the Paterson 
group’s total synthesis of the aplyronines, we decided not to remove the PMB group with 
standard DDQ conditions. Pleasingly, by irradiating H20 in an nOe experiment, the enhanced 
H19 resonance could be clearly seen as a ddd (Figure 35). 
 
Figure 35: Revealing the shape of the H19 resonance in an nOe experiment by irradiating H20  
 
The NMR spectra of diene 202 were compared against hemicalide1 and the Ardisson fragment35 
65 as well (Figure 36). As diene 202 lacked the C1-C15 region of the natural product, it was not 
surprising that the molecule appeared to be a poorer fit with hemicalide compared to the Ardisson 
fragment 65 at positions C14-C18. Within the lactone ring, diene 202 exhibited an improved 
correlation in 1H NMR chemical shifts for H19 and H22 against Ardisson’s intermediate 65. 
These were considered diagnostic signals in their stereochemical assignment. With Ardisson’s 
truncate 65, H19 and H22 showed chemical shift deviations of 0.12 and –0.10 ppm respectively 
while the corresponding resonances in diene 202 had much smaller differences of –0.01 and –
0.04 ppm. 
 
In addition, the peak shape and J values of H19 (ddd, J = 11.6, 7.7, 3.7 Hz) in diene 202 strongly 
agree with the reported values for natural hemicalide (ddd, J = 11.3, 7.5, 3.5 Hz), unlike the 
Ardisson fragment 65 (ddd, J = 13.2, 6.1, 3.9 Hz). Based on these observations, the 
stereochemical relationship between C18 and C19 was thus confidently reassigned from anti to 
syn in support of the earlier computational work.36 
 
Ardisson’s pursuit of an 18,19-anti relationship can be understood as a result of the misleading 
studies conducted on fragments that were structurally different from the natural product. These 
model candidates terminated in an oxy-methylene carbon at C17 instead of a diene which is 
present in hemicalide (See Chapter 1.4.2).33 Following our group’s published reassignment of the 





18,19-syn relationship,36 the Ardisson–Cossy team acknowledged that their 18,19-anti 
intermediates did not correlate well with hemicalide and updated their synthetic route to reflect 
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3.3 Fragment Union 
 
3.3.1 Access to Vinyl Stannanes via Lithium-Halogen Exchange 
 
The failure to install an organotin handle on the C16-C28 fragment reliably by MacGregor, 
together with the success of synthesising vinyl stannane 201 via a lithium-halogen exchange, 
prompted a change in our fragment coupling strategy. 
 
To avoid chemoselectivity issues arising from a lithium-halogen exchange approach in the C1-
C15 fragment, the vinyl stannane would have to be installed before the C1 methyl ester is 
appended via the HWE reaction.47 Using the conditions employed previously, vinyl iodide 144 
was transformed into vinyl stannane 203 by first deprotonating with NaH, then carrying out a 
lithium-halogen exchange with a SnBu3Cl trap. This step suffered greatly from the formation of 
olefin 204 as an inseparable by-product (Scheme 50). The amount of olefin 204 formed was 
inconsistent and confounded attempts to diagnose the problem as arising from proto-
destannylation of the product or quenching of the in situ generated vinyl lithium species. 
 
Reagents and conditions: (a) NaH, 144, THF 0 °C, then t-BuLi, SnBu3Cl, –78 °C, 59% 
Scheme 50: Preparing vinyl stannanes 203 via lithium-halogen exchange 
 
The next step in oxidising alcohol 203 to aldehyde 205 also proved to be more problematic than 
expected. The various conditions screened (Table 6) either led to poor conversion, further proto-
destannylation leading to aldehyde 206 or epimerisation at C8. Due to these disappointing results, 
the idea of advancing intermediates bearing the vinyl stannane functional group towards the 
























Entry Conditions Result 
1 DMP, NaHCO3 
Full conversion; extensive proto-destannylation; 
no epimerisation 
2 DMSO, Et3N, SO3py 
Incomplete conversion; some proto-destannylation; 
no epimerisation 
3 TEMPO, BAIB Incomplete conversion; moderate proto-destannylation; some epimerisation 
 
Table 6: Conditions examined for the oxidation 203 to 205 
 
Given the apparent sensitivity of the vinyl stannane functional group, intermediate 203 was then 
submitted to a Stille coupling108 with the C16-C28 fragment 102 immediately. Gratifingly, this 
cross coupling proceeded smoothly to give 13,18-syn diene 207 with 78% yield (Scheme 51). 
Any proto-destannylated by-product 204 from the lithium-halogen exchange step did not interfere 
in the Stille coupling. It was envisaged that by-product 204 could be recycled by subjecting it to a 
Heck reaction111 with vinyl iodide 102 to generate the desired 13,18-syn diene 207. However, this 
idea was not explored further due to the scarcity of 204.  
 
The C7 alcohol was then oxidised with Dess–Martin periodinane46 (99%) and used immediately 
in a HWE reaction47 with phosphonate 104 to yield the complete 13,18-syn diastereomer of the 
C1-C28 truncate 99 with a yield of 54% (Scheme 51). Despite employing an excess of the 
phosphonate, no reaction was observed at the C27 ketone under the reaction conditions. By 
repeating the process with ent-203, the 13,18-anti series of intermediates could be obtained in an 


























Reagents and conditions: (a) Pd(PPh3)4, CuTC, [NBu4][Ph2PO2], DMF, 0 °C, 78%; (b) DMP, NaHCO3, 
CH2Cl2, rt, 99%; (c) 104, LDA, THF, –78 °C ® –40 °C, 52%; (d) Pd(PPh3)4, CuTC, [NBu4][Ph2PO2], DMF, 
0 °C, 74%; (e) DMP, NaHCO3, CH2Cl2, rt, 99%; (f) 104, LDA, THF, –78 °C ® –40 °C, 55% 
Scheme 51: Successful Stille coupling and HWE olefination to produce C1-C28 truncates 99 and 100 
 
This represents the first successful attempt at synthesising the two possible diastereomers, 13,18-
syn 99 and 13,18-anti 100, of the full C1-C28 region of hemicalide. However, this was not the 
most efficient method of fulfilling this objective. As the longest linear sequence involves the 
C16-C28 fragment 102, stepwise elaboration of the C7-C28 fragments 207 and 208 makes the 




























































































3.3.2 Access to Vinyl Stannanes via Wulff–Stille Reactions 
 
To maximise convergency, the Stille coupling should be performed last in the fragment coupling 
sequence. This requires the vinyl stannane to be installed on the C1-C15 fragment 101 in the 
presence of the C1 methyl ester. Alternatively, a more robust replacement for trimethylstannane 
209 had to be synthesised. As such, the Wulff–Stille reaction106 was re-examined in both cases to 
see if this was possible. 
 
Entry Transformation Conditions Result 
1 102 ® 210 Pd(PPh3)4, LiCl, (Bu3Sn)2 No reaction 
2 102 ® 210 Pd(PPh3)2Cl2, Li2CO3, (Bu3Sn)2 No reaction 
3 101 ® 212 Pd(PPh3)2Cl2, Li2CO3, (Bu3Sn)2 No reaction 
4 101 ® 211 Pd(PPh3)2Cl2, Li2CO3, (Me3Sn)2 Full conversion, 70% yield 
 
Table 7: Exploring different vinyl iodide substrates and conditions for the Wulff–Stille reaction 
 
Tributylstannane derivatives were considered as a replacement for trimethylstannes due to their 
increased stability. The success of intermediates 201 and 203 in their respective Stille couplings 
showed that they were reactive enough to be viable coupling partners. Unfortunately, the use of 
(Bu3Sn)2 instead of (Me3Sn)2 in the Wulff–Stille reaction106 of 101 or 102 simply returned the 
starting material unchanged (Table 7, Entries 1-3). Examples in the literature for this type of 
reaction invariably used 1,2-disubstituted olefins. Ostensibly, the Me group at C14 presents 
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Having exhausted various methods of accessing the vinyl tributylstannane 212, the only recourse 
left was installing a vinyl trimethylstannane on the C1-C15 fragment 101. Gratifingly, 
trimethylstannane 211 was synthesised in good yield (Table 7, Entry 4) and could be stored in 
the freezer for a reasonable length of time without degradation. 
 
Due to insufficient quantities of the C16-C28 fragment 102, the remainder of the fragment union 
was continued with the enantiomeric fragment ent-102 prepared by Lam. This did not affect any 
subsequent conclusions as we are only investigating the relative configuration between the C8-
C13 and C18-C24 stereoclusters. 
 
Reagents and conditions: (a) Pd(PPh3)4, CuTC, [NBu4][PhPO2], DMF, 0 °C, 70%; (b) Pd(PPh3)4, CuTC, 
[NBu4][PhPO2], DMF, 0 °C, 72% 
Scheme 52: Final revised fragment union to produce C1-C28 truncates ent-99 and ent-100 
 
The critical Stille coupling of vinyl iodide ent-102 and vinyl stannane 211 was carried out under 
Fürstner conditions108 previously used to synthesise dienes 207 and 208. This delivered the 
13,18-anti diastereomer ent-100 of the C1-C28 truncate in good yield (72%). This result was 
highly reproducible and worked well on various scales (up to 0.150 mmol). By selecting the 
appropriate enantiomer of vinyl stannane 211, both the 13,18-syn and 13,18-anti diastereomers of 
the C1-C28 truncate, ent-99 and ent-100 respectively, were successfully prepared by Lam71 and 
























































At this point, it was noted that the 13,18-syn and 13,18-anti diastereomers did exhibit notable 
differences in their 1H and 13C NMR spectra when recorded in CDCl3 despite the distal 1,6-
related nature of the two stereoclusters. Obviously, a meaningful comparison can only be made 
with the protecting groups removed and with the appropriate solvent (d4-MeOD) but, at the time, 
it strengthened our confidence in this synthesis-enabled stereochemical assignment via NMR 
studies. 
 
3.4 Derivatisation and NMR Studies 
 
At this point, the revised fragment union using an elaborate Stille coupling108 had now reliably 
delivered the full carbon chain in the C1-C28 region of hemicalide. While it appeared tempting to 
subject ent-99 and ent-100 to a global deprotection, this was not done for two reasons. Firstly, the 
natural product does not feature a ketone at C27 so these truncates would not be suitable for 
NMR correlation studies.1 More importantly, MacGregor had demonstrated that without a 
protecting group, the C21 hydroxyl group would spontaneously hemiketalise37 with the C27 
ketone, leading to a completely unrelated structure 213 that would complicate our spectroscopic 
studies (Scheme 53). 
 
Reagents and conditions: (a) HFpy, THF, 0 °C ® rt, 50% 
Scheme 53: Hemiketalisation during MacGregor’s attempt to deprotect C16-C28 fragment 102 
 
To overcome these issues, the C27 ketone in ent-100 was first reduced to 214 (NaBH4). In the 
absence of any significant stereocontrol elements, a 2:1 mixture of epimers was obtained. To 
simplify NMR interpretation, a CBS reduction112 was also attempted on the C16-C28 fragment 
102 as a model reaction but a similar d.r. was observed, indicating that reagent control is not 
possible due to poor steric differentiation in the ketone. Methylation of 214 (Meerwein salt, 
Proton Sponge®, 4A MS) occurred uneventfully to give 215 in good yield. A similar set of 
reactions was also carried out by Lam71 in the 13,18-syn series beginning with ent-99 to give 216 




















Cossy noted that in a system such as 38A (Figure 17), epimers at this distal stereocentre were 
expected to display quasi-identical NMR spectra.38 Indeed, the C27 epimers of 215 and 217 
exhibited signals that were indistinguishable in the C1-C24 region. While there were differences 
within the C25-C28 region due to their proximity to the epimeric C27 stereocentre, this region of 
the molecule was deemed less diagnostic due to its proximity to the truncated end and thus 
excluded from any NMR correlation studies. 
 
Reagents and conditions: (a) NaBH4, MeOH, rt, 92%; (b) Me3OBF4, Proton Sponge®, 4Å MS, CH2Cl2, rt, 
68%; (c) NaBH4, MeOH, rt, 95%; (d) Me3OBF4, Proton Sponge®, 4Å MS, CH2Cl2, rt, 87% 
Scheme 54: Transforming the C27 ketone into a methyl ether in 215 and for 217 for further studies 
 
 
Henceforth, the stage was set for examining the global deprotection. Previously, model studies 
for the deprotection had been conducted on the C1-C15 fragment 101 and the C16-C28 fragment 
102 by the author (Scheme 46) and MacGregor37 (Scheme 53) respectively. These results 
suggested that HFpy was a suitable reagent to remove all four TES groups from the C1-C28 


























































































diastereomer 215, no further conversion could be achieved by extending the reaction time. 
Disappointingly, increasing the concentration of HFpy only led to degradation of the whole 
molecule. 
 
Further investigation by Lam revealed an interesting observation that the C11 and C13 TES 
groups were orthogonal to the C21 and C22 TES groups.71 Various conditions (HFpy, 
HF/MeCN, TsOH, PPTS, TBAF, TASF) were screened on the constituent fragments ent-211 and 
ent-102. The results showed that when one reagent was successful at deprotecting one pair of the 
TES groups, it was either inert to the other or would cause degradation. After extensive trials, a 
two-step sequence was established where the C21 and C22 TES groups were first removed with 
TASF and the crude mixture submitted directly to HFpy/py to furnish the 13,18-syn tetraol 218. 
Pleasingly, this newly developed protocol also worked for the 13,18-anti series to yield the 
13,18-anti tetraol 219. Finally, both methyl esters 218 and 219 were subjected to a basic 
hydrolysis with Ba(OH)28H2O (Scheme 55). A low yield was noted for both the 13,18-syn and 
13,18-anti acids 220 and 221 respectively; this was most likely due to their increased hydrophilic 
character leading to material losses during the aqueous work-up. 
 





Reagents and conditions: (a) TASF, THF/DMF, 0 °C ® rt, then HFpy/py, THF, 0 °C ® rt, 67%; (b) 
Ba(OH)28H2O, MeOH, rt, 50%; (c) TASF, THF/DMF, 0 °C ® rt, then HFpy/py, THF, 0 °C ® rt, 95%; (d) 
Ba(OH)28H2O, MeOH, rt, 50% 
Scheme 55: Global deprotection of C1-C28 truncates arriving at free acids 220 and 221 
 
Although diastereomers ent-99 and ent-100 exhibited clear NMR chemical shift differences in 
CDCl3, the target compounds 220 and 221 showed more subtle differences in d4-MeOD, with the 
largest differences not exceeding 0.04 ppm in 1H NMR or 0.6 ppm in 13C NMR. Overall, the 
13,18-syn acid 220 displayed a remarkably good fit with 0 ppm deviations in the majority of its 
1H and 13C resonances. Resonances that displayed poor correlations in the constituent C1-C15 
fragment 101 or C16-C28 fragment 102 now showed significant improvements. This was 
particularly evident for H11 (DδH –0.19 ® 0 ppm, DδC –1.4 ® 0 ppm), H15 (DδH –0.08 ® 0 ppm, 
DδC –2.1 ® 0 ppm) and C20 (DδC 1.7 ® 0.1 ppm) amongst other examples. The extraordinarily 
good NMR correlations of diastereomer 220, particular in the 1H NMR spectrum, strongly 

























































































Figure 37: NMR correlations of the 13,18-syn truncate 220 and 13,18-anti truncate 221 compared against 



































































































13,18-anti acid 221 13,18-syn acid 220 Subunit 94




While the 13,18-anti diastereomer 221 was not as good a fit as its syn counterpart, the chemical 
shift differences for each resonance were still much smaller than the corresponding signal in the 
uncoupled fragments. This lends further support to the idea that the overall conformation of 
hemicalide is dependent on the presence of certain structural features. In addition, the 13,18-anti 
diastereomers 221 also correlates well with the Ardisson–Cossy fragment63 94, featuring the 
revised 18,19-syn relationship, an indirect verification of the anti relationship between C13 and 
C18 in both compounds. 
 
As mentioned in Chapter 1.4.1, Ardisson raised the prospect that natural hemicalide was isolated 
as a carboxylate salt with an unknown counterion instead of a free acid.32 This was based on the 
finding that carboxylate 31 and carboxylic acid 30 have a similar 1H NMR deviation profile as 
fragment 29A and hemicalide in the C1-C7 trienic region. To investigate this claim, carboxylates 
222 and 223 were also studied by deprotonating carboxylic acids 220 and 221 with Na2CO3 
(Scheme 56). 
 
Reagents and conditions: (a) Na2CO3, d4-MeOD, rt, 99%; (b) Na2CO3, d4-MeOD, rt, 99% 
Scheme 56: Deprotonation of C1-C28 truncates 220 and 221 
 
Like the carboxylic acids 220 and 221, the C8-C24 region was first studied in the carboxylate 
salts 222 and 223. The sum of errors, as well as the maximum error, for the 1H and 13C NMR 
spectra of carboxylates 222 and 223 were tabulated (Table 8) and compared against the known 
acids 220, 221 and 94. Once again, the 13,18-syn carboxylate 222 emerged as the better match to 
natural hemicalide compared to the 13,18-anti carboxylate 223 (Entry 2 vs. 4). However, it was 
also clear that the anion had a worse correlation than the free acid for both the 13,18-syn and 
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Entry Compound Sum |ΔδH| Max |ΔδH| Sum |ΔδC| Max |ΔδC| 
1 13,18-syn acid 220 0.05 0.01 0.8 0.1 
2 13,18-syn salt 222 0.08 0.02 1.7 0.2 
3 13,18-anti acid 221 0.22 0.04 4.1 0.6 
4 13,18-anti salt 223 0.22 0.04 4.3 0.7 
5 Cossy acid 94 0.26 0.04 3.8 0.5 
 
Table 8: Tabulated values for the sum of errors and maximum errors in the 1H and 13C NMR spectra of 





Figure 38: NMR correlations of the 13,18-syn acid 220, 13,18-syn salt 222, 13,18-anti acid 221 and 
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The electronic properties of the C1 carboxyl group had a substantial influence on the chemical 
shifts of C1-C7 but otherwise did not significantly affect the resonances from C8 onwards. If only 
considering the C1-7 region, it would appear that neither 13,18-syn carboxylate 222 nor 13,18-
anti carboxylate 223 correlate well with natural hemicalide, with both compounds performing 
worse than the carboxylic acids 220 and 221 again (Figure 38). 
 
Lam proposed that the precise chemical shifts of the C1-C7 region depended on the protonation 
state of the free acid.71 Even the slightest trace of acetic acid, which was used as an eluent 
additive during chromatographic purification of the free acid, could cause the 1H NMR 
resonances to drift in an irreproducible fashion. 
 
When free acids 220 and 221 were in a strongly acidic environment, such as post-HCl workup, or 
fully deprotonated with Na2CO3, all resonances appeared sharp. When the spectra were recorded 
post-chromatography, the signals were sometimes observed to broaden, particularly in the 13C 
NMR spectra for C1, C2 and C3 in acid 220.71 This was attributed to the rapid auto-ionisation 
equilibrium of the free acid. 
 
These results suggest that the NMR spectra of natural hemicalide were in fact acquired as a 
carboxylic acid rather than the carboxylate salt as suggested by Ardisson. However, the 
sensitivity of the resonances relating to C1-C7 towards the pH of the NMR sample makes this 




The revised fragment coupling strategy now features a convergent synthetic route to the C1-C28 
intermediate ent-99 spanning 19 steps in the longest linear sequence with an overall yield of 2.9% 
(Scheme 52).113 This is a productive intermediate that can be used in a planned boron-mediated 
aldol reaction to forge the C28-C29 bond to assemble the full carbon and oxygen skeleton of 
hemicalide. 
 
Various stereochemical and structural corrections have also been made in this region of 
hemicalide with the aid of NMR spectroscopic analysis. Most notably, the 18,19-anti relationship 
has been reassigned to 18,19-syn and the 13,18-anti relationship also reassigned to 13,18-syn as 
indicated in structure 220. Furthermore, the C1 carboxyl group has also been reassigned from a 
carboxylate salt to a carboxylic acid (Figure 39).113 




























CHAPTER FOUR: BEYOND THE C1-C28 REGION 
 
4.1 DP4 Analysis and Application to the C26-C35 Region 
 
The use of ab initio calculations of NMR chemical shifts has been central to the Paterson group’s 
approach towards the total synthesis of hemicalide. In particular, it was instrumental in 
identifying the misassigned 18,19-anti stereochemistry in the absence of any further experimental 
evidence at the time.36 
 
Previous attempts by MacGregor to study the C26-C35 region of hemicalide were met with 
inconclusive results.37 The low quality of the experimental NMR data has been suggested as one 
possible reason. In the 1H NMR spectrum of natural hemicalide, there is a broad 22H multiplet 
spanning 2.02-1.22 ppm, encompassing H26, H28, H30, H32, H33.1 All of these signals were 
recorded as 1.62 ppm, the midpoint of the multiplet, as the experimental value. Without access to 
various 2D NMR spectra of hemicalide, it is not possible to refine their chemical shifts further. 
This has consequences for the scaling factor employed to arrive at the corrected predicted 
chemical shift values.26 The inadequacies of the experimental data can be mitigated by 
synthesising a library of fragments (Figure 40) alongside their virtual counterparts. While it still 
may not be possible to completely resolve the afflicted resonances, we expect to be able to find 
more accurate values for their chemical shifts, hence improving the scaling factor used in the 
computational work to refine the DP4 predictions for this region. 
 
Figure 40: Library of fragments for the C26-C35 region of hemicalide 
 
Synthesising a library of fragments in this region of hemicalide also provides an opportunity to 
study the planned aldol reaction that will be used to couple the C1-C28 fragment ent-99 to the 
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4.2 Towards the synthesis of a library of fragments for the C26-C35 region 
 
The synthesis of the library fragments commenced with the lithium aldol reaction of ethyl acetate 
and methacrolein to give racemic aldol adduct 224 (Scheme 57). The allylic alcohol functionality 
in 224 enables a kinetic resolution114 via a Sharpless asymmetric epoxidation115 to obtain 
enantioenriched 224 if required. However, this was not pursued as the DP4 analysis only 
distinguishes between diastereomers but not enantiomers. Following a silyl protection of the C31 
hydroxyl group (TBSCl, imidazole), a controlled reduction of ester 225 to aldehyde 226 with 
DIBAL was carried out at –78 °C (84% over two steps). 
 
Reagents and conditions: (a) LDA, EtOAc, THF, –78 °C, then methacrolein, –78 °C, 93%; (b) TBSCl, 
imidazole, CH2Cl2, rt, 88%; (c) DIBAL, CH2Cl2, –78 °C, 95% 
Scheme 57: Synthesis of aldol adduct 226 from aldol adduct 224 
 
By using the silyl enol ether derived from acetone as a surrogate for the C1-C28 truncates, a 
Mukaiyama aldol reaction116 with aldehyde 226 was investigated. The use of BF3Et2O delivered 
the presumed 1,3-anti product 227 (vide infra) with a d.r. of 5:1 in 78% yield (Table 9, Entry 1). 
Lowering the temperature to –100 °C did not improve the diastereoselectivity (Entry 2). Other 
Lewis acids were also screened for the Mukaiyama aldol reaction but none were superior to 
BF3Et2O in terms of stereoselectivity (Entries 3-5). 
 
Non-Mukaiyama aldol conditions were also investigated in parallel. The use of LDA gave a 
poorer d.r. than BF3Et2O, while a boron-mediated aldol had the lowest d.r. and in the opposite 
sense as well (Table 9, Entries 6-7). The epimeric products 227 and 228 could not be separated 
at this stage nor any point further downstream. With this in mind, the use of chiral Ipc ligands for 
the aldol reaction may be required when incorporating this fragment coupling strategy into the 
























Entry M Conditions Temperature Result (227:228) 
1 SiMe3 BF3Et2O, –78 °C d.r. 5:1 
2 SiMe3 BF3Et2O –100 °C d.r. 5:1 
3 SiMe3 TiCl4 –78 °C d.r. 3:1 
4 SiMe3 Me2AlCl –78 °C d.r. 2:1 
5 SiMe3 MeAlCl2 –78 °C d.r. 2:1 
6 Li LDA –78 °C d.r. 4:1 
7 BCy2 Cy2BCl, Et3N –78 °C d.r. 1:2 
 
Table 9: Conditions examined for the aldol reaction with aldehyde 226 
 
As aldol adduct 227 was formed as a racemate, the Mosher ester analysis81–83 could not be used to 
verify the configuration of C29. Instead, the stereochemistry of the aldol adduct 227 was probed 
by deprotecting the TBS group to trigger in situ cyclisation (Scheme 58). The configuration at 
C29 could then be studied through the relevant 1H–1H coupling constants and nOe interactions in 
the expected hemiacetals 229 and 230. Disappointingly, various attempts to do so either led to 
complex mixtures (aq. HCl or HFpy/py) or the formation of acetal 231 as a single diastereomer 
(HC(OMe)3, CSA, MeOH). The stereoconvergence can be rationalised by a rapid and reversible 
E1cb/conjugate addition of MeOH prior to acetal formation, leading to 231 as the thermodynamic 
product. 
 
Reagents and conditions: (a) HC(OMe)3, CSA, MeOH, rt; (b) HCl (aq.), THF, rt;  
(c) HFpy/py, THF, rt 
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The results of the aldol reaction screening indicate that an open transition state, by employing 
Mukaiyama conditions, offers the best diastereoselectivity. Despite a failure to secure definitive 
proof of the C29 stereochemistry, it was assumed that the 1,3-anti stereoinduction was in 
accordance with the Evans polar model (Scheme 59).117 The reactive conformer for the aldehyde 
has the OTBS group pointing away from the carbonyl to oppose its dipoles, where TS-XVIII is 
the lower energy transition state by having the small H group at the β position point into the 
carbonyl, leading to 227 as the major product. The expected anti diastereoselectivity is in 
agreement with various examples in the literature, such as Evans’ stereochemical studies117 on 
232 and 233 as well as Hsung’s synthesis118 of intermediates 234 and 235 while investigating 
spirastrellolide A  (Scheme 60). 
 
Scheme 59: Evans polar model for the Mukaiyama aldol reaction of aldehyde 226 
 
 
Scheme 60: Examples of diastereoselective Mukaiyama aldols operating solely under 1,3-stereoinduction  
 
Aldol adduct 227 could be elaborated in two complementary ways to obtain either a 1,3-syn diol 
or 1,3-anti diol. By performing a Narasaka reduction119 (Cy2BCl, LiBH3(OMe)),120 1,3-syn diol 





















































P = TBS  234, 24% yield, d.r. 7:1
P = PMB 235, 60% yield, d.r. 3:1
P = TBS  232, 84% yield, d.r. 4:1
P = PMB 233, 91% yield, d.r. 11:1
1,3-anti
1,3-anti




hydroxyl group and the ketone, allowing the molecule to adopt a half-chair conformation in TS- 
where hydride delivery is expected to occur from an axial approach. 
 
Reagents and conditions: (a) Cy2BCl, Et3N, THF, –78 °C, then LiBH3OMe, –78 °C ® 0 °C, 82% 
Scheme 61: Narasaka reduction of aldol adduct 227 
 
In contrast, submitting aldol adduct 227 to an Evans-Tischenko reduction121 (SmI2, EtCHO) 
followed by ester cleavage (K2CO3, MeOH) furnished the 1,3-anti diol 237 with a d.r. of 10:1. 
The active catalytic species is believed to be a Sm(III) species 238 arising from a pinacol reaction 
between EtCHO and SmI2. The free hydroxyl group then forms a hemiacetal with EtCHO and 
chelates to the Sm Lewis acid, leading to a highly organised transition state TS-XXI with all 
substituents in the equatorial position. This allows for an intramolecular delivery of hydride to 
account for the anti diastereoselectivity (Scheme 62). 
 
Reagents and conditions: (a) SmI2, EtCHO, THF, rt; (b) K2CO3, MeOH, rt, 89% over two steps 
Scheme 62: Evans-Tischenko reduction of aldol adduct 227 followed by acyl cleavage 
 
By forming acetonides 239 and 240, the relative configuration of diols 236 and 237 could be 
confirmed with the Rychnovsky method (Scheme 63).122,123 1,3-syn acetonides are known to take 
up a chair conformation with one of the acetal methyl groups axial and the other equatorial. 
These methyl groups are expected to have different 13C NMR chemical shifts (ca. 20 ppm and 30 
ppm respectively). In contrast, 1,3-anti acetonides adopt a twist-boat conformation where both 
acetal methyl groups are in quasi-identical environments, hence displaying similar 13C chemical 
shifts (ca. 24 ppm). Inspection of the 13C NMR of acetonides 239 and 240 indicated resonances 
that are characteristic of their respective syn and anti stereochemistry, thus validating the 
diastereoselective nature of the Narasaka reduction119 and the Evans-Tischenko reduction.121 
















































uneventfully to give 241 and 242 respectively to set the stage for chain extension beyond C33 
(Scheme 63). 
 
Reagents and conditions: (a) PPTS, CMe2(OMe)2, rt, 95%; (b) NaH, THF, 0 °C, then MeI, 0 °C ® rt, 93%; 
(c) PPTS, CMe2(OMe)2, rt, 96%; (d) NaH, THF, 0 °C, then MeI, 0 °C ® rt, 90% 
Scheme 63: Formation of acetonides 239 and 240 and bis-methyl ethers 241 and 242 
 
It was envisaged that a hydroboration could be used to configure the final stereocentre in this 
fragment as well as provide a borane handle for a subsequent sp2-sp3 Suzuki coupling.56 This is 
an attractive solution for many challenging natural product syntheses for its reliability. First 
discovered by Suzuki and Miyaura in 1986, this palladium-catalysed union of alkyl boranes with 
vinyl halides is hailed for its chemoselectivity and mildness, including tolerance of aqueous 
conditions. The alkyl borane partner can be readily accessed via hydroboration of an olefin and 
telescoped into the Suzuki coupling without isolation. This was successfully carried out in 
Danishefsky’s synthesis124 of epothilone A to generate intermediate 245 (via vinyl iodide 243 and 
olefin 244) and Paterson’s second-generation synthesis125 of spirastrellolide A methyl ester 














































Scheme 64: Examples of a two-stage hydroboration-Suzuki coupling in total synthesis 
 
The mechanism is thought to conform to the general catalytic cycle seen in palladium-catalysed 
cross couplings, involving the sequence of oxidative addition, transmetallation and reductive 
elimination (Figure 41). The Suzuki coupling is unique by requiring a base to activate the boron 
partner via a tetrahedral ‘ate’ complex, thus facilitating transmetallation. 9-BBN is an excellent 
choice of borane for the two-stage hydroboration-Suzuki coupling as its steric bulk enhances the 
regioselectivity of the hydroboration while the secondary alkyl ligands on boron transmetallate 
more slowly than the desired primary alkyl group. 
 
Like all sp2-sp3 cross couplings, the sp3 component is prone to β-hydride elimination (Figure 41). 
This can be overcome by employing the dppf ligand to accelerate the rate of reductive 
elimination relative to β-hydride elimination. The ligand’s large bite angle also enforces a cis 













1. 243, 9-BBN, THF
2. PdCl2(dppf) (10 mol%), 
    Ph3As (10 mol%), 
    244, Cs2CO3, H2O, DMF






















1. 246, 9-BBN, THF
2. PdCl2(dppf) (10 mol%), 
    Ph3As (10 mol%), 
    247, Cs2CO3, H2O, DMF













Figure 41: Mechanism of the Suzuki coupling 
 
The hydroboration was first conducted on olefin 249 with 9-BBN as a model study, followed by 
oxidative workup of the borane intermediate 250 to verify the stereochemical outcome (Scheme 
65). In the event, alcohol 251 was produced as a single diastereomer with the expected anti 
relative configuration and all spectroscopic data matched existing literature values.126 
 
Reagents and conditions: (a) 9-BBN, THF, rt; (b) H2O2, NaOH, THF, 0 °C ® rt, 63% over two steps 
Scheme 65: Model hydroboration on TBS ether 249 with oxidative work-up 
 
Kishi first suggested that the allylic chiral centre dictates the sense of stereoinduction by having 
the smallest group eclipse the olefin, thus biasing the reagent to approach via the medium group 
instead of the large group to minimise steric hindrance.102 Additional computational work 
undertaken by Houk led to a revised model which takes into account further stereoelectronic 
parameters.127 As the olefin becomes more electron deficient in the transition state TS-XXII, the 
molecule adopts a conformation where the C–O s* bond of the TBS group is orthogonal to the 
C=C p bond to minimise further electron density withdrawal. The borane reagent then approaches 
from the less hindered face of the olefin, leading to the observed anti diastereoselectivity. 
 
With confidence that the hydroboration result was reproducible, it was performed again on olefin 
241 but this time telescoped into the Suzuki coupling with vinyl iodide (Scheme 66). 








































product 253 and any unreacted 241 could not be separated from 253 by chromatography. The 
hydroboration proved difficult to monitor by TLC due to the instability of borane 252 on silica. 
Presumably, the extended carbon chain in 241 adopts a conformation that presents extra steric 
bulk to the olefin, thus slowing down hydroboration. Although a β-hydride elimination pathway 
during the reaction would regenerate the starting material 241, the use of the dppf ligand in this 
reaction should suppress this. Due to a lack of time, this reaction could not be fully investigated 
prior to the conclusion of this project. 
 
Reagents and conditions: (a) 9-BBN, THF, rt; (b) PdCl2(dppf), Ph3As, CH2=CHI, Cs2CO3, H2O/DMF, rt, 
yield N.C. 



















This study has led to the successful synthesis of several mid-stage to late-stage key intermediates 
for hemicalide, culminating in the synthesis of the advanced C1-C28 fragment ent-99. 
 
Work on the C1-C15 fragment 101 has been complementary to MacGregor’s established route37 
in both enantiomeric series and improvements have been made in several areas to enable a gram 
scale synthesis. This route features several highly diastereoselective key reactions which installs 
all but one stereocentre in the contiguous stereohexad. This work further demonstrates the 
synthetic utility of boron-mediated aldol reactions for their excellent and reliable levels of 
stereoinduction under mild conditions (Scheme 67). 
 
Scheme 67: Summary of the synthesis of C1-C15 intermediate 101 from building blocks 107, 45 and 106 
 
For the C16-C28 fragment 102, synthetic efforts have successfully accessed the final intermediate 
102. Modifications from MacGregor’s established route37 involve a change in choice of 
protecting group for the ketone in the aldol reaction, as well as other relevant downstream 
intermediates. The diastereoselectivity of the aldol reaction was also enhanced through the use of 
chiral ligands. Further improvements were also made in the dehydration and dihydroxylation 
reactions. A stereochemical reassignment of the proposed 18,19-anti relationship by Ardisson to 
18,19-syn was successfully conducted by using diene 202 for NMR correlation studies (Scheme 
68).36 The Cossy group subsequently revisited their earlier work and concurred with our 
























































Scheme 68: Summary of the synthesis of C16-C28 intermediate 102 and diene 202 from building blocks 
ent-130 and 153 
 
Fragment union strategies leading to the C1-C28 fragment ent-100 have also been explored 
(Scheme 69). To maximise convergency, the C1-C15 fragment 101 was transformed into vinyl 
stannane 211 in a Wulff-Stille reaction, followed by a modified Stille coupling with C16-C28 
vinyl iodide ent-102. In conjunction with co-worker Lam,71 this led to the generation of two 
diastereomeric truncates, 13,18-syn 220 and 13,18-anti 221 in good yield. Further derivatisation 
and NMR correlation studies indicated that the 13,18-syn diastereomer 220 was an exceedingly 
good match for natural hemicalide, pointing towards the likely relative configuration between the 
two distal stereoclusters.113 To date, the Cossy group has only worked in the 13,18-anti series 




































(4.4% over 18 steps)






Scheme 69: Summary of the synthesis of 13,18-anti C1-C28 truncate ent-100 and its derivatisation into 
221 for NMR correlation studies alongside subunit 220 
 
To aid the computational work on the C27-C35 region of hemicalide, a library of fragments will 
be synthesised to help improve ab initio NMR predictions. This objective will allow more robust 
DP4 probabilities to be obtained regarding the most likely stereochemistry in this region. 
Currently, diastereoselective reactions to configure three of the four stereocentres in this region 
have been developed (Scheme 70). Studies into this region have also provided valuable insight 
for the planned late-stage fragment coupling via an aldol reaction and a hydroboration-Suzuki 
coupling. 
 
Scheme 70: Summary of the synthesis of two intermediates 241 and 242 towards a library of eight 
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4.4 Future Work 
 
Having developed a successful synthesis to access the C1-C28 methyl ketone subunit, attention 
should now be directed towards the C29-C46 section, featuring the α-hydroxylactone. 
Preliminary investigations into this region have been undertaken by Stockdale.128 
 
The synthesis of the α-hydroxylactone begins with a reagent-controlled aldol reaction between 
ketone ent-153 and aldehyde 254, both obtained from the corresponding enantiomer of Roche 
ester in three steps, mediated by (+)-DIPCl. In the absence of chiral Ipc ligands, the reaction has 
been shown to proceed with a modest d.r. of 2:1. Following a TBS protection, intermediate 255 
was further elaborated to the α,β-unsaturated δ-lactone 256 in an analogous fashion to the C16-
C28 fragment. Configuring the C39 stereocentre remains a bottleneck in this route as most 
conjugate reduction strategies either deliver the undesired epimer or show no reactivity (Scheme 
71). 
 
Investigations into the reduction of the α,β-unsaturated lactone have now focused on a hydroxyl-
directed hydrogenation. This can be achieved by removing the PMB group with DDQ and using 
Crabtree’s catalyst61 under an atmosphere of hydrogen gas. Intermediate 257 can then be further 
functionalised by a two step sequence of DMP-mediated oxidation46 and a HWE olefination91 
with phosphonate 190 to reach the C46 terminus. A CBS reduction112 using catalyst 258 can be 
conducted on enone 259 to configure C45 because of the large steric differentiation between the 
C46 methyl group and the C43-C44 olefin. A diastereoselective α-oxidation at C40 with the 
Davis oxaziridine60 260, followed by bis-TES protection then affords intermediate 261. Catalytic 
hydrogenation of the C43-C44 olefin should also effect concomitant benzyl deprotection before 
exposure to DMP to reveal aldehyde 262 as a key intermediate. A Takai olefination129 would then 
generate vinyl iodide 263 in a single transformation but other olefination methods may also be 
explored at this stage (Scheme 71). 






Reagents and conditions: (a) ent-153, (+)-DIPCl, Et3N, Et2O, 0 °C, then 250, –78 °C ® –20 °C, 79% 
(d.r. >20:1); (b) TBSOTf, 2,6-lutidine, CH2Cl2, –78 °C, 81%; (c) LDA, EtOAc, THF, –78 °C, 99%; (d) 
TsOH   , MeOH, rt, 94%; (e) Ac2O, DMAP, py, PhH, 125 °C, 90%; (f) DDQ, CH2Cl2/pH 7 buffer, 0 °C 
® rt; (g) H2 (1 atm), [Ir(COD)(PCy3)(py)]PF6 (cat.), CH2Cl2, rt; (h) DMP, NaHCO3, CH2Cl2, rt; (i) 190, 
Ba(OH)2, THF, rt, then 253, 0 °C ® rt; (j) BH3SMe2, 254 (cat.), THF; (k) LiHMDS, 256, THF, –78 °C; (l) 
TESOTf, 2,6-lutidine, CH2Cl2; –78 °C; (m) H2 (1 atm), Pd/C, MeOH, rt; (n) DMP, NaHCO3, CH2Cl2, rt; (o) 
CHI3, CrCl2, THF, 0 °C 
Scheme 71: Planned synthesis of intermediate 259 by Stockdale 
 
Synthetic studies into the flexible C27-C35 polyacetate region for computational input have 
currently paused at the penultimate anti hydroboration-Suzuki coupling stage. Further 
investigations will need to address the slow conversion of olefin 241 into borane 252. Protocols 
for performing a syn hydroboration will also require exploration, including a rhodium-catalysed 
process130 to yield 265, or a hydroxyl-directed reaction with 266 leading to 268 (Scheme 72). 
Alternatively, the synthesis could be redesigned to allow for a lithium-halogen exchange with 
iodide 269, followed by trapping with 9-BBN-OMe to access borane 252. This modification 
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Reagents and conditions: (a) Rh(PPh3)3Cl, catecholborane, THF, rt; (b) PdCl2(dppf), Ph3As, CH2=CHI, 
Cs2CO3, H2O/DMF, rt; (c) 9-BBN, THF, rt; (d) t-BuLi, THF, –78 °C, then 9-BBN-OMe, –78 °C 
Scheme 72: Other methods for accessing syn and anti alkyl boranes 
 
 
Scheme 73: Planned completion of the library of C26-C35 fragments 
 
To synthesise a full library of fragments, a syn-selective aldol reaction of aldehyde 226 needs to 
be developed to complement the anti-selective Mukaiyama aldol. Subsequent elaboration of the 
syn aldol adduct 270 to the diols 271 and 272 will then be analogous to the established route in 
the anti series (Scheme 73). Having access to the complete set of fragments will be useful in 
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Narasaka reduction Evans-Tischenko reduction Narasaka reduction Evans-Tischenko reduction





endgame for the total synthesis of hemicalide as the final bond constructions take place in this 
region. 
 
The endgame strategy for hemicalide involves a telescoped hydroboration-Suzuki coupling of 
olefin 263 with the C34-C46 fragment 273 to arrive at fragment 274. A selective deprotection of 
the primary TES ether at C29 followed by a mild oxidation will lead to aldehyde 275 which can 
then be coupled with the C1-C28 fragment ent-99 in a boron-mediated aldol reaction. The final 
stereocentre can be set by a stereoselective reduction to give diol 276. Finally, a bis-methylation 
and global deprotection will give one possible diastereomer of hemicalide 277 (Scheme 74). 
 
Without any further stereochemical information about the C29-C46 region, several diastereomers 
of hemicalide will presumably have to be made in order to fully assign the relative configuration 
in the rest of the molecule. This can be achieved by using ent-263 and ent-273 during the 
hydroboration-Suzuki coupling step, as well as the complementary stereoselective methods for 
the hydroboration, boron-mediated aldol reaction and the subsequent reduction. A total of 16 
diastereomers can be made in this fashion, representing a major synthetic effort. However, as 
computational efforts exponentially diminish in efficiency with increasing molecular size, total 
synthesis remains the most effective tool in validating a proposed structure. 



















































































CHAPTER FIVE: EXPERIMENTAL 
 
5.1 General Experimental Procedures 
 
Reactions were carried out under an atmosphere of argon using oven dried glassware and 
standard techniques for handling air sensitive chemicals, unless the reaction contained aqueous 
reagents or unless otherwise stated. 
 
Reagents were purified using standard laboratory procedures. Solvents used for extraction and 
chromatography were distilled. All solvents and reagents were distilled under an argon 
atmosphere. Where stated, solvents were degassed using the freeze–pump–thaw method. Benzene 
(PhH), cyclohexene, 1,5-cyclooctadiene, dichloromethane (CH2Cl2), diisopropylamine (i-Pr2NH), 
acetonitrile (MeCN), N-methyl-2-pyrrolidone (NMP), oxalyl chloride (COCl2), pyridine (py), 
toluene (PhMe), 2,6-lutidine, and triethylamine (Et3N) were distilled from calcium hydride 
(CaH2). Tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled from potassium and 
sodium wire/benzophenone ketyl radical respectively. Dimethyl sulfoxide (DMSO), N,N-
dimethylformamide (DMF) and tributyltin chloride (SnBu3Cl) were distilled from 4Å MS. 
Diisopropylethylamine (DIPEA) was first distilled from ninhydrin and then from CaH2. DDQ 
was recrystallised from chloroform (CHCl3), Proton Sponge® was recrystallised from methanol 
and NBS was recrystallised from water. Anhydrous barium hydroxide (Ba(OH2), lithium 
carbonate (Li2CO3) and lithium chloride (LiCl) were prepared by drying at 130 °C in vacuo. All 
other chemicals were used as received from the manufacturer unless otherwise stated. 
 
Aqueous solutions of ammonium chloride (NH4Cl), sodium bicarbonate (NaHCO3), Rochelle’s 
salt (Na/K tartrate), sodium thiosulfate (Na2S2O3), sodium sulfite (Na2SO3) and brine (NaCl) 
were saturated. 
 
Purification by flash column chromatography was carried out using Kieselgel 60 (230-400) mesh 
and a positive solvent pressure unless otherwise stated. 
 
  




5.2 Analytical Procedures 
 
TLC was carried out using Merck Kieselgel 60 F254 plates which were visualised using UV light 
(254 nm) and stained using potassium permanganate (KMnO4) or phosphomolybdic 
acid/Ce2(SO4)3 dips. 
 
NMR spectra were recorded using the following machines: Bruker Avance BB500, Avance TCI-
ATM 500 cryo and DRX400. 1H NMR spectra were recorded at 298 K using an internal 
deuterium lock for CDCl3 (δH = 7.26). 
1H NMR data is presented as: chemical shift δ (in ppm, 
relative to TMS (δTMS = 0), integration, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, qn = quintet, sx = sextet, m = multiplet, br = broad, obs = obscured) and coupling 
constants (J in Hz). Signals are assigned according to the numbering scheme for hemicalide 
(Figure 1) shown at the start of the data for that compound. Assignments were determined either 
on the basis of unambiguous chemical shift or coupling patterns, 2D NMR experiments, or by 
analogy to fully interpreted spectra for structurally related compounds. Protons of OH groups are 
missing in some spectra due to proton exchange. 13C NMR spectra were recorded at 298 K with 
proton decoupling and an internal deuterium lock for CDCl3 (δC = 77.0) Data is listed by 
chemical shift (δ in ppm) relative to TMS (δTMS = 0). 
 
Fourier transform IR spectroscopy (FT-IR) was carried out using a Perkin-Elmer Spectrum One 
spectrometer and spectra were recorded as a thin film. Wavelengths of maximum absorption (νmax) 
are reported in wavenumbers (cm–1) and particularly broad (br) or weak (w) peaks are noted.  
 
Optical rotations were measured using a Perkin-Elmer 241 polarimeter at the sodium D line (589 
nm) and are reported as [α]D
20, concentration (c in g / 100 mL) and solvent. 
 
High and low resolution mass spectra were recorded by the EPSRC Mass Spectrometry facility 
(Swansea, UK), using chemical ionisation (CI), electron impact (EI) or electron spray ionisation 
(ESI) techniques. The calculated and observed mass of the parent ion
 
are quoted. High resolution 
values are calculated to 4 decimal places from the molecular formula. 
  





5.3 Preparation of reagents used 
 
Dibutylboron triflate (Bu2BOTf)132,133  
 
A two-neck flask was set up for distillation under reduced pressure and thoroughly dried. The 
setup was then carefully backfilled with argon and allowed to cool to rt. Tributylborane (16.3 mL, 
66.63 mmol) was added to the two-neck flask, followed by a small portion of triflic acid (10 g, 
66.63 mmol) with gentle warming to achieve a homogenous solution before adding the remaining 
triflic acid dropwise at rt to control the exothermic reaction. The reaction was left to stir for 45 
min and distilled directly under reduced pressure (45 °C, 0.1 torr) to obtain Bu2BOTf as a 
colourless oil (17.1 g, 61.3 mmol, 92%). This reagent is extremely moisture sensitive and was 




To a stirring solution of cyclohexene (40.0 mL, 400 mmol) in Et2O (250 mL) at –10 °C was 
added dropwise BH2ClSMe2 (20.6 ml, 200 mmol) over 30 min. The rate of addition was limited 
to control the rate of the highly exothermic reaction. The reaction mixture was allowed to warm 
to 0 °C and stirred for 1 h, then warmed to rt and stirred for a further 1 h. The solvent was 
removed by atmospheric distillation and then distillation under reduced pressure (95-97 °C, 0.3 
torr) gave Cy2BCl as a colourless liquid. 
 
(–)-B-Chlorodiisopinocamphenylborane ((–)-Ipc2BCl, (–)-DIPCl)135 
 
To a stirred solution of (+)-α-pinene (1.11 mL, 7.02 mmol) in Et2O (1.88 mL) at –10 °C was 
added BH2ClSMe2 (0.35 mL, 3.34 mmol). The mixture was stirred at 10 °C for 16 h to give a ca. 















9-Borabicyclo[3.3.1]nonane dimer (9-BBN)136 
 
A three-neck flask equipped with a single-piece distillation apparatus, dropping funnel and 
thermometer was charged with BH3SMe2 (15.3 mL, 153 mmol) and DME (50 mL). 1,5-
cyclooctadiene (16.4 g, 152 mmol) was added via the dropping funnel over ca. 1 h, so as to 
maintain a steady reaction temperature of 50-60 °C. Following the addition, ca. 30 mL of the 
solution was distilled to reach a final distillation temperature of 85 °C, indicating the complete 
removal of SMe2. Further DME was added to bring the total volumne to ca. 100 mL. The mixture 
was heated to effect dissolution of all solids and allowed to cool slowly to 0 °C. The supernatant 
was decanted, the product washed with ice-cold DME (100 mL) and dried in vacuo to provide 9-
BBN dimer (13.2 g, 106 mmol, 70%) as large white needles. 
 
Iodoxybenzoic acid (IBX)137 
 
To a stirred solution of OxoneTM (181 g, 290 mmol) in water (650 mL) was added 2-iodobenzoic 
acid (50.0 g, 202 mmol) in one portion. The suspension was heated to 70 °C for 3 h, then cooled 
to –5 °C for 1.5 h. The solids were collected by filtration, washed with water (6 x 100 mL) and 
acetone (2 x 100 mL) and dried under vacuum for 12 h to afford IBX (39.8 g, 142 mmol, 70%) as 
a white powder. 
 
Dess–Martin periodinane (DMP)138 
 
To a suspension of IBX (39.8 g, 142 mmol) in Ac2O (160 mL) was added TsOH•H2O (270 mg, 
1.42 mmol) and the resulting mixture was heated to 85 °C for 2.5 h, then cooled to 0 °C for 1 h. 
The precipitate was collected by filtration, washed with Et2O (5 x 30 mL) and dried under 
vacuum overnight to afford Dess–Martin periodinane (51.3 g, 121 mmol, 85%) as a white powder 




















4-Methoxybenzyl 2,2,2-trichloroacetimidate (PMBTCA)131 
 
To a vigorously stirring solution of aq. KOH (50% w/v, 130 mL) at rt was added a solution of 4-
methoxybenzyl alcohol (18.0 g, 130 mmol) in CH2Cl2 (130 mL) followed by NBu4HSO4 (4.4 g, 
13.0 mmol). Cl3CCN (14.3 mL, 143 mmol) was added dropwise over 20 min and the reaction left 
to stir for 1 h while warming to rt. Upon completion, the phases were separated and the aqueous 
layer extracted with Et2O (3 x 80 mL). The combined organic extracts were washed with brine 
(50 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by 
flash column chromatography (alumina, 5% EtOAc/PE 40-60) to give PMBTCA as a colourless 
oil (33.8 g, 120 mmol, 92%). 
 
Rf: 0.50 (10% EtOAc/PE, alumina plate); 1H NMR (400 MHz, CDCl3): δ 8.36 (1H, s, =NH), 
7.37 (2H, d, J = 8.4 Hz, ArH), 6.91 (2H, d, J = 8.8 Hz, ArH), 5.28 (2H, s, OCH2Ar) 3.82 (3H, s, 
ArOMe). 
 
Isopropylmagnesium chloride (i-PrMgCl) 
 
To a suspension of Mg turnings (3.74 g, 154 mmol) and I2 (1 crystal) in THF (70 mL) was added 
2-chloropropane (12.8 mL, 140 mmol) dropwise to control the rate of the exothermic reaction. 
Upon complete addition, the reaction mixture was refluxed for a further 1 h before cooling to rt to 
give a dark grey solution of i-PrMgCl (ca. 2.0 M in THF). 
 
Ethylmagnesium bromide (EtMgBr) 
 
To a suspension of Mg turnings (5.70 g, 231 mmol) in Et2O (70 mL) was added bromoethane 
(15.7 mL, 210 mmol) dropwise to control the rate of the exothermic reaction. Upon complete 
addition, the reaction mixture was refluxed for a further 1 h before cooling to rt to give a dark 













Lithium diisopropylamide (LDA) 
 
n-BuLi (1.6 M in hexanes, 1.70 mL, 2.72 mmo) was added to a solution of i-Pr2NH (0.4 mL, 2.85 
mmol) in THF (3.6 mL) at 0 ˚C. The reaction mixture was stirred for 10 min to give a solution of 
LDA (ca. 0.5 M in THF). 
 
Samarium diiodide (SmI2)139,140  
 
A flask was charged with Sm (45.1 mg, 0.300 mmol), 1,2-diiodoethane (42.3 mg, 0.150 mmol) 
and THF (1.5 mL) at rt. The mixture was sonicated for 1 h to give a deep blue solution of SmI2 




To a stirred suspension of Cu(OAc)2•H2O (50 mg, 0.25 mmol) and PPh3 (130 mg, 0.50 mmol) in 
degassed PhMe (9.3 mL) was added 1,1,3,3-tetramethyldisiloxane (0.70 mL, 3.78 mmol) at rt. 
The turquoise solution was stirred for 16 h at rt and the resulting blood red solution of Stryker’s 
reagent was stored under an atmosphere of Ar at 4 °C. It was used as a ca. 0.025 M solution with 
respect to Cu(OAc)2•H2O. 
 
  









L−phenylalanine 108 (5.00 g, 30.3 mmol) was dissolved in THF (60 mL) and cooled to 0 °C 
before adding LiAlH4 (2.30 g, 60.6 mmol) portionwise carefully while stirring. The reaction was 
warmed to rt for 1 h, then cooled to 0 °C again and successively quenched with H2O (2.5 mL), 
NaOH (15%, 7.5 mL) and H2O (7.5 mL) before warming to rt. The precipitate was removed by 
filtration and washed on the filter with Et2O (3 x 20 mL). The combined organic portions were 
washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. The resulting 
yellow solid was recrystallised from EtOAc/n-hexane (9:1, two batches) to give the title 
compound as an off-white crystalline solid (3.44 g, 22.7 mmol, 75%). Ent-109 was prepared in 
an analogous fashion from D−phenylalanine ent-108 (24.0 g, 145 mmol) to give an off-white 
crystalline solid (16.2 g, 107 mmol, 74%). 
 
1H NMR (500 MHz, CDCl3): δH 7.31 (2H, t, J = 7.4 Hz, ArH), 7.23 (1H, t, J = 7.4 Hz, ArH), 
7.19 (2H, d, J = 7.2 Hz, ArH), 3.64 (1H, dd, J = 10.5, 3.9 Hz, Ha), 3.38 (1H, dd, J = 10.5, 7.2 Hz, 
Ha’), 3.12 (1H, dddd, J = 8.8, 7.2, 5.2, 3.9 Hz, Hb), 2.79 (1H, dd, J = 13.4, 5.1 Hz, Hc), 2.53 (1H, 
dd, J = 13.5, 8.6 Hz, Hc’); 13C NMR (125 MHz, CDCl3): δC 138.8, 129.3, 128.7, 126.6, 66.5, 
54.3, 41.1; 109 [α]D
20 = –20.2 (c 1.0, CHCl3), ent-109 [α]D
20 = +20.0 (c 1.0, CHCl3). 
 




A suspension of aminoalcohol 109 (3.44 g, 22.7 mmol) and K2CO3 (314 mg, 2.27 mmol) in 
diethyl carbonate (5.50 mL, 45.4 mmol) was heated to 130 °C. EtOH was removed via distillation 
as the reaction progressed. After 3 h, the reaction was cooled to rt before diluting with CH2Cl2 
(10 mL). The organic phase was washed sequentially with water (10 mL), NaHCO3 (10 mL) and 
















recrystallised from EtOAc/n-hexane (3:2, two batches) to give the title compound as a white 
crystalline solid (3.14 g, 17.7 mmol, 78%).  Ent-110 was prepared in an analogous fashion from 
ent-109 (16.2 g, 107 mmol) to give a white crystalline solid (12.4 g, 70.0 mmol, 65%). 
 
1H NMR (400 MHz, CDCl3): δH 7.34 (2H, m, ArH), 7.29 (1H, m, ArH), 7.18 (1H, m, ArH), 4.48 
(1H, dd, J = 8.2, 8.2 Hz, Ha), 4.16 (1H, dd, J = 8.6, 5.6 Hz, Ha’), 4.09 (1H, m, Hb), 2.90 (1H, dd, 
J = 13.6, 6.0 Hz, Hc), 2.85 (1H, dd, J = 13.7, 7.8 Hz, Hc’); 110 [α]D
20 = –54.8 (c 1.0, CHCl3), ent-
110 [α]D
20 = +54.1 (c 1.0, CHCl3). 
 




A solution of oxazolidinone 95 (3.14 g, 17.7 mmol) in THF (100 mL) was cooled to −78 °C and 
n-BuLi (1.6 M in hexanes, 11.6 mL, 18.6 mmol) was added dropwise. The resulting red-brown 
solution was stirred at −78 °C for 30 min and propionyl chloride (1.85 mL, 21.2 mmol) was 
added dropwise. After 2.5 h, the reaction was quenched with NH4Cl (10 mL) and warmed to rt 
before diluting with CH2Cl2 (100 mL). The phases were separated and the organic phase was 
washed with NaOH (1 M, 50 mL). The combined aqueous phases were extracted with CH2Cl2 (2 
x 50 mL) and the combined organic phases washed with brine (50 mL), dried (MgSO4), filtered 
and concentrated in vacuo. The residue was recrystallised from Et2O/n-hexane (1:1, two batches) 
to give the title compound as white needles (3.51 g, 15.0 mmol, 85%). Ent-45 was prepared in an 
analogous fashion from ent-110 (12.4 g, 70.0 mmol) to give a white crystalline solid (13.2 g, 56.7 
mmol, 81%). 
 
Rf: 0.45 (30% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 7.34 (2H, m, ArH), 7.29 (1H, 
m, ArH), 7.21 (2H, m, ArH), 4.71-4.64 (1H, m, Hb), 4.24-4.15 (2H, m, Ha), 3.31 (1H, d, J = 13.4, 
3.2 Hz, Hc), 3.05-2.87 (2H, m, H12), 2.77 (1H, dd, J = 13.4, 9.6 Hz, Hc’), 1.21 (3H, t, J = 7.4 Hz, 
Me12); 45 [α]D
20 = +56.6 (c 1.0, CHCl3), ent-45 [α]D
20 = –56.2 (c 1.0, CHCl3). 
 















(E)-3-Iodo-2-methylacrylic acid (113) 
 
Sodium hydride (60 wt% in oil dispersion, 5.2 g, 130 mmol) was suspended in Et2O and diethyl 
methylmalonate (16 mL, 92.8 mmol) was added over 30 min with vigorous stirring. Upon 
complete addition, the reaction mixture was heated to reflux for 1 h before adding CHI3 (36.5 g, 
92.8 mmol) in one portion while continuing to reflux overnight. The reaction mixture was then 
cooled to 0 °C, diluted with Et2O (100 mL) and quenched with aq. HCl (3 M, 150 mL). The 
layers were separated and the aqueous layer extracted with Et2O (3 x 60 mL). The combined 
organic extracts were dried (MgSO4), filtered and concentrated in vacuo to afford a brown 
residue which was triturated with ice-cold pentanes (50 mL) before filtering through a short plug 
of Celite® to obtain a brown oil. The filtrate was concentrated in vacuo and taken up in EtOH (50 
mL) before adding aq. KOH (13 g in 90 mL H2O) and refluxed overnight. After cooling to rt, the 
reaction mixture was concentrated in vacuo to remove volatiles and the layers separated. The 
aqueous phase was diluted with aq. K2CO3 (1 M, 70 mL), washed with CH2Cl2 (2 x 30 mL), 
acidified with HCl (9 M, 50 mL) and extracted with CH2Cl2 (5 x 50 mL). The combined organic 
extracts were dried (MgSO4), filtered and concentrated in vacuo to afford the title compound as a 
yellow oil (11.4 g, 53.8 mmol, 58%) which was used without further purification. 
 
Rf: 0.10 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 8.02 (1H, q, J = 1.2 Hz, H15), 
2.06 (1H, d, J = 1.2 Hz, Me14); 13C NMR (125 MHz, CDCl3): δC 169.0, 139.1, 101.9, 20.0; FT-
IR (Thin film): νmax 3500-2400 (br), 1688, 1595, 1412, 1300, 1235, 1109, 992, 917, 842, 729, 
686. 
 




Carboxylic acid 60 (5 g, 23.6 mmol) was dissolved in Et2O (100 mL) and cooled to 0 °C before 
adding LiAlH4 (1.17 g, 30.7 mmol) portionwise carefully while stirring. The reaction was 
warmed to rt for 1 h, then cooled to 0 °C again and successively quenched with H2O (1.5 mL), 
NaOH (15%, 1.5 mL) and H2O (4.5 mL) before warming to rt. The precipitate was removed by 













washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo to afford the title 
compound as a pale yellow oil (3.69 g, 18.6 mmol, 79%) which was used without further 
purification. 
 
Rf: 0.33 (20% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 6.29 (1H, q, J = 1.3 Hz, H15), 
4.13 (2H, d, J = 1.3 Hz, H14), 1.85 (3H, s, Me14); 13C NMR (100 MHz, CDCl3): δC 147.4, 77.5, 
67.3, 21.5; FT-IR (Thin film): νmax 3293 (br), 2917, 2851, 1623, 1445, 1377, 1276, 1253, 1147, 
1069, 1012, 943, 775, 666. 
 




Method A (using MnO2) 
Activated manganese dioxide (2.23 g, 25.7 mmol) was added to a solution of allylic alcohol 62 
(509 mg, 2.57 mmol) in CH2Cl2 (5 mL) at rt and stirred for 24 h. The reaction mixture was 
filtered through a short plug of Celite® and carefully concentrated in vacuo to give a solution of 
the title compound in CH2Cl2 (ca. 10 mL) which was used without further purification. 
 
Method B (using aerobic oxidation) 
To a solution of allylic alcohol 62 (3.97 g, 20.04 mmol) in MeCN (10 mL) was added copper (I) 
bromide (143.5 mg, 1.00 mmol), bipyridyl (156.2 mg, 1.00 mmol), TEMPO (156.3 mg, 1.00 
mmol) and DMAP (122.2 mg, 2.00 mmol). The reaction flask was fitted with an O2 balloon and 
evacuated to backfill the flask with O2. The evacuation/backfill procedure was repeated two more 
times and the reaction left to stir for 5 h where it turned green-blue upon complete reaction. H2O 
(10 mL) was added and the aqueous layer extracted with Et2O (4 x 10 mL). The organic extracts 
were washed with brine (2 mL), dried (MgSO4) and carefully concentrated in vacuo to give a 
solution of the title compound in Et2O (ca. 20 mL) which was used without further purification. 
 
Rf: 0.23 (5% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δ 9.50 (1H, s, H13), 7.79 (1H, q, J 
= 1.1 Hz, H15), 1.90 (3H, d, J = 1.1 Hz, Me14). 
 













Method A (Evans conditions) 
A flame-dried flask was charged with oxazolidinone 57 (3.90 g, 16.7 mmol) dissolved in CH2Cl2 
(25 mL) and cooled to –78 °C before adding Bu2BOTf (4.66 mL, 20.0 mmol) and DIPEA (4.95 
mL, 28.4 mmol) dropwise. The reaction was warmed to –10 °C and stirred for 30 min before 
cooling to –78 °C again. A solution of aldehyde 107 (3.93 g, 20.00 mmol) in CH2Cl2 (20 mL) 
was added via cannula (2 x 2 mL wash) and left to stir at –78 °C for 3 h before transferring to a 
freezer for 16 h. The reaction was quenched with MeOH (10 mL), pH 7 buffer (20 mL) and the 
reaction stirred for 1 h while warming to rt. The reaction mixture was concentrated in vacuo and 
the residue was taken up in CH2Cl2 (25 mL). The phases were separated and the aqueous layer 
extracted with CH2Cl2 (3 x 25 mL). The combined organic extracts were washed with brine (5 
mL), dried (MgSO4), filtered and concentrated in vacuo. The crude product was azeotroped with 
MeOH (5 x 10 mL) before purifying by flash column chromatography (20% ® 50% EtOAc/PE 
40-60) to give the title compound as an off-white crystalline solid (5.74 g, 13.4 mmol, 80%, d.r. 
20:1). Ent-121 was prepared in an analogous fashion from ent-45 (537 mg, 2.30 mmol) and 
aldehyde 107 (541 mg, 2.76 mmol) to give an off-white crystalline solid (781 mg, 1.82 mmol, 
79%, d.r. 20:1). 
 
Method B (Crimmins conditions) 
A flame-dried flask was charged with oxazolidinone 45 (3.38 g, 14.5 mmol) dissolved in CH2Cl2 
(120 mL) and cooled to 0 °C. TiCl4 (1.68 mL, 15.3 mmol) was added dropwise and stirred for 10 
min, during which time a yellow colour developed. DIPEA (2.72 mL, 16.0 mmol) was added 
dropwise, where the yellow reaction mixture turned wine-red, and stirred for 30 min. NMP (1.40 
mL, 14.5 mmol) was added and stirred for 10 min before adding a solution of aldehyde 107 (3.14 
g, 16.0 mmol) in CH2Cl2 (20 mL) via cannula (2 x 2 mL wash). The reaction was left to stir for 
another 3 h and quenched with half-saturated NH4Cl. The phases were separated and the aqueous 
layer extracted with CH2Cl2 (3 x 25 mL). The combined organic extracts were washed with brine 
(5 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by 
flash column chromatography (20% ® 50% EtOAc/PE 40-60) to give the title compound as an 














analogous fashion from ent-45 (3.22 g, 13.8 mmol) and aldehyde 101 (2.98 g, 15.2 mmol) to give 
an off-white crystalline solid (5.22 g, 12.1 mmol, 88%, d.r. 10:1). 
 
Rf: 0.38 (30% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 7.35 (2H, t, J = 7.7 Hz, ArH), 
7.30 (1H, t, J = 7.7 Hz, ArH), 7.22 (2H, d, J = 7.7 Hz, ArH), 6.42 (1H, s, H15), 4.70 (1H, ddt, J = 
9.5, 7.6, 3.1 Hz, Hb), 4.51 (1H, m, H13), 4.25 (1H, dd, J = 9.1 Hz, 7.7 Hz, Ha), 4.21 (1H, dd, J = 
9.2, 3.0 Hz, Ha’), 4.01 (1H, qd, J = 7.0, 3.6, Hz, H12), 3.36 (1H, d, J = 3.2 Hz, OH), 3.26 (1H, dd, 
J = 13.5, 3.4 Hz, Hc), 2.82 (1H, dd, J = 13.5, 9.3 Hz, Hc’), 1.82 (3H, d, J = 1.7 Hz, Me14), 1.20 
(3H, d, J = 7.1 Hz, Me12); 13C NMR (125 MHz, CDCl3): δC 176.4, 153.0, 146.0, 135.0, 129.4, 
129.0, 127.5, 79.3, 75.3, 66.4, 55.3, 40.2, 37.7, 21.5, 10.5; FT-IR (Thin film): νmax 3504 (br), 
2920, 1774, 1698, 1455, 1380, 1290, 1209, 1110, 1079, 1050, 1005, 968, 923, 790, 762, 748, 702; 
HRMS (ES+) Calc. for C17H20INO4H [M+H]+
 
430.0510, found 430.0510; 121 [α]D
20 = +32.0 (c 
1.0, CHCl3), ent-121 [α]D
20 = –33.0 (c 1.0, CHCl3). 
 




Pre-dried NHMeOMe•HCl (4.33 g, 44.4 mmol) was suspended in THF (60 mL) at 0 °C before 
adding AlMe3 (2 M in PhMe, 22.2 mL, 44.4 mmol) dropwise. The reaction was warmed to rt and 
stirred for 1 h before cooling to 0 °C again. A solution of oxazolidinone 121 (6.35 g, 14.8 mmol) 
in THF (10 mL) was added to the reaction via cannula (2 x 2 mL wash) and left to stir overnight 
while warming to rt. The reaction mixture was cooled to 0 °C and carefully quenched with 
Rochelle’s salt (50 mL), followed by vigorous stirring for 1 h while warming to rt. The phases 
were separated and the aqueous layer extracted with Et2O (3 x 50 mL). The combined organic 
extracts were washed with brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (30% ® 50% EtOAc/PE 40-60) to 
give the title compound as a white crystalline solid (4.31 g, 13.8 mmol, 93%). 
 
Rf: 0.28 (50% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 6.43 (1H, s, H15), 4.42 (1H, s, 
H13), 4.26 (1H, br s, OH), 3.73 (3H, s, OMe), 3.21 (3H, s, NMe), 3.14-3.05 (1H, m, H12), 1.79 
(3H, s, Me14), 1.08 (3H, d, J = 7.2 Hz, Me12); 13C NMR (100 MHz, CDCl3): δC 177.3, 145.2, 



















Alcohol 125 (2.02 g, 6.48 mmol) and imidazole (658 mg, 9.67 mmol) were dissolved in CH2Cl2 
(35 mL) at rt and stirred until a clear homogenous solution was obtained, followed by the 
dropwise addition of TESCl (1.41 mL, 8.38 mmol). The reaction was stirred overnight and 
carefully quenched with NH4Cl (25 mL). The phases were separated and the aqueous layer 
extracted with CH2Cl2 (3 x 30 mL). The combined organic extracts were washed with brine (5 
mL), dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (10% ® 30% EtOAc/PE 40-60) to give the title compound as a 
colourless oil (2.60 g, 6.09 mmol, 94%). 
 
Rf: 0.29 (30% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 6.17 (1H, s, H15), 4.32 (1H, d, 
J = 9.0 Hz, H13), 3.64 (3H, s, OMe), 3.18-3.07 (1H, m, H12), 3.12 (3H, s, NMe), 1.80 (3H, d, J = 
0.9 Hz, Me14), 1.19 (3H, d, J = 6.8 Hz, Me12), 0.94 (9H, t, J = 8.0 Hz, OSiCH2CH3), 0.58 (6H, q, 
J = 8.0 Hz, OSiCH2CH3); 13C NMR (100 MHz, CDCl3): δC 174.8, 148.4, 127.9, 78.9, 78.3, 61.2, 
40.2, 31.7, 19.1, 13.9, 6.4, 4.2; FT-IR (Thin film): νmax 2959, 2877, 1660, 1458, 1414, 1382, 










Alcohol 121 (5.50 g, 12.8 mmol) and imidazole (1.31 g, 19.2 mmol) were dissolved in CH2Cl2 
(120 mL) at rt and stirred until a homogenous solution was obtained, followed by the dropwise 
addition of TESCl (2.58 mL, 15.4 mmol). The reaction was stirred overnight and quenched with 
NH4Cl (30 mL). The phases were separated and the aqueous layer extracted with CH2Cl2 (3 x 30 




















and concentrated in vacuo. The crude product was purified by flash column chromatography (10% 
® 30% EtOAc/PE 40-60) to give the title compound as a colourless oil (6.39 g, 11.8 mmol, 92%). 
Ent-127 was prepared in an analogous fashion from ent-121 (5.80 g, 13.5 mmol) to give a 
colourless oil (7.13 g, 13.1 mmol, 97%). 
 
Rf: 0.26 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.34 (2H, t, J = 7.3 Hz, ArH), 
7.29 (1H, t, J = 7.3 Hz, ArH), 7.21 (2H, d, J = 7.0 Hz, ArH), 6.21 (1H, s, H15), 4.70 (1H, dq, J = 
6.5, 3.1 Hz, Hb), 4.43 (1H, d, J = 7.4 Hz, H13), 4.20-4.15 (2H, m, Ha), 4.06 (1H, qn, J = 6.9, Hz, 
H12), 3.25 (1H, dd, J = 13.4, 3.3 Hz, Hc), 2.76 (1H, dd, J = 13.4, 9.7 Hz, Hc’), 1.80 (3H, d, J = 
1.0 Hz, Me14), 1.23 (3H, d, J = 6.7 Hz, Me12), 0.93 (9H, t, J = 8.0 Hz, OSiCH2CH3), 0.57 (6H, q, 
J = 7.8 Hz, OSiCH2CH3); 13C NMR (125 MHz, CDCl3): δC 174.6, 153.2, 149.0, 135.4, 129.6, 
129.1, 127.5, 79.3, 78.4, 63.3, 55.9, 42.8, 37.9, 19.9, 13.1, 6.9, 4.8; FT-IR (Thin film): νmax 2954, 
2910, 2876, 1781, 1696, 1455, 1379, 1262, 1209, 1087, 1009, 967, 853, 745, 702; HRMS (ES+) 
Calc. for C23H34INO4SiH [M+H]+
 
544.1375, found 544.1370; 127 [α]D
20 = +49.7 (c 1.0, CHCl3), 
ent-127 [α]D




Oxazolidinone 127 (6.50 g, 12.0 mmol) was dissolved in Et2O (120 mL) and cooled to –78 ˚C 
while stirring before adding LiBH4 (4 M in Et2O, 6.00 mL, 23.9 mmol) dropwise. The reaction 
was slowly warmed to 0 ˚C and stirred for 1 h. Upon complete reaction, the reaction mixture was 
quenched with NH4Cl (40 mL). The layers were separated and the aqueous layer extracted with 
Et2O (3 x 50 mL). The combined organic extracts were washed with brine (30 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (10% ® 30% EtOAc/PE 40-60) to give the title compound as a colourless oil 
(3.56 g, 9.60 mmol, 80%). Ent-128 was prepared in an analogous fashion from ent-127 (7.13 g, 
13.1 mmol) to give a colourless oil (4.00 g, 10.8 mmol, 82%). 
 
Rf: 0.19 (10% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 6.17 (1H, d, J = 1.0 Hz, H15), 
4.21 (1H, d, J = 5.3 Hz, H13), 3.55-3.39 (2H, m, H11), 2.01 (1H, br s, OH), 1.88 (1H, m, H12), 
1.77 (3H, s, Me14), 0.92 (9H, t, J = 8.3 Hz, OSiCH2CH3), 0.84 (3H, d, J = 6.6 Hz, Me12), 0.56 












21.2, 11.7, 6.9, 4.8; FT-IR (Thin film): νmax 3353 (br), 2955, 2911, 2876, 1457, 1414, 1378, 1263, 
1240, 1141, 1078, 1006, 828, 726; HRMS (ES+) Calc. for C13H27IO2SiH [M+H]+
 
393.0717, 
found 393.0719; 128 [α]D
20 = –35.0 (c 1.0, CHCl3), ent-128 [α]D
20 = +38.2 (c 1.0, CHCl3). 
 





Method A (via Weinreb amide reduction) 
Weinreb amide 126 (215 mg, 0.503 mmol) was dissolved in PhMe (2 mL) and cooled to –30 °C. 
DIBAL (1 M in hexanes, 755 μL, 0.755 mmol) was added dropwise and the reaction left to stir at 
–30 °C for 2 h. Upon complete reaction, the reaction was diluted with Et2O (2 mL) and carefully 
quenched with ice-cold Rochelle’s salt (2 mL) while stirring vigorously at 0 °C for 1 h. The 
phases were separated and the aqueous layer extracted with Et2O (3 x 5 mL). The combined 
organic extracts were washed with Rochelle’s salt (1 mL), brine (1 mL), dried (MgSO4), filtered 
and concentrated in vacuo. The crude product was filtered through a short plug of silica to give 
the title compound as a colourless oil (130 mg, 0.352 mmol, 70%). 
 
Method B (via Swern oxidation) 
Anhydrous DMSO (1.56 mL, 22.0 mmol) was added to a stirred solution of (COCl)2 (0.93 mL, 
11.0 mmol) in CH2Cl2 (88 mL) at −78 °C. The solution was stirred at −78 °C for 20 min before 
adding a solution of alcohol 128 (3.25 g, 8.78 mmol) in CH2Cl2 (5 mL) via cannula (2 x 1 mL 
wash). The reaction mixture was stirred at −78 °C for 15 min, then Et3N (6.12 mL, 43.9 mmol) 
was added dropwise and warmed up to –20 °C over 15 min. The reaction was quenched with 
NH4Cl (20 mL) and warmed to rt. The layers were separated and the aqueous phase extracted 
with Et2O (3 x 20 mL). The combined organic phases were washed with brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo to give the title compound as a yellow oil (3.20 g, 
8.69 mmol, 99%) which was used immediately without further purification. Ent-105 was 
prepared in an analogous fashion from ent-128 (3.70 g, 9.99 mmol) to give a colourless oil (3.50 













Rf: 0.49 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 9.69 (1H, d, J = 1.4 Hz, H11), 
6.29 (1H, s, H15), 4.58 (1H, d, J = 4.4 Hz, H13), 2.50 (1H, qdd, J = 6.8, 1.7, 5.1 Hz, H12), 1.79 
(3H, d, J = 0.8 Hz, Me14), 1.06 (3H, d, J = 7.1 Hz, Me12), 0.93 (9H, t, J = 8.0 Hz, OSiCH2CH3), 
0.58 (6H, q, J = 8.1 Hz, OSiCH2CH3); 13C NMR (125 MHz, CDCl3): δC 203.8, 147.8, 79.5, 76.6, 
50.6, 21.3, 8.4, 7.0, 5.0; FT-IR (Thin film): νmax 2955, 2912, 2877, 1725, 1457, 1413, 1379, 1269, 
1241, 1145, 1108, 1083, 1035, 1005, 976, 946, 929, 820, 783, 740, 727, 696; HRMS (ES+) Calc. 
for C13H25IO2SiH [M+H]+
 
369.0741, found 369.0735; 105 [α]D
20 = –37.2  (c 1.0, CHCl3), ent-105 
[α]D
20 = +42.2 (c 1.0, CHCl3) 
 
Data in agreement with that reported by Müller.143 
 
Methyl (R)-3-((4-methoxybenzyl)oxy)-2-methylpropanoate (130) 
 
(R)-3-hydroxy-2-methylpropionate (R)-40 (4.17 g, 35.3 mmol) was dissolved in CH2Cl2 (30 mL) 
at 0 °C. A solution of PMBTCA (11.98 g, 42.4 mmol) in CH2Cl2 (15 mL) was added, followed 
by PPTS (887 mg, 3.53 mmol). The reaction was warmed to rt and stirred for 5 h before carefully 
quenching with NaHCO3 (50 mL). The phases were separated and the aqueous layer extracted 
with CH2Cl2 (3 x 50 mL). The combined organic extracts were dried (MgSO4 and concentrated in 
vacuo. The crude product was triturated with ice-cold hexanes (ca. 30 mL) and filtered through a 
short plug of Celite®. The filtrate was concentrated in vacuo and purified by flash column 
chromatography (5% ® 20% EtOAc/PE 40-60) to give the title compound as a colourless oil 
(7.15 g, 30.0 mmol, 85%). Ent-130 was prepared in an analogous fashion from (S)-40 (10.9 g, 
92.6 mmol) to give a colourless oil (20.0 g, 89.1 mmol, 96%). 
 
Rf: 0.30 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.23 (2H, d, J = 8.7 Hz, ArH), 
6.87 (2H, d, J = 8.8 Hz, ArH), 4.46 (1H, d, J = 11.8 Hz, OCH2Ar), 4.43 (1H, d, J = 11.8 Hz, 
OCH2Ar), 3.80 (3H, s, ArOMe), 3.69 (3H, s, OMe), 3.62 (1H, dd, J = 9.1, 7.3 Hz, H7a), 3.45 (1H, 
dd, J = 9.2, 5.9 Hz, H7b), 2.77 (1H, qnd, J = 7.1, 6.3 Hz, H8), 1.16 (3H, d, J = 7.1 Hz, Me8); 13C 
NMR (125 MHz, CDCl3): δC 175.3, 159.2, 130.2, 129.2, 113.8, 72.7, 71.7, 55.2, 51.7, 40.1, 14.0; 
FT-IR (Thin film): νmax 2951 (w), 1735, 1612, 1586 (w), 1512, 1459, 1363, 1302, 1244, 1199, 
1173, 1085, 1033, 818, 759 (w), 710 (w); HRMS (ES+) Calc. for C13H18O4NH4 [M+NH4]+
 
256.1543, found 256.1539; [α]D20
 















Ester 130 (8.41 g, 35.3 mmol) and pre-dried NHMeOMe•HCl (5.17 g, 53.0 mmol) were 
suspended in THF (80 mL) and cooled to –20 °C. i-PrMgCl (2.0 M in THF, 53.0 mL, 106 mmol) 
was added dropwise over 1 h while maintaining the reaction mixture temperature below –10 °C. 
The reaction mixture was stirred at –10 °C overnight before carefully quenching with NH4Cl 
(100 mL). The reaction was warmed to rt with stirring before allowing the phases to separate and 
extracting the aqueous layer with EtOAc (3 x 100 mL). The combined organic extracts were 
washed with brine (30 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography (30% ® 50% EtOAc/PE 40-60) to give 
the title compound as a colourless oil (8.33 g, 31.1 mmol, 88%). 
 
Rf: 0.17 (30% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 7.23 (2H, d, J = 8.6 Hz, ArH), 
6.86 (2H, d, J = 8.6 Hz, ArH), 4.48 (1H, d, J = 11.6 Hz, OCH2Ar), 4.41 (1H, d, J = 11.7 Hz, 
OCH2Ar), 3.80 (3H, s, ArOMe), 3.69 (3H, s, OMe), 3.68 (1H, t, J = 8.6 Hz, H7a), 3.39 (1H, dd, J 
= 8.9, 5.9 Hz, H7b), 3.32-3.22 (1H, m, H8), 3.20 (3H, s, NMe), 1.10 (3H, d, J = 7.0 Hz, Me8); 
13C NMR (125 MHz, CDCl3): δC 175.8, 159.0, 130.4, 129.0, 113.6, 72.8, 72.2, 61.4, 55.1, 35.7, 
32.0, 14.1; FT-IR (Thin film): νmax 2937 (w), 1655, 1613, 1586 (w), 1513, 1464, 1387, 1302, 
1246, 1174, 1096, 1034, 993, 820, 758 (w); HRMS (ES+) Calc. for C14H21NO4H [M+H]+
 
268.1543, found 268.1545; [α]D20
 
= –3.1 (c 1.0, CHCl3). 
 




Weinreb amide 131 (12.5 g, 46.8 mmol) was dissolved in Et2O (100 mL) and cooled to –78 °C. 
EtMgBr (3.0 M in Et2O, 46.7 mL, 140 mmol) was added dropwise and the reaction stirred 
vigorously at –10 °C overnight before carefully quenching with NH4Cl (100 mL). The reaction 
was warmed to rt with stirring before allowing the phases to separate and extracting the aqueous 













dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (15% ® 50% EtOAc/PE 40-60) to give the title compound as a 
colourless oil (10.4 g, 44.0 mmol, 94%). Ent-106 was prepared in an analogous fashion from 
ketone ent-131 (5.10 g, 19.1 mmol) to give a colourless oil (4.11 g, 17.4 mmol, 91%). 
 
Rf: 0.35 (20% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 7.21 (2H, d, J = 8.6 Hz, ArH), 
6.87 (2H, d, J = 8.7 Hz, ArH), 4.43 (1H, d, J = 11.6 Hz, OCH2Ar), 4.39 (1H, d, J = 11.6 Hz, 
OCH2Ar), 3.80 (3H, s, ArOMe), 3.59 (1H, dd, J = 9.1, 7.8 Hz, H7a), 3.42 (1H, dd, J = 9.1, 5.5 Hz, 
H7b), 2.86 (1H, qnd, J = 7.2, 5.6 Hz, H8), 2.50 (2H, q, J = 7.3 Hz, H10), 1.06 (3H, d, J = 7.1 Hz, 
Me8), 1.04 (3H, t, J = 7.2 Hz, Me10); 13C NMR (100 MHz, CDCl3): δC 213.1, 158.8, 129.9, 
128.7, 113.3, 72.4, 71.7, 54.8, 45.8, 34.8, 13.2, 7.2; FT-IR (Thin film): νmax 2973, 2938, 1712, 
1612, 1586 (w), 1512, 1458, 1362, 1302, 1245, 1173, 1089, 1033, 952, 819, 758, (w), 709 (w); 
HRMS (ES+) Calc. for C14H20O3H [M+H]+
 
254.1751, found 254.1747; 106 [α]D20
 
= –20.8 (c 1.0, 
CHCl3), ent-106 [α]D20
 
= +22.4 (c 1.0, CHCl3). 
 





A flame-dried flask was charged with Cy2BCl (2.00 mL, 11.4 mmol) in Et2O (50 mL) at –10 ˚C 
before adding Et3N (2.20 mL, 15.8 mmol) dropwise with stirring. A solution of ketone 106 (2.90 
g, 12.3 mmol) in Et2O (10 mL) was added via cannula (2 x 2 mL wash) and the reaction stirred at 
–10 ˚C for 1 h before cooling to –78 ˚C. A solution of aldehyde 105 (3.20 g, 8.69 mmol) in Et2O 
(20 mL) was then added via cannula (2 x 2 mL wash) and the reaction stirred at –78 ˚C for 3 h 
before transferring to the freezer overnight. The reaction was quenched with MeOH (10 mL), pH 
7 buffer (10 mL) and then warmed to rt. The phases were separated and the aqueous layer was 
extracted with Et2O (3 x 40 mL). The combined organic extracts were concentrated in vacuo to 
ca. 40 mL and stirred over silica gel (ca. 20 g) for 1 h. The silica gel was removed by filtration, 
washed with EtOAc (3 x 30 mL) and the solvent removed in vacuo. The crude product was 
purified by flash column chromatography (15% ® 40% EtOAc/PE 40-60) to give the title 













fashion from ketone ent-106 (3.30 g, 14.0 mmol) and ent-105 (3.68 g, 9.99 mmol) to give a 
colourless oil (4.26 g, 7.04 mmol, 74%). 
 
Rf: 0.33 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.22 (2H, d, J = 8.7 Hz, ArH), 
6.88 (2H, d, J = 8.7 Hz, ArH), 6.07 (1H, s, H15), 4.42 (1H, d, J = 11.3 Hz, OCH2Ar), 4.37 (1H, d, 
J = 11.5 Hz, OCH2Ar), 4.16 (1H, d, J = 8.3 Hz, H13), 3.80 (3H, s, ArOMe), 3.65 (1H, t, J = 9.0 
Hz, H7a), 3.59 (1H, ddd, J = 9.5, 4.0, 2.1 Hz, H11), 3.38 (1H, dd, J = 8.8, 4.6 Hz, H7b), 3.05 (1H, 
dqd, J = 9.2, 7.0, 4.8 Hz, H8), 2.86 (1H, d, J = 4.2 Hz, OH), 2.77 (1H, dq, J = 9.5, 7.1 Hz, H10), 
1.76 (3H, d, J = 1.2 Hz, Me14), 1.72-1.67 (1H, m, H12), 1.02 (3H, d, J = 7.1 Hz, Me12), 0.96 
(3H, d, J = 7.1 Hz, Me10), 0.93 (9H, t, J = 8.0 Hz, OSiCH2CH3), 0.93 (3H, d, J = 7.0 Hz, Me8), 
0.57 (6H, q, J = 8.0 Hz, OSiCH2CH3); 13C NMR (125 MHz, CDCl3): δC 217.3, 159.6, 149.2, 
129.9, 129.8, 114.1, 80.6, 79.9, 73.4, 72.7, 72.5, 55.5, 51.2, 44.4, 38.1, 19.7, 14.5, 12.9, 8.4, 7.1, 
5.0; FT-IR (Thin film): νmax 3485 (br), 2957, 2877, 1711, 1614, 1514, 1459, 1376, 1303, 1248, 
1174, 1066, 1037, 1006, 976, 865, 822, 744, 664; HRMS (ES+) Calc. for C27H45IO5SiH [M+H]+
 
605.2154, found 605.2151; 132 [α]D
20  = –21.1 (c 1.0, CHCl3), ent-132 [α]D






Alcohol 132 (1.70 g, 2.81 mmol) was dissolved in CH2Cl2 (28 mL) and cooled to –78 ˚C, 
followed by the sequential addition of 2,6-lutidine (0.479 mL, 4.07 mmol) and TESOTf (0.738 
mL, 3.27 mmol). The reaction was stirred for 2 h before quenching with MeOH (4 mL) and 
NaHCO3 (5 mL). The phases were separated and the aqueous layer extracted with CH2Cl2 (3 x 10 
mL). The combined organic extracts were washed with brine (5 mL), dried (Na2SO4), filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography (5% ® 
10% EtOAc/PE 40-60) to give the title compound as a colourless oil (1.84 g, 2.56 mmol, 91%). 
Ent-136 was prepared in an analogous fashion from ent-132 (4.26 g, 7.04 mmol) to give a 
colourless oil (4.91 g, 6.83 mmol, 97%). 
 
Rf: 0.32 (5% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 7.21 (2H, d, J = 8.6 Hz, ArH), 
6.86 (2H, d, J = 8.7 Hz, ArH), 6.20 (1H, s, H15), 4.43 (1H, d, J = 11.5 Hz, OCH2Ar), 4.38 (1H, d, 












1.8 Hz, H11), 3.59 (1H, dd, J = 9.1, 6.8 Hz, H7a), 3.45 (1H, dd, J = 9.1, 5.6 Hz, H7b), 2.94 (1H, 
qn, J = 7.2 Hz, H10), 2.87 (1H, sx, J = 6.6 Hz, H8), 1.78-1.72 (1H, m, H12), 1.71 (3H, d, J = 0.6 
Hz, Me14), 1.05 (3H, d, J = 7.0 Hz, Me12), 0.96 (3H, d, J = 7.1 Hz, Me10), 0.95 (3H, d, J = 6.7 
Hz, Me8), 0.94 (9H, t, J = 8.0 Hz, OSiCH2CH3), 0.93 (9H, t, J = 7.9 Hz, OSiCH2CH3), 0.56 (6H, 
q, J = 7.9 Hz, OSiCH2CH3), 0.55 (6H, q, J = 8.1 Hz, OSiCH2CH3); 13C NMR (125 MHz, CDCl3): 
δC 214.4, 159.5, 150.0, 130.6, 129.5, 114.1, 80.8, 79.4, 73.4, 73.3, 72.1, 55.6, 50.7, 47.2, 40.4, 
19.6, 13.9, 13.6, 10.5, 7.5, 7.2, 6.0; FT-IR (Thin film): νmax 2956, 2911, 2877, 1713, 1615, 1514, 
1459, 1409, 1379, 1248, 1173, 1067, 1039, 1004, 820, 736, 663; HRMS (ES+) Calc. for 
C33H59IO5Si2H [M+H]+
 
719.3018, found 719.3018; 136	[α]D20
 
= –11.5 (c 1.0, CHCl3), ent-136 
[α]D





Ketone 136 (1.93 g, 2.69 mmol) was dissolved in CH2Cl2 (28 mL) and cooled to –78 ˚C. DIBAL 
(1 M in hexanes, 4.04 mL, 4.04 mmol) was added dropwise at this temperature and then warmed 
to –40 ˚C for 4 h. Upon complete reaction, the reaction was quenched with MeOH (5 mL) and 
warmed to rt. Rochelle’s salt (10 mL) was added while stirring vigorously for 1 h. The phases 
were separated and the aqueous layer extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were washed with brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (5% ® 20% EtOAc/PE 40-60) to 
give the title compound as a colourless oil (1.60 g, 2.26 mmol, 84%, d.r. 20:1). Ent-137 was 
prepared in an analogous fashion from ent-136 (2.78 g, 3.87 mmol) to give a colourless oil (2.23 
g, 3.17 mmol, 82%, d.r. 20:1). 
 
Rf: 0.24 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.25 (2H, d, J = 8.7 Hz, ArH), 
6.88 (2H, d, J = 8.8 Hz, ArH), 6.17 (1H, s, H15), 4.44 (2H, br s, OCH2Ar), 4.07 (1H, d, J = 7.6 
Hz, H13), 3.81 (3H, s, ArOMe), 3.78 (1H, dd, J = 4.1, 3.0 Hz, H9), 3.62 (1H, d, J = 10.0 Hz, 
H11), 3.51 (1H, dd, J = 8.9, 6.3 Hz, H7a), 3.44 (1H, dd, J = 9.0, 5.1 Hz, H7b), 2.89 (1H, d, J = 
2.1 Hz, H12), 1.94-1.83 (1H, m, H8), 1.81-1.73 (1H, m, H10), 1.78 (3H, s, Me14), 0.98 (9H, t, J 
= 7.9 Hz, OSiCH2CH3), 0.95 (3H, t, J = 7.8 Hz, Me12), 0.94 (9H, t, J = 7.8 Hz, OSiCH2CH3), 
0.89 (3H, d, J = 7.0 Hz, Me10), 0.80 (3H, d, J = 7.0 Hz, Me8), 0.64 (6H, q, J = 7.6 Hz, 













150.0, 130.6, 129.4, 113.9, 80.2, 79.4, 74.8, 74.1, 74.0, 73.1, 55.4, 41.7, 40.5, 35.0, 20.1, 13.6, 
11.2, 9.3, 7.2, 7.0, 5.7, 4.9; FT-IR (Thin film): νmax 3500 (br), 2956, 2913, 2877, 1614, 1514, 
1459, 1413, 1380, 1302, 1248, 1173, 1085, 1039, 1005, 865, 821, 738; HRMS (ES+) Calc. for 
C33H61IO5Si2H [M+H]+
 
721.3175, found 721.3174; 137 [α]D
20  = –9.4 (c 1.0, CHCl3), ent-137 
[α]D
20 = +10.0 (c 1.0, CHCl3). 
 
Mosher ester analysis for alcohol 136 
 
DCC (1 M in CH2Cl2, 3.47 μL, 34.7 μmol) was added in portion to a stirred solution of ent-136 
(5.0 mg, 6.94 μmol), (S)-α-methoxy-α-trifluoromethylphenylacetic acid (S-MTPA) (8.1 mg, 34.7 
μmol) and DMAP (4.2 mg, 34.7 μmol) in CH2Cl2 (70 μL). The mixture was stirred for 24 h at rt, 
during which a white precipitate formed. The mixture was filtered through cotton wool and the 
filtrate reduced to dryness. Purification by flash chromatography (2% EtOAc/PE 40-60) afforded 
the product (S)-MTPA ester 139 as a pale-yellow oil (3.4 mg, 4.16 μmol, 60%). The 
corresponding diastereomer was synthesised from ent-16 (5.0 mg, 6.94 μmol) to afford the 
diastereomeric ester (R)-MTPA ester 140 (5.5 mg, 5.82 μmol, 84%). 
 
(S)-MTPA ester 139 
Rf: 0.35 (5% EtOAc/PE 40-60);  1H NMR (400 MHz, CDCl3): δH 7.55-7.48 (2H, m, ArH), 7.42-
7.32 (3H, m, ArH), 7.19 (2H, d, J = 8.7 Hz, ArH), 6.86 (2H, d, J = 8.7 Hz, ArH), 6.10 (1H, s, 
H15), 5.65 (1H, dd, J = 4.3, 1.4 Hz, H9), 4.43 (1H, d, J = 2.4 Hz, H13), 4.37 (1H, d, J = 11.6 Hz, 
OCH2Ar), 4.34 (1H, d, J = 11.7 Hz, OCH2Ar), 3.81 (3H, s, ArOMe), 3.65 (1H, dd, J = 8.7, 3.3 
Hz, H11), 3.48 (3H, s, OMe), 3.12-3.02 (2H, m, H7), 2.61-2.51 (1H, m, H8), 2.25-2.15 (1H, m, 
H10), 1.99-1.89 (1H, m, H12), 1.67 (3H, s, Me14), 1.06 (3H, d, J = 7.2 Hz, Me10), 0.97 (9H, t, J 
= 7.9 Hz, OSiCH2CH3), 0.89 (9H, t, J = 8.0 Hz, OSiCH2CH3), 0.82 (3H, d, J = 6.8 Hz, Me12), 
0.81 (3H, d, J = 6.7 Hz, Me8), 0.64 (6H, q, J = 7.9 Hz, OSiCH2CH3), 0.56-0.44 (6H, m, 
OSiCH2CH3). 
 
(R)-MTPA ester 140 
Rf: 0.33 (5% EtOAc/PE 40-60);  1H NMR (400 MHz, CDCl3): δH 7.55-7.49 (2H, m, ArH), 7.40-




























H15), 5.59 (1H, dd, J = 4.8, 1.6 Hz, H9), 4.44 (1H, d, J = 2.2 Hz, H13), 4.40 (1H, d, J = 11.6 Hz, 
OCH2Ar), 4.35 (1H, d, J = 11.5 Hz, OCH2Ar), 3.80 (3H, s, ArOMe), 3.61 (1H, dd, J = 8.7, 3.0 
Hz, H11), 3.47 (3H, s, OMe), 3.14 (2H, d, J = 6.9 Hz, H7), 2.63-2.52 (1H, m, H8), 2.22-2.13 (1H, 
m, H10), 1.98-1.85 (1H, m, H12), 1.70 (3H, s, Me14), 0.96 (9H, t, J = 7.9 Hz, OSiCH2CH3), 0.93 
(9H, t, J = 7.9 Hz, OSiCH2CH3), 0.90 (3H, d, J = 7.2 Hz, Me10), 0.85 (3H, d, J = 6.8 Hz, Me8), 
0.76 (3H, d, J = 6.7 Hz, Me12), 0.62 (6H, q, J = 7.8 Hz, OSiCH2CH3), 0.59-0.49 (6H, m, 
OSiCH2CH3). 
 
Proton δH (S)-MTPA 139 δH (R)-MTPA 140 Δδ = δS – δR 
H12 1.94 1.92 +0.02 
Me12 0.82 0.76 +0.06 
H11 3.65 3.61 +0.04 
H10 2.20 2.18 +0.02 
Me10 1.06 0.89 +0.17 
H8 2.56 2.58 –0.02 
Me8 0.81 0.85 –0.04 
H7a 3.10 3.14 –0.04 
H7b 3.07 3.14 –0.07 
ArCH2a 4.37 4.40 –0.03 
ArCH2b 4.34 4.35 –0.01 
 





A flame-dried flask was charged with a suspension of Me3OBF4 (2.30 g, 15.5 mmol), Proton 
Sponge® (5.00 g, 23.3 mmol), activated 4 Å MS (ca. 6 g) in CH2Cl2 (16 mL). A solution of 
alcohol 137 (1.12 g, 1.55 mmol) in CH2Cl2 (2 mL) was added via cannula (2 x 1 mL wash) and 
the reaction left to stir for 7 h before quenching with NaHCO3 (5 mL). The solids were removed 
by filtration and the layers were separated. The aqueous layer was extracted with Et2O (3 x 10 
mL) and the combined organic extracts were washed with citric acid (10% w/v, 3 x 5 mL), brine 













flash column chromatography (2% ® 10% EtOAc/PE 40-60) to give the title compound as a 
colourless oil (808 mg, 1.10 mmol, 71%). Ent-141 was prepared in an analogous fashion from 
ent-137 (4.00 g, 5.55 mmol) to give a colourless oil (2.94 g, 4.00 mmol, 72%). 
 
Rf: 0.30 (4% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.26 (2H, d, J = 8.6 Hz, ArH), 
6.87 (2H, d, J = 8.7 Hz, ArH), 6.12 (1H, s, H15), 4.43 (2H, br s, OCH2Ar), 4.20 (1H, d, J = 5.0 
Hz, H13), 3.81 (3H, s, ArOMe), 3.62 (1H, dd, J = 6.4, 2.1 Hz, H11), 3.45 (1H, t, J = 8.6 Hz, H7a), 
3.39 (1H, dd, J = 9.3, 2.0 Hz, H9), 3.33 (1H, dd, J = 9.0, 6.4 Hz, H7b), 3.30 (3H, s, OMe9), 2.01-
2.00 (1H, m, H12), 1.99-1.98 (1H, m, H8), 1.95-1.91 (1H, m, H10) 1.72 (3H, d, J = 0.9 Hz, 
Me14), 0.97 (9H, t, J = 8.0 Hz, OSiCH2CH3), 0.93 (9H, t, J = 8.0 Hz, OSiCH2CH3), 0.88 (3H, d, 
J = 8.0 Hz, Me12), 0.87 (3H, d, J = 7.0 Hz, Me10), 0.84 (3H, d, J = 6.9 Hz, Me8), 0.62 (6H, q, J 
= 7.8 Hz, OSiCH2CH3), 0.55 (6H, q, J = 7.9 Hz, OSiCH2CH3); 13C NMR (125 MHz, CDCl3): δC 
159.5, 150.2, 130.9, 129.3, 113.9, 81.5, 78.8, 78.1, 77.0, 73.6, 72.7, 59.9, 55.5, 40.3, 39.0, 36.0, 
21.1, 16.1, 11.0, 10.4, 7.4, 7.1, 5.9, 5.1; FT-IR (Thin film): νmax 2955, 2910, 2877, 1613, 1514, 
1458, 1377, 1246, 1079, 1006, 822, 738; HRMS (ES+) Calc. for C34H63IO5Si2H [M+H]+
 
735.3335, found 735.3331; 141 [α]D20
 
= –15.7 (c 1.0, CHCl3), ent-141 [α]D






DDQ (375 mg, 1.65 mmol) was added to a solution of PMB ether 141 (808 mg, 1.10 mmol) in 
CH2Cl2/pH 7 buffer (9:1, 10 mL). After 1 h, the reaction was quenched with NaHCO3 (2 mL). 
The phases were separated and the aqueous layer extracted with CH2Cl2 (3 x 5 mL). The 
combined organic phases were washed with brine (5 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography (50% 
PhMe/CH2Cl2 ® 30% EtOAc/PE 40-60) to give the title compound as a colourless oil (510 mg, 
0.846 mmol, 77%). Ent-144 was prepared in an analogous fashion from ent-141 (2.10 g, 2.86 
mmol) to give a colourless oil (1.41 g, 2.29 mmol, 80%). 
 
Rf: 0.17 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 6.13 (1H, s, H15), 4.19 (1H, d, 
J = 5.0 Hz, H13), 3.67-3.60 (3H, m, H7a, H7b, H9), 3.38 (1H, dd, J = 8.9, 2.2 Hz, H11), 3.36 (3H, 












J = 7.8 Hz, OSiCH2CH3), 0.93 (9H, t, J = 9.1 Hz, OSiCH2CH3), 0.91 (6H, d, J = 8.9 Hz, Me8, 
Me12), 0.88 (3H, d, J = 7.1 Hz, Me10), 0.63 (6H, q, J = 8.0 Hz, OSiCH2CH3), 0.59-0.52 (6H, m, 
OSiCH2CH3); 13C NMR (125 MHz, CDCl3): δC 150.0, 8.9, 78.8, 78.2, 77.0, 67.0, 59.4, 40.3, 
38.8, 37.9, 21.0, 15.8, 11.0, 10.7, 7.3, 7.0, 5.9, 5.0; FT-IR (Thin film): νmax 3374 (br), 2958, 2910, 
2877, 1458, 1377, 1239, 1138, 1077, 737; HRMS (ES+) Calc. for C26H55IO4Si2H [M+H]+
 
615.2756, found 615.2753; 144 [α]D
20 = –13.2 (c 1.0, CHCl3), ent-144 [α]D
20 = +8.7 (c 1.0, CHCl3). 
 
Methyl sorbate (142) 
 
SOCl2 (13.0 mL, 178 mmol) was added slowly to a solution of sorbic acid 54 (20.0 g, 178 mmol) 
in MeOH (200 mL) at 0 °C. The reaction was heated at reflux for 3 h, then cooled to rt before 
diluting with CH2Cl2 (200 mL). The solution was washed with NaHCO3 (100 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The crude product was purified by distillation under 
reduced pressure (48 ˚C, 10 torr) to give the title compound as a colourless oil (21.3 g, 169 mmol, 
95%). 
 
Rf: 0.45 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.26 (1H, dd, J = 15.4, 10.0 
Hz, H3), 6.25-6.08 (2H, m, H4, H5), 5.78 (1H, d, J = 15.3 Hz, H2), 3.74 (3H, s, CO2Me), 1.85 
(3H, d, J = 5.7 Hz, H6). 
 
Data in agreement with that reported by Law.144 
 
methyl (2E,4E)-6-bromohexa-2,4-dienoate (143) 
 
Methyl sorbate 142 (6 g, 47.5 mmol) and NBS (10.5 g, 59.4 mmol) were brought to reflux in PhH 
(100 mL). BzOOBz (75% w/w with water, 3.10 g, 2.50 mmol) was added in one portion and the 
reaction was maintained at this temperature for 4 h. After cooling to rt, the solvent was 
concentrated in vacuo and the residue was taken up in Et2O (100 mL). The solution was washed 
with 10% NaOH until the washings were clear (5 x 20 mL) and then with H2O (20 mL), dried 
(MgSO4), filtered and concentrate in vacuo. The crude product was purified by flash column 













Rf: 0.29 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.26 (1H, dd, J = 15.2 Hz, 
10.8 Hz, H3), 6.39 (1H, dd, J = 15.0 Hz, 11.0 Hz, H4), 6.27-6.21 (1H, m, H5), 5.94 (1H, d, J = 
15.3 Hz, H2), 4.03 (2H, d, J = 7.5 Hz, H6), 3.75 (3H, s, CO2Me); 13C NMR (125 MHz, CDCl3): 
δC 167.0, 142.9, 136.8, 131.9, 122.8, 51.8, 31.3. 
 
Data in agreement with that reported by Law.144 
 
methyl (2E,4E)-6-(diethoxyphosphoryl)hexa-2,4-dienoate (104) 
 
Allyl bromide 143 (3.56 g, 17.4 mmol) and triethyl phosphite (20.8 mL, 122 mmol) were heated 
to 120 °C for 1 h, then cooled to 50 °C. The excess triethyl phosphite was removed under reduced 
pressure (42 ˚C, 10 torr) to give the title compound as a yellow oil (4.29 g, 16.4 mmol, 94%). 
 
Rf: 0.23 (EtOAc); 1H NMR (500 MHz, CDCl3): δH 7.26 (1H, dd, J = 15.7 Hz, 10.8 Hz, H3), 
6.33-6.27 (1H, m, H4), 6.09-6.01 (1H, m, H5), 5.85 (1H, dd, 3JH,H = 15.5 Hz, 4JP,H = 2.6 Hz, H2), 
4.13-4.07 (4H, m, OCH2CH3), 3.74 (3H, s, CO2Me), 2.71 (2H, dd, 1JP,H = 23.1 Hz, 3JH,H = 7.7 Hz, 
H6), 1.31 (6H, t, J = 7.1 Hz, OCH2CH3); 13C NMR (125 MHz, CDCl3): δC 167.4 (1C, d, J = 1.4 
Hz), 143.9 (1C, d, J = 4.8 Hz), 132.8 (1C, d, J = 14.7 Hz), 131.8 (1C, d, J = 12.5 Hz), 120.9 (1C, 
d, J = 4.3 Hz), 62.3 (1C, d, J = 6.7 Hz), 51.7 (1C, s), 31.4 (1C, d, J = 139.2 Hz), 16.6 (1C, d, J = 
5.8 Hz). 
 





To a stirred suspension of alcohol 144 (520 mg, 0.846 mmol) and NaHCO3 (284 mg, 3.38 mmol) 
in CH2Cl2 (8.5 mL) was added DMP (717 mg, 1.69 mmol). After 1 h, the reaction was diluted 
with CH2Cl2 (5 mL) and quenched with NaHCO3 (3 mL) and Na2S2O3 (3 mL) and stirring 
continued for another 30 min until a clear phase boundary was observed. The layers were 
separated and the aqueous phase extracted with CH2Cl2 (3 x 5 mL). The combined organic phases 


















product was rapidly filtered through a short plug of silica, eluting with 20% Et2O/PE 40-60 to 
give the title compound as a colourless oil (492 mg, 0.804 mmol, 95%). Ent-103 was prepared in 
an analogous fashion from ent-144 (400 mg, 0.651 mmol) to give a colourless oil (399 mg, 0.651 
mmol, 99%). 
 
Rf: 0.47 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 9.84 (1H, s, H7), 6.14 (1H, s, 
H15), 4.13 (1H, d, J = 6.5 Hz, H13), 3.77 (1H, dd, J = 9.2, 1.7 Hz, H9), 3.74 (1H, dd, J = 4.7, 3.2 
Hz, H11), 3.13 (3H, s, OMe9), 2.50-2.44 (1H, m, H8), 2.03-1.95 (1H, m, H10), 1.93-1.86 (1H, m, 
H12), 1.74 (3H, d, J = 1.0 Hz, Me14), 1.11 (3H, d, J = 7.1 Hz, Me8), 0.98 (9H, t, J = 7.9 Hz, 
OSiCH2CH3), 0.95-0.90 (15H, m, OSiCH2CH3, Me10, Me12), 0.65-0.53 (12H, m, OSiCH2CH3 
x2); 13C NMR (125 MHz, CDCl3): δC 204.9, 149.9, 80.9, 79.3, 78.8, 74.5, 58.5, 49.2, 40.1, 39.8, 
20.3, 14.8, 11.1, 7.3, 7.0, 6.8, 5.82, 5.0; FT-IR (Thin film): νmax 2954, 2877, 1726, 1457, 1329; 
HRMS (ES+) Calc. for C26H53IO4Si2Na [M+Na]+
 
635.2419, found 635.2414; 103 [α]D20
 
= –12.5 
(c 1.0, CHCl3), ent-103 [α]D20
 





LDA (5.92 mL, 2.96 mmol, 0.5 M in THF) was added to a solution of phosphonate 104 (776 mg, 
2.96 mmol) in THF (8.5 mL) at –78 °C to give a bright yellow-orange solution. The reaction was 
stirred for 30 min and then a solution of aldehyde 103 (492 mg, 0.804 mmol) in THF (1 mL) was 
added via cannula (2 x 0.5 mL wash). The reaction was stirred at –78 ˚C for 30 min, and then at –
40 ˚C for 30 min before quenching with NH4Cl (2 mL). The layers were separated and the 
aqueous phase extracted with Et2O (3 x 3 mL). The combined organic phases were washed with 
brine (1 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified 
by flash column chromatography (5% EtOAc/PE 40-60) to give the title compound as a 
colourless oil (329 mg, 0.456 mmol, 70%). Ent-101 was prepared in an analogous fashion from 
ent-103 (399 mg, 0.651 mmol) to give a colourless oil (329 mg, 0.456 mmol, 70%). 
 
Rf: 0.23 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.32 (1H, d, J = 15.2, 11.2 Hz, 
H3), 6.55 (1H, d, J = 14.7, 10.8 Hz, H5), 6.26 (1H, d, J = 14.9, 11.3 Hz, H4), 6.17 (1H, d, J = 













Hz, H2), 4.08 (1H, d, J = 7.5 Hz, H13), 3.74 (3H, s, CO2Me), 3.63 (1H, t, J = 3.8 Hz, H9), 3.31 
(3H, s, OMe9), 3.04 (1H, dd, J = 7.0, 5.0 Hz, H11), 2.47-2.37 (1H, m, H8), 2.02-1.92 (1H, m, 
H12), 1.90-1.83 (1H, m, H10), 1.73 (3H, d, J = 0.6 Hz, Me14), 1.05 (3H, d, J = 6.7 Hz, Me8), 
0.98-0.89 (24H, m, Me10, Me12, OSiCH2CH3 x2), 0.60-0.52 (12H, m, OSiCH2CH3 x2); 13C 
NMR (125 MHz, CDCl3): δC 167.7, 150.5, 145.1, 144.0, 141.3, 129.3, 128.5, 120.0, 87.0, 79.5, 
78.8, 73.8, 60.3, 51.6, 41.0, 40.00, 39.97, 20.1, 15.0, 14.6, 10.9, 7.3, 7.0, 5.9, 4.9; FT-IR (Thin 
film): νmax 2953, 2910, 2877, 1720, 1618, 1457, 1264, 1241, 1134, 1113, 1005, 727; HRMS (ES+) 
Calc. for C33H61IO5Si2H [M+H]+
 
721.3175, found 721.3176; 101 [α]D20
  
= –10.1 (c 1.0, CHCl3), 
ent-101 [α]D20
 
 = +13.6 (c 1.0, CHCl3). 
 
  








Ester ent-130 (20.0 g, 89.1 mmol) was dissolved in THF (250 mL) and cooled to 0 °C before 
adding LiAlH4 (3.89 g, 102.6 mmol) portionwise carefully while stirring. The reaction was 
warmed to rt for 3 h, then cooled to 0 °C again and carefully quenched with H2O (4 mL), NaOH 
(4 mL) and H2O (12 mL) successively. The precipitate was removed by filtration and washed on 
the filter with Et2O (3 x 50 mL). The combined organic portions were washed with brine (30 mL), 
dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (20% ® 40% EtOAc/PE 40-60) to afford the title compound as a pale 
yellow oil (16.9 g, 80.4 mmol, 90%). 
 
Rf: 0.25 (40% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 7.24 (2H, d, J = 8.5 Hz, ArH), 
6.87 (2H, d, J = 8.7 Hz, ArH), 4.43 (2H, br s, OCH2Ar), 3.79 (3H, s, ArOMe), 3.62-3.53 (2H, m, 
H19), 3.52-3.45 (1H, m, H17a), 3.39 (1H, t, J = 8.6 Hz, H17b), 2.70 (1H, m, H18), 2.91-2.71 (1H, 
m, OH), 0.87 (3H, d, J = 7.1 Hz, Me18); 13C NMR (125 MHz, CDCl3): δC 159.5, 130.4, 129.5, 
114.0, 75.1, 73.2, 67.7, 55.5, 35.8, 13.8; FT-IR (Thin film): νmax 3386 (br), 2872, 1612, 1586, 
1512, 1463, 1362, 1302, 1244, 1173, 1085, 1033, 818, 757, 709; HRMS (ES+) Calc. for 
C12H18O3Na [M+Na]+
 
233.1148, found 233.1149; [α]D
20 = +14.6 (c 1.0, CHCl3). 
 




DMSO (7.3 mL, 103 mmol) was added dropwise to a stirring solution of (COCl)2 (4.4 mL, 51.7 
mmol) in CH2Cl2 (120 mL) at –78 °C and stirred for 15 min. A solution of alcohol 155 (8.7 g, 
4.76 mmol) in CH2Cl2 (10 mL) was added dropwise to the reaction mixture via cannula (2 x 5 
mL wash) at –78 °C and stirred for 15 min. Et3N (28.8 mL, 207 mmol) was added dropwise and 
the reaction stirred for another 45 min before quenching with NH4Cl (30 mL) while warming to 















mL), dried (Na2SO4), filtered and concentrated in vacuo to give a solution of the title compound 
in CH2Cl2 (ca. 20 mL) and used without further purification. 
 
Rf: 0.25 (40% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 9.71 (1H, d, J = 1.5 Hz, H17), 
7.24 (2H, d, J = 8.8 Hz, ArH), 6.88 (2H, d, J = 8.8 Hz, ArH), 4.46 (2H, br s, OCH2Ar), 3.81 (3H, 
s, ArOMe), 3.65 (1H, dd, J = 9.3, 6.8 Hz, H19a), 3.60 (1H, dd, J = 9.3, 4.9 Hz, H19b), 2.61-2.69 
(1H, m, H18), 1.12 (3H, d, J = 7.3 Hz, Me18). 
 




To a stirring solution of CBr4 (27.4 g, 82.8 mmol) in CH2Cl2 (150 mL) at 0 °C was added PPh3 
(43.4 g, 166 mmol) and stirred for 30 min. A solution of aldehyde 156 (assumed 8.6 g, 41.4 
mmol) in CH2Cl2 (20 mL) was added to the reaction mixture at 0 °C via cannula (2 x 10 mL 
wash). The reaction mixture was stirred at –78 °C for 30 min, then at 0 °C for 30 min before 
quenching with NH4Cl (50 mL) and warmed up to rt. The layers were separated and the aqueous 
layer extracted with CH2Cl2 (3 x 50 mL). The combined organic extracts were washed with brine 
(5 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by 
flash column chromatography (5% ® 20% EtOAc/PE 40-60) to afford the title compound as a 
colourless oil (11.6 g, 31.9 mmol, 77% over two steps). 
 
Rf: 0.29 (5% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 7.25 (2H, d, J = 8.5 Hz, ArH), 
6.88 (2H, d, J = 8.5 Hz, ArH), 6.30 (1H, d, J = 9.0 Hz, H17), 4.46 (1H, d, J = 12.0 Hz, OCH2Ar), 
4.43 (1H, d, J = 11.9 Hz, OCH2Ar), 3.81 (3H, s, ArOMe), 3.36 (1H, dd, J = 9.0, 6.3 Hz, H19a), 
3.33 (1H, dd, J = 8.7, 5.6 Hz, H19b), 2.82-2.72 (1H, m, H18), 1.05 (3H, d, J = 6.8 Hz, Me18); 
13C NMR (100 MHz, CDCl3): δC 158.5, 140.6, 130.0, 128.4, 113.0, 88.0, 72.0, 71.9, 54.5, 38.0, 
15.1; [α]D
20 = –15.6 (c 1.0, CHCl3). 
 















To a solution of vinyl dibromide 157 (12.5 g, 34.3 mmol) in THF (200 mL) at –78 °C was added 
n-BuLi (1.6 M in hexanes, 42.9 mL, 68.7 mmol) over 10 min. The reaction mixture was stirred 
for 1 h before adding MeI (6.4 mL, 103 mmol) and stirred for another 30 min. The reaction was 
quenched with NH4Cl (50 mL) while warming to rt and the layers separated. The aqueous layer 
was extracted with Et2O (3 x 50 mL). The combined organic extracts were washed with brine (20 
mL), dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (5% ® 20% EtOAc/PE 40-60) to afford the title compound as a 
colourless oil (6.90 g, 31.6 mmol, 92%). 
 
Rf: 0.37 (5% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 7.27 (2H, d, J = 8.7 Hz, ArH), 
6.88 (2H, d, J = 8.7 Hz, ArH), 4.51 (1H, d, J = 11.8 Hz, OCH2Ar), 4.47 (1H, d, J = 11.9 Hz, 
OCH2Ar), 3.81 (3H, s, ArOMe), 3.45 (1H, dd, J = 9.1, 6.1 Hz, H19a), 3.29 (1H, dd, J = 9.0, 7.5 
Hz, H19b), 2.70-2.65 (1H, m, H18), 1.79 (3H, d, J = 2.4 Hz, Me16), 1.16 (3H, d, J = 6.9 Hz, 
Me18); 13C NMR (100 MHz, CDCl3): δC 159.1, 130.4, 129.1, 113.7, 81.1, 76.3, 74.0, 72.5, 55.2, 
26.6, 18.0, 3.5; FT-IR (Thin film): νmax 2858, 1612, 1512, 1457, 1358, 1302, 1245, 1173, 1087, 
1035, 819; HRMS (ES+) Calc. for C14H18O2H [M+H]+
 
219.1380, found 219.1381; [α]D
20 = +2.3 (c 
1.0, CHCl3). 
 




The following reaction was carried out in darkness due to the light sensitivity of the Schwartz 
reagent Cp2Zr(H)Cl. 
 
DIBAL (1 M in hexanes, 63.2 mL, 63.2 mmol) was added to a suspension of Cp2ZrCl2 (18.5 g, 
63.2 mmol) in THF (90 mL) at 0 °C and stirred for 30 min. A solution of alkyne 158 (6.90 g, 31.6 
mmol) in THF (80 mL) was added to the reaction mixture via cannula (2 x 5 mL wash) before 
warming to rt and left to stir for 7 h. The reaction was cooled to –78 °C, followed by adding a 













quenched with HCl (1 M, 50 mL) and warmed to rt. The reaction mixture was diluted with Et2O 
(50 mL) and the layers separated. The aqueous layer was extracted with Et2O (3 x 50 mL) and the 
combined organic extracts washed with Na2S2O3 (2 x 50 mL), brine (20 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (5% ® 20% EtOAc/PE 40-60) to afford the title compound as a yellow oil (8.28 
g, 0.357 mmol, 76%). 
 
Rf: 0.37 (5% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 7.23 (2H, d, J = 8.7 Hz, ArH), 
6.87 (2H, d, J = 8.8 Hz, ArH), 5.98 (1H, dq, J = 9.5, 1.4 Hz, H17), 4.46 (2H, br s, OCH2Ar), 3.79 
(3H, s, ArOMe), 3.29 (2H, dd, J = 6.7, 2.8 Hz, H19), 2.74-2.65 (1H, m, H18), 2.38 (3H, d, J = 1.6 
Hz, Me16), 0.97 (3H, d, J = 6.8 Hz, Me18); 13C NMR (125 MHz, CDCl3): δC 159.2, 143.9, 130.5, 
129.2, 113.8, 94.5, 73.9, 72.7, 55.3, 36.2, 28.0, 17.0; FT-IR (Thin film): νmax 2960, 2852, 1612, 
1586, 1512, 1456, 1358, 1302, 1246, 1172, 1091, 1036, 819, 757; HRMS (ES+) Calc. for 
C14H19IO2NH4 [M+NH4]+
 
364.0768, found 364.0770; [α]D
20 = +10.8 (c 1.0, CHCl3). 
 




To a stirred solution of the PMB ether 159 (4.99 g, 14.4 mmol) in CH2Cl2/pH 7 buffer (9:1, 140 
mL) at 0 °C was added DDQ (4.93 g, 21.7 mmol). The reaction mixture was warmed to rt and 
stirred for 2 h before being quenched with NaHCO3 (50 mL) and diluted with H2O (30 mL). The 
layers were separated and the aqueous layer extracted with CH2Cl2 (3 x 50 mL). The combined 
organic extracts were washed with brine (30 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The crude product was purified by flash column chromatography (5% ® 40% Et2O/PE 
30-40) to afford the title compound as a colourless oil (2.94 g, 13.0 mmol, 90%). 
 
Rf: 0.25 (20% Et2O/PE 30-40); 1H NMR (400 MHz, CDCl3): δH 5.95 (1H, dq, J = 9.7, 1.4 Hz, 
H17), 3.43 (1H, dd, J = 10.8, 5.9 Hz, H19a), 3.38 (1H, dd, J = 10.7, 7.5 Hz, H19b), 2.65-2.57 (1H, 
m, H18), 2.39 (3H, d, J = 2.0 Hz, Me16), 0.94 (3H, d, J = 7.0 Hz, Me18); 13C NMR (125 MHz, 
CDCl3): δC 114.4, 95.4, 66.9, 38.5, 28.1, 16.4; FT-IR (Thin film): νmax 3335, 2960, 2925, 2871, 
1636, 1602, 1429, 1377, 1258, 1117, 1076, 1030, 996, 977, 936, 906, 857; HRMS (ES+) Calc. 
for C6H11IOH [M–H]+
 
224.9771, found 224.9776; [α]D














A slurry of DMP (810 mg, 1.91 mmol) and NaHCO3 (160 mg, 1.91 mmol) in CH2Cl2 (15 mL) 
was stirred at rt for 10 min before cooling to 0 °C. A solution of alcohol 160 (354 mg, 0.956 
mmol) in CH2Cl2 (1 mL) was added via cannula (2 x 0.5 mL wash) and the reaction warmed to rt. 
Upon complete reaction, the reaction was cooled to 0 °C and quenched with Na2S2O3 (3 mL) and 
NaHCO3 (3 mL) and stirred vigorously for 30 min while warming to rt. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were washed with brine (2 mL), dried (Na2SO4), filtered and carefully concentrated in 
vacuo to give the title compound. This solution was kept at 0 °C when left idle and was used 
without further purification. 
 
Rf: 0.27 (10% Et2O/PE 30-40); 1H NMR (400 MHz, CDCl3): δH 9.51 (1H, d, J = 1.7 Hz, H19), 
6.06 (1H, dq, J = 9.2, 1.3 Hz, H17), 3.30-3.24 (1H, m, H18), 2.45 (3H, d, J = 1.5 Hz, Me18), 1.20 
(3H, d, J = 7.0 Hz, Me16). 
 




Weinreb amide ent-131 (4.10 g, 15.3 mmol) was dissolved in Et2O (150 mL) and cooled to –
78 °C. MeMgBr (3.0 M in Et2O, 15.3 mL, 46.0 mmo) was added dropwise and the reaction 
stirred vigorously at –10 °C overnight before carefully quenching with NH4Cl (50 mL). The 
reaction was warmed to rt with stirring before allowing the phases to separate and extracting the 
aqueous layer with EtOAc (3 x 30 mL). The combined organic extracts were washed with brine 
(30 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by 
flash column chromatography (10% ® 20% EtOAc/PE 40-60) to give the title compound as a 















Rf: 0.35 (20% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 7.23 (1H, d, J = 8.7 Hz, ArH), 
6.87 (1H, d, J = 8.7 Hz, ArH), 4.44 (1H, d, J = 11.7 Hz, OCH2Ar), 4.41 (1H, d, J = 11.7 Hz, 
OCH2Ar), 3.80 (3H, s, ArOMe), 3.59 (1H, dd, J = 9.2, 7.6 Hz, H25a), 3.45 (1H, dd, J = 9.3, 5.5 
Hz, H25b), 2.89-2.78 (1H, m, H24), 2.17 (3H, s, H20), 1.08 (3H, d, J = 7.1 Hz, Me24); [α]D
20 = 
+14.8 (c 1.0, CHCl3). 
 




A solution of ketone 153 (642 mg, 3.08 mmol) in Et2O (5 mL) was added via cannula (2 x 2 mL 
wash) to a stirred solution of (–)-Ipc2BCl (1.0 M in Et2O, 2.83 mL, 2.83 mmol) and NEt3 (0.57 
mL, 4.11 mmol) at 0 °C. The resulting yellow suspension was stirred for 1 h at 0 °C then cooled 
to −78 °C. A solution of aldehyde 154 (575 mg, 2.57 mmol) in Et2O (5 mL) was dried over 
activated 4 Å MS and added to the reaction mixture via cannula (2 x 1 mL wash). After 3 h, the 
reaction mixture was transferred to a freezer and left for a further 16 h. The reaction was then 
quenched with MeOH (5 mL) and pH 7 buffer (5 mL) and H2O2 (30% aq., 5 mL). The mixture 
was warmed to rt, stirred for 1 h and the layers separated. The aqueous layer was extracted with 
EtOAc (5 x 10 mL) and the combined organic phases washed with water (5 mL), brine (5 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. The resulting residue was purified by flash 
column chromatography (20% → 50% EtOAc/PE 40-60) to give the title compound as a 
colourless oil (807 mg, 1.80 mmol, 70% over two steps) as a single diastereomer. 
 
Rf: 0.24 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.21 (2H, d, J = 8.8 Hz, ArH), 
6.88 (2H, d, J = 8.7 Hz, ArH), 5.96 (1H, dq, J = 10.2, 1.6 Hz, H17), 4.43 (1H, d, J = 11.8 Hz, 
OCH2Ar), 4.40 (1H, d, J = 11.6 Hz, OCH2Ar), 3.84-3.78 (1H, m, H19), 3.83 (3H, s, ArOMe), 
3.57 (1H, dd, J = 9.0, 8.4 Hz, H25a), 3.45 (1H, dd, J = 9.0, 5.0 Hz, H25b), 3.15 (1H, d, J = 4.1 
Hz, OH), 2.92-2.85 (1H, m, H24), 2.72 (1H, dd, J = 17.4, 2.5 Hz, H20a), 2.49 (1H, dd, J = 17.5, 
9.5 Hz, H20b), 2.46 (1H, dd, J = 10.1, 7.2 Hz, H18), 2.38 (3H, d, J = 1.6 Hz, Me16), 1.05 (3H, d, 
J = 7.1 Hz, Me24), 1.02 (3H, d, J = 6.8 Hz, Me18); 13C NMR (125 MHz, CDCl3): δC 215.0, 
160.0, 143.4, 130.0, 129.7, 114.2, 95.1, 73.4, 72.2, 71.1, 55.6, 47.0, 46.9, 41.3, 28.4, 16.5, 14.5, 
13.5; FT-IR (Thin film): νmax 3485 (br), 2933, 1707, 1613, 1514, 1462, 1376, 1203, 1248, 1174, 
25 24 20 16
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O OHPMBO




1091, 1034, 821; HRMS (ES+) Calc. for C19H27IO4NH4 [M+NH4]+
 
464.1292, found 464.1282; 
[α]D
20 = +46.6 (c 1.0, CHCl3). 
 
Mosher ester analysis for aldol adduct 152 
 
DCC (1 M in CH2Cl2, 89.6 μL, 896 μmol) was added in portion to a stirred solution of ent-16 
(5.0 mg, 11.2 μmol), (S)-α-methoxy-α-trifluoromethylphenylacetic acid (S-MTPA) (21.0 mg, 
89.6 μmol) and DMAP (11.0 mg, 89.6 μmol) in CH2Cl2 (50 μL). The mixture was stirred for 24 h 
at rt, during which a white precipitate formed. The mixture was filtered through cotton wool and 
the filtrate reduced to dryness. Purification by flash chromatography (10% ® 20% EtOAc/PE 40-
60) afforded the product (S)-MTPA ester 165 as a pale-yellow oil (3.7 mg, 5.59 μmol, 50%). 
The corresponding diastereomer was synthesised from ent-16 (5.0 mg, 11.2 μmol) to afford the 
diastereomeric ester (R)-MTPA ester 166 (5.6 mg, 8.45 μmol, 75%). 
 
(S)-MTPA ester 165 
Rf: 0.26 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.52-7.46 (2H, m, ArH), 7.42-
7.37 (3H, m, ArH), 7.20 (2H, d, J = 8.7 Hz, ArH), 6.87 (2H, d, J = 8.8 Hz, ArH), 5.87 (1H, dq, J 
= 10.3, 1.4 Hz, H17), 5.42 (1H, q, J = 5.8 Hz, H19), 4.41 (1H, d, J = 11.4 Hz, OCH2Ar), 4.37 (1H, 
d, J = 11.6 Hz, OCH2Ar), 3.80 (3H, s, ArOMe), 3.52 (1H, t, J = 8.7 Hz, H25a), 3.49 (3H, s, 
OMe), 3.44 (1H, dd, J = 9.0, 5.1 Hz, H25b), 2.84-2.76 (4H, m, H18, H20a, H20b, H24), 2.32 (3H, 
d, J = 1.5 Hz, Me16), 0.99 (3H, d, J = 7.0 Hz, Me24), 0.87 (3H, d, J = 6.7 Hz, Me18). 
 
(R)-MTPA ester 166 
Rf: 0.26 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.19 (2H, d, J = 8.8 Hz, ArH), 
6.88 (2H, d, J = 8.7 Hz, ArH), 5.98 (1H, dq, J = 9.8, 1.4 Hz, H17), 5.42 (1H, dt, J = 6.9, 5.2 Hz, 
H19), 4.40 (1H, d, J = 11.6 Hz, OCH2Ar), 4.37 (1H, d, J = 11.7 Hz, OCH2Ar), 3.81 (3H, s, 
ArOMe), 3.57 (1H, m, H25a), 3.49 (3H, s, OMe), 3.41 (1H, dd, J = 9.0, 5.1 Hz, H25b), 2.92-2.86 
(1H, m, H24), 2.85 (1H, dd, J = 18.1, 7.0 Hz, H20a), 2.49 (1H, dd, J = 18.1, 5.5 Hz, H20b), 2.80-
2.74 (1H, m, H18), 2.40 (3H, d, J = 1.5 Hz, Me16), 0.94 (3H, d, J = 7.1 Hz, Me24), 0.92 (3H, d, J 
= 6.9 Hz, Me18). 
 


















Proton δH (S)-MTPA 165 δH (R)-MTPA 166 Δδ = δS – δR 
H25a 3.55 3.49 +0.06 
H25b 3.46 3.41 +0.05 
H24 N.A.a 2.88 N.A. 
Me24 0.99 0.94 +0.05 
H20a N.A.a 2.85 N.A. 
H20b N.A.a 2.75 N.A. 
H18 N.A.a 2.76 N.A. 
Me18 0.87 0.92 –0.05 
H17 5.87 5.98 –0.11 
Me16 2.32 2.40 –0.08 
a obscured in a 4H multiplet 





To a stirred solution of alcohol 152 (980 mg, 2.20 mmol) in CH2Cl2 (20 mL) at −78 °C was 
added 2,6-lutidine (0.38 mL, 3.29 mmol) and TBSOTf (0.61 mL, 2.64 mmol). After 30 min the 
reaction was quenched with MeOH (5 mL) and NaHCO3 (5 mL). The aqueous layer was 
extracted with CH2Cl2 (3 x 10 mL) and the organics dried (Na2SO4), filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (5-20% EtOAc/PE 40-60) to 
give the title compound as a colourless oil (1.18 g, 2.10 mmol, 95%). 
 
Rf: 0.17 (5% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.21 (2H, d, J = 8.6 Hz, ArH), 
6.87 (2H, dq J = 8.6 Hz, ArH), 6.03 (1H, dq, J = 9.8, 1.4 Hz, H17), 4.43 (1H, d, J = 11.6 Hz, 
OCH2Ar), 4.39 (1H, d, J = 11.7 Hz, OCH2Ar), 4.13 (1H, td, J = 6.0, 4.0 Hz, H19), 3.80 (3H, s, 
ArOMe), 3.57 (1H, dd, J = 9.0, 7.7 Hz, H25a), 3.44 (1H, dd, J = 9.1, 5.4 Hz, H25b), 2.80 (1H, 
qnd, J = 7.2, 5.4 Hz, H24), 2.72 (1H, dd, J = 17.7, 6.2 Hz, H20a), 2.49 (1H, dd, J = 17.7, 5.7 Hz, 
H20b), 2.53-2.46 (1H, m, H18), 2.39 (3H, d, J = 1.4 Hz, Me16), 1.05 (3H, d, J = 7.0 Hz, Me24), 
0.90 (3H, d, J = 6.8 Hz, Me18), 0.86 (9H, s, OSit-BuMe2), 0.07 (3H, s, OSit-BuMe2), –0.02 (3H, 
s, OSit-BuMe2); 13C NMR (125 MHz, CDCl3): δC 211.4, 159.6, 144.9, 130.4, 129.6, 114.1, 94.6, 
73.3, 72.2, 70.9, 55.6, 48.0, 47.5, 41.1, 28.3, 26.2, 18.4, 14.5, 13.5, –4.2, –4.5; FT-IR (Thin film): 
νmax 2933, 2856, 1714, 1613, 1514, 1462, 1376, 1302, 1249, 1173, 1097, 1037, 836, 777; HRMS 
25 24 20 16
I
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(ES+) Calc. for C25H41IO4SiNH4 [M+NH4]+
 
578.2157, found 578.2143; [α]D






To a stirred solution of i-Pr2NH (3.00 mL, 21.4 mmol) in THF (4 mL) at 0 °C was added n-BuLi 
(11.7 mL, 18.7 mmol, 1.6 M in hexanes). The resulting pale yellow solution was stirred at 0 °C 
for 15 min then cooled to −78 °C. Ethyl acetate (1.74 mL, 17.8 mmol) was added dropwise. The 
reaction mixture was stirred at −78 °C for 1 h to give a ca. 0.9 M solution of the derived lithium 
enolate. 
 
A solution of ketone 167 (1.00 g, 1.78 mmol) in THF (10 mL) was cooled to −78 °C before 
adding the above lithium enolate solution (0.9 M in THF, 9.89 mL, 8.90 mmol). The reaction was 
quenched after 1.5 h with NaHCO3 (10 mL) and warmed to rt. The mixture was diluted with Et2O 
(20 mL) and the aqueous layer extracted with Et2O (3 x 20 mL). The organic phases were dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (10% EtOAc/PE 40-60) to give the title compound as a colourless oil (1.12 g, 
1.72 mmol, 97%) as a mixture of diastereomers (d.r. 5:1). 
 
Major isomer: Rf: 0.16 (5% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.24 (2H, d, J = 
8.7 Hz, ArH), 6.88 (2H, d, J = 8.8 Hz, ArH), 6.18 (1H, dq, J = 9.5, 1.5 Hz, H17), 4.44 (1H, d, J = 
11.6 Hz, OCH2Ar), 4.40 (1H, d, J = 11.5 Hz, OCH2Ar), 4.12 (2H, q, J = 7.3 Hz, OCH2CH3), 
3.99-3.95 (1H, m, H19), 3.97 (1H, s, OH), 3.81 (3H, s, ArOMe), 3.60 (1H, dd, J = 9.2, 5.0 Hz, 
H25a), 3.39 (1H, dd, J = 9.3, 6.4 Hz, H25b), 2.74-2.66 (1H, m, H24), 2.58 (1H, d, J = 15.3 Hz, 
H22a), 2.53 (1H, d, J = 15.3 Hz, H22b), 2.38 (3H, d, J = 1.4 Hz, Me16), 2.12-2.03 (1H, m, H18), 
1.79 (1H, dd, J = 15.0, 5.8 Hz, H20a), 1.68 (1H, dd, J = 14.9, 5.9 Hz, H20b), 1.24 (3H, t, J = 7.1 
Hz, OCH2CH3) 1.00 (3H, d, J = 7.0 Hz, Me24), 0.93 (3H, d, J = 7.0 Hz, Me18), 0.89 (9H, s, 
OSit-BuMe2), 0.08 (3H, s, OSit-BuMe2), 0.07 (3H, s, OSit-BuMe2); 13C NMR (125 MHz, 
CDCl3): δC 172.3, 159.2, 144.7, 130.4, 129.3, 113.8, 93.8, 74.3, 73.0, 72.1, 72.0, 60.6, 55.3, 42.1, 
41.1, 40.8, 39.3, 28.1, 26.0, 18.1, 14.2, 14.1, 12.9, –4.1, –4.3; HRMS (ES+) Calc. for 
C29H49IO6SiH [M+H]+
 


















A solution of ester 168 (1.12 g, 1.72 mmol) in THF (5 mL) was cooled to 0 °C before slowly 
adding HFpy (1.5 mL). The reaction mixture was allowed to warm to rt and stirred for 3 h. The 
reaction mixture was transferred to an ice-cold NaHCO3 (20 mL) portionwise and stirred until 
effervescence ceased. The layers were separated and the aqueous layer extracted with EtOAc (3 x 
30 mL). The combined organic phases were dried (MgSO4), filtered and concentrated in vacuo. 
The residue was purified by flash column chromatography (30% → 50% EtOAc/PE 40-60) to 
give the title compound as a colourless oil (713 mg, 1.46 mmol, 85%) as a mixture of 
diastereomers (d.r. 5:1). 
 
Method B 
TsOHH2O (140 mg, 0.74 mmol) was added to a solution of ester 168 (1.20 g, 1.85 mmol) in 
MeOH (20 mL) at rt and stirred for 16 h. The reaction was quenched with NaHCO3 (5 mL) and 
concentrated in vacuo before partitioning between EtOAc (20 mL) and H2O (10 mL). The phases 
were separated and the aqueous phase extracted with EtOAc (3 x 10 mL). The organic phases 
were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (30% → 50% EtOAc/PE 40-60) to give the title compound as a 
colourless oil (750 mg, 1.54 mmol, 83%) as a mixture of diastereomers (d.r. 5:1). 
 
Major isomer: Rf: 0.32 (40% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.23 (2H, d, J = 
8.7 Hz, ArH), 6.90 (2H, d, J = 8.7 Hz, ArH), 5.98 (1H, dq, J = 10.0, 1.5 Hz, H17), 4.48 (1H, d, J 
= 11.5 Hz, OCH2Ar), 4.41 (1H, d, J = 11.5 Hz, OCH2Ar), 3.88 (1H, ddd, J = 11.4, 7.2, 4.5 Hz, 
H19), 3.87 (1H, s, OH), 3.82 (3H, s, ArOMe), 3.70 (1H, dd, J = 9.6, 3.4 Hz, H25a), 3.44 (1H, dd, 
J = 9.8, 5.1 Hz, H25b), 2.75-2.65 (1H, m, H18), 2.58 (2H, s, H22), 2.38 (3H, d, J = 1.6 Hz, 
Me16), 2.00 (1H, dd, J = 14.6, 4.5 Hz, H20a), 1.85-1.77 (1H, m, H24), 1.68 (1H, dd, J = 14.5, 
11.1 Hz, H20b), 1.09 (3H, d, J = 6.7 Hz, Me18), 1.04 (3H, d, J = 7.0 Hz, Me24); 13C NMR (125 
MHz, CDCl3): δC 171.4, 159.7, 141.2, 129.7, 129.1, 114.1, 96.0, 79.1, 73.6, 73.5, 72.1, 55.4, 42.6, 


















To a stirred solution of lactone 169 (480 mg, 0.983 mmol) in Ac2O/pyr/PhH (1:5:5, 11 mL) was 
added DMAP (100 mg, 0.983 mmol). The reaction mixture was heated to reflux for 16 h then 
cooled to rt, diluted with CH2Cl2 (3 mL) and carefully quenched with NaHCO3 (3 mL). The 
layers were separated and the aqueous layer extracted with CH2Cl2 (3 x 5 mL). The combined 
organic phases were dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified 
by flash column chromatography (30% → 50% EtOAc/PE 40-60) to give the title compound as a 
pale yellow oil (384 mg, 0.816 mmol, 83%). 
 
Rf: 0.15 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.22 (2H, d, J = 8.7 Hz, ArH), 
6.89 (2H, d, J = 8.7 Hz, ArH), 5.97 (1H, dq, J = 10.1, 1.4 Hz, H17), 5.82 (1H, s, H22), 4.44 (1H, 
d, J = 11.6 Hz, OCH2Ar), 4.39 (1H, d, J = 11.6 Hz, OCH2Ar), 4.06 (1H, ddd, J = 11.0, 6.8, 4.4 
Hz, H19), 3.81 (3H, s, ArOMe), 3.45 (1H, dd, J = 9.4, 5.6 Hz, H25a), 3.41 (1H, dd, J = 9.4, 7.6 
Hz, H25b), 2.76-2.66 (1H, m, H18), 2.66-2.54 (1H, m, H24), 2.40 (3H, d, J = 1.6 Hz, Me16), 
2.26 (1H, dd, J = 17.6, 4.6 Hz, H20a), 2.19 (1H, dd, J = 17.6, 11.4, 1.4 Hz, H20b), 1.10 (3H, d, J 
= 7.0 Hz, Me24), 1.09 (3H, d, J = 7.0 Hz, Me18); 13C NMR (125 MHz, CDCl3): δC 165.2, 163.2, 
159.5, 141.2, 130.0, 129.5, 115.7, 114.1, 96.0, 80.0, 73.1, 72.6, 55.5, 40.4, 39.9, 29.7, 28.3, 16.2, 
15.7; FT-IR (Thin film): νmax 2964, 2932, 2870, 1715, 1637, 1612, 1586, 1513, 1457, 1380, 1359, 
1302, 1248, 1208, 1173, 1091, 1034, 868, 820, 733, 666; HRMS (ES+) Calc. for C21H27IO4NH4 
[M+NH4]+
 
488.1292, found 488.1283; [α]D





To a stirred solution of enoate 151 (160 mg, 0.340 mmol) in THF/t-BuOH/H2O (1:1:1, 0.6 mL) 
was added citric acid (130 mg, 0.680 mmol), K2OsO42H2O (2.5 mg, 6.8 μmol) and NMO (50 wt% 
in H2O, 49 μL, 0.238 mmol). The reaction mixture was stirred for 5 h then quenched with 
Na2SO3 (0.5 mL) and NaHCO3 (0.5 mL). The layers were separated and the aqueous layer 




















concentrated in vacuo. The residue was purified by flash column chromatography (20% → 50% 
EtOAc/PE 40-60) to give the title compound as a colourless oil (94.3 mg, 0.187 mmol, 55%, 85% 
brsm) as a single diastereomer. The stereochemistry was confirmed by the diagonostic nOe 
interaction of H20b and H22. 
 
Rf: 0.43 (50% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.23 (2H, d, J = 8.8 Hz, ArH), 
6.88 (2H, d, J = 8.7 Hz, ArH), 6.02 (1H, dq, J = 10.0, 1.5 Hz, H17), 4.50 (1H, ddd, J = 11.5, 6.6, 
3.7 Hz, H19), 4.44 (2H, s, OCH2Ar), 4.19 (1H, d, J = 1.2 Hz, H22), 3.92 (1H, d, J = 1.9 Hz, 
OH22), 3.81 (3H, s, ArOMe), 3.68 (1H, dd, J = 9.7, 8.4 Hz, H25a), 3.57 (1H, br s, OH21), 3.50 
(1H, dd, J = 9.7, 4.2 Hz, H25b), 2.71-2.61 (1H, m, H18), 2.38 (3H, d, J = 1.5 Hz, Me16), 2.22-
2.12 (1H, m, H24), 1.85 (1H, dd, J = 14.2, 3.7 Hz, H20a), 1.76 (1H, ddd, J = 14.5, 11.1, 1.9 Hz, 
H20b), 1.06 (3H, d, J = 6.7 Hz, Me18), 0.98 (3H, d, J = 7.1 Hz, Me24); 13C NMR (125 MHz, 
CDCl3): δC 174.8, 159.5, 141.0, 129.7, 129.6, 114.1, 96.1, 80.3, 74.4, 73.3, 73.0, 71.8, 55.4, 40.3, 
40.1, 33.6, 28.3, 15.9, 12.2; FT-IR (Thin film): νmax 3441 (br), 2963, 2933, 2862, 1731, 1637, 
1613, 1586, 1514, 1461, 1302, 1218, 1174, 1100, 1033, 821, 760, 669; HRMS (ES+) Calc. for 
C21H29IO6NH4 [M+NH4]+
 
522.1347, found 522.1339; [α]D





A solution of diol 174 (170 mg, 0.337 mmol) in CH2Cl2 (3 mL) was cooled to 0 °C and 2,6-
lutidine (0.31 mL, 2.70 mmol) and TESOTf (0.38 mL, 1.69 mmol) were added sequentially. The 
reaction mixture was stirred at 0 °C for 24 h then quenched with NaHCO3 (1 mL). The layers 
were separated and the aqueous layer extracted with CH2Cl2 (3 x 5 mL). The combined organic 
phases were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (5% → 10% EtOAc/PE 40-60) to give the title compound as a 
colourless oil (218 mg, 0.297 mmol, 88%). 
 
Rf: 0.44 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.21 (2H, d, J = 8.6 Hz, ArH), 
6.89 (2H, d, J = 8.6 Hz, ArH), 6.00 (1H, dq, J = 10.0, 1.3 Hz, H17), 4.41 (1H, d, J = 11.6 Hz, 
OCH2Ar), 4.38 (1H, d, J = 11.6 Hz, OCH2Ar), 4.37-4.30 (1H, m, H19), 4.22 (1H, s, H22), 3.81 
(3H, s, ArOMe), 3.32 (1H, dd, J = 9.5, 4.9 Hz, H25a), 3.23 (1H, dd, J = 9.5, 5.4 Hz, H25b), 2.69-














14.2, 3.5 Hz, H20a), 1.60 (1H, dd, J = 14.0, 11.8 Hz, H20b), 1.03 (3H, d, J = 6.8 Hz, Me18), 0.99 
(3H, d, J = 7.0 Hz, Me24), 0.94 (9H, t, J = 8.0 Hz, OSiCH2CH3), 0.94 (9H, t, J = 8.0 Hz, 
OSiCH2CH3), 0.90 (12H, m, OSiCH2CH3); 13C NMR (125 MHz, CDCl3): δC 172.7, 159.5, 141.4, 
130.1, 129.7, 114.0, 96.0, 79.6, 78.8, 74.1, 73.5, 71.8, 55.4, 40.1, 37.7, 33.0, 28.3, 16.1, 11.9, 7.4, 
7.2, 6.7, 5.3; FT-IR (Thin film): νmax 2955, 2912, 2876, 1751, 1612, 1514, 1458, 1379, 1302, 









To an emulsion of PMB ether 187 (190 mg, 0.260 mmol) in CH2Cl2/pH 7 buffer (9:1, 2 mL) at 
0 °C was added DDQ (118 mg, 0.520 mmol). The resulting green suspension was stirred for 2 h 
then quenched with NaHCO3 (2 mL). The layers were separated and the aqueous layer extracted 
with CH2Cl2 (3 x 10 mL). The combined organic phases were washed with brine (5 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (10% → 20% EtOAc/PE 40-60) to give the title compound as a colourless oil 
(125 mg, 0.208 mmol, 80%). 
 
Rf: 0.14 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 6.00 (1H, dq, J = 9.7, 1.5 Hz, 
H17), 4.36 (1H, ddd, J = 11.6, 6.6, 3.5 Hz, H19), 4.29 (1H, s, H22), 3.63-3.51 (2H, m, H25), 
2.71-2.61 (1H, m, H18), 2.41 (3H, d, J = 1.5 Hz, Me16), 2.31-2.22 (1H, m, H24), 1.85 (1H, dd, J 
= 14.1, 3.6 Hz, H20a), 1.57 (1H, dd, J = 14.0, 11.8 Hz, H20b), 1.06 (3H, d, J = 6.8 Hz, Me18), 
1.02-0.97 (12H, m, Me24, OSiCH2CH3), 0.92 (9H, t, J = 7.9 Hz, OSiCH2CH3), 0.84-0.72 (6H, m, 
OSiCH2CH3), 0.72-0.58 (6H, m, OSiCH2CH3); 13C NMR (125 MHz, CDCl3): δC 172.5, 141.3, 
95.9, 79.5, 79.7, 74.2, 64.6, 40.3, 39.6, 33.3, 28.4, 16.2, 11.4, 7.4, 7.3, 6.7, 5.4; FT-IR (Thin 
film): νmax 3477 (br), 2955, 2876, 1731, 1638, 1458, 1416, 1380, 1239, 1161, 1044, 1008, 977, 
832, 730; HRMS (ES+) Calc. for C25H49IO5Si2H [M+H]+
 
613.2236, found 613.2228; [α]D
20  = 



















DMP (125 mg, 294 μmol) and NaHCO3 (49.4 mg, 588 μmol) were added to a stirred solution of 
alcohol 188 (60.0 mg, 98.0 μmol) in CH2Cl2 (1 mL) at 0 °C then warmed to rt. After 1 h, the 
reaction was quenched with Na2S2O3 (1 mL) and NaHCO3 (1 mL) at 0 °C and stirred for 10 min 
at rt. The layers were separated and the aqueous layer extracted with CH2Cl2 (3 x 5 mL). The 
combined organic phases were dried (MgSO4), filtered and concentrated in vacuo to give the title 
compound as a colourless oil which was used immediately without further purification. 
 
Rf: 0.43 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 9.69 (1H, d, J = 1.0 Hz, H25), 
5.98 (1H, dq, J = 9.9, 1.5 Hz, H17), 4.44 (1H, s, H22), 4.34 (1H, ddd, J = 11.3, 7.2, 4.0 Hz, H19), 
3.00 (1H, dq, J = 7.5, 0.9 Hz, H24), 2.71-2.61 (1H, m, H18), 2.40 (3H, d, J = 1.5 Hz, Me16), 1.86 
(1H, dd, J = 14.0, 4.0 Hz, H20a), 1.76 (1H, dd, J = 14.0, 11.5 Hz, H20b), 1.22 (3H, d, J = 7.6 Hz, 
Me24), 1.07 (3H, d, J = 6.7 Hz, Me18), 0.97 (9H, t, J = 7.9 Hz, OSiCH2CH3), 0.93 (9H, t, J = 7.9 
Hz, OSiCH2CH3), 0.79-0.69 (6H, m, OSiCH2CH3), 0.69-0.59 (6H, m, OSiCH2CH3); 13C NMR 
(125 MHz, CDCl3): δC 202.3, 171.6, 141.0, 96.2, 79.1, 77.7, 73.7, 50.7, 40.4, 33.9, 29.8, 28.3, 
16.2, 7.3, 7.1, 6.7, 5.2; FT-IR (Thin film): νmax 2953, 2877, 1755, 1722, 1457, 1379, 1240, 1147, 
1010, 975, 830, 730; HRMS (ES+) Calc. for C25H47IO5Si2H [M+H]+
 
611.2079, found 611.2070; 
[α]D





Dimethyl (2-oxopropyl)phosphonate 190 (67.7 μL, 490 μmol) was added to a stirred suspension 
of oven-dried Ba(OH)2 (50.3 mg, 294 μmol) in THF (0.5 mL) at rt. After 30 min, the reaction 
mixture was cooled to 0 °C and a solution of aldehyde 189 (60.0 mg, 98.0 μmol) in THF/H2O 
(40:1, 0.5 mL) added via cannula (0.5 mL wash). The reaction mixture was warmed to rt and 
after 16 h, the reaction was quenched with NH4Cl (1 mL) and diluted with CH2Cl2 (5 mL). The 
layers were separated and the aqueous layer extracted with CH2Cl2 (3 x 10 mL). The combined 
organic phases were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by flash column chromatography (10% → 20% EtOAc/PE 40-60) to give the title compound as a 
























Rf: 0.20 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 6.65 (1H, dd, J = 15.8, 8.3 Hz, 
H25), 6.23 (1H, d, J = 15.8 Hz, H26), 5.97 (1H, dq, J = 10.0, 1.4 Hz, H17), 4.35 (1H, ddd, J = 
11.3, 6.9, 3.4 Hz, H19), 3.98 (1H, s, H22), 3.02-2.93 (1H, m, H18), 2.69-2.59 (1H, m, H24), 2.41 
(3H, d, J = 1.4 Hz, Me16), 2.26 (3H, s, H28), 1.89 (1H, dd, J = 13.9, 3.4 Hz, H20a), 1.76 (1H, dd, 
J = 13.9, 11.6 Hz, H20b), 1.10 (3H, d, J = 7.0 Hz, Me24), 1.07 (3H, d, J = 6.7 Hz, Me18), 1.00 
(9H, t, J = 7.8 Hz, OSiCH2CH3), 0.93 (9H, t, J = 7.9 Hz, OSiCH2CH3), 0.83-0.74 (6H, m, 
OSiCH2CH3), 0.74-0.60 (6H, m, OSiCH2CH3); 13C NMR (125 MHz, CDCl3): δC 197.6, 171.8, 
146.4, 141.0, 132.1, 96.2, 79.3, 78.8, 74.4, 41.5, 40.3, 32.6, 28.4, 28.2, 16.3, 13.4, 7.4, 7.3, 6.7, 
5.6; FT-IR (Thin film): νmax 2956, 2877, 1751, 1679, 1626, 1458, 1380, 1238, 1143, 1059, 1006, 
978, 826, 730; HRMS (ES+) Calc. for C28H51IO5Si2H [M+H]+
 
651.2392, found 651.2406; [α]D
20 = 





To a solution of enone 191(45 mg, 69 μmol) in degassed PhMe (100 μL) at rt was added a 
solution of Stryker’s reagent (2.73 mL, 1.0 eq wrt Cu, 69 μmol). The reaction mixture was stirred 
for 2 h and then diluted with hexanes (2 mL) and stirred vigorously with exposure to air. The 
resulting suspension was filtered through a plug of silica gel, eluting with 10% EtOAc/PE 40-60. 
The solvent was removed in vacuo and the resulting residue purified by flash column 
chromatography (5% → 20% EtOAc/PE 40-60) to give the title compound as a colourless oil (30 
mg, 46 μmol, 67%). 
 
Rf: 0.27 (10% EtOAc-Pet. Ether; 1H NMR (400 MHz, CDCl3): δH 5.98 (1H, dq, J = 10.1, 1.4 Hz, 
H17), 4.34 (1H, ddd, J = 11.6, 7.0, 3.6 Hz, H19), 4.22 (1H, s, H22), 2.69-2.52 (2H, m, H18, 
H26a), 2.37-2.27 (1H, m, H26b), 2.41 (3H, d, J = 1.5 Hz, Me16), 2.17 (3H, s, H28), 2.02-1.92 
(1H, m, H24), 1.78 (1H, dd, J = 13.9, 3.5 Hz, H20a), 1.43 (1H, dd, J = 13.8, 11.7 Hz, H20b), 
1.66-1.56 (1H, m, H25a), 1.27-1.17 (1H, m, H25b), 1.06 (3H, d, J = 6.7 Hz, Me18), 0.98 (9H, t, J 
= 7.9 Hz, OSiCH2CH3), 0.91 (9H, t, J = 7.9 Hz, OSiCH2CH3), 0.90 (3H, d, J = 7.0 Hz, Me24), 
0.80-0.70 (6H, m, OSiCH2CH3), 0.68-0.58 (6H, m, OSiCH2CH3); 13C NMR (100 MHz, CDCl3): 
δC 208.2, 172.5, 141.2, 95.9, 79.8, 79.5, 73.2, 42.4, 40.4, 37.0, 32.1, 30.2, 28.4, 25.7, 16.3, 13.0, 















1014, 912, 829, 728; HRMS (ES+) Calc. for C28H53IO5Si2H [M+H]+
 
653.2549, found 653.2542; 
[α]D
20 = +2.2 (c 0.50, CHCl3) 
 
  









A solution of HFpy/py was prepared by the addition of HFpy (100 μL) to a solution of py (200 
μL) in THF (1 mL) at 0 °C and stirred for 30 min at rt before use. 
 
To a stirring solution of silyl ether 101 (4 mg, 5.5 μmol) in THF (200 uL) at 0 °C was added a 
solution of HFpy/py (200 μL). The reaction mixture was stirred for 5 h at rt before diluting with 
THF (1 mL) and quenched with NaHCO3 (1 mL). The layers were separated and the aqueous 
phase extracted with Et2O (3 x 2 mL) and the combined organic extracts were washed with 
NaHCO3 (0.5 mL), dried (Na2SO4) and concentrated in vacuo. The crude product was purified by 
flash column chromatography (10% ® 20% EtOAc/PE 40-60) to give the title compound as a 
colourless oil (2 mg, 4.06 μmol, 75%). 
 
Rf: 0.23 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.41 (1H, dd, J = 15.1, 11.3 
Hz, H3), 6.71 (1H, dd, J = 15.0, 10.8 Hz, H5), 6.34 (1H, dd, J = 15.0, 11.3 Hz, H4), 6.31 (1H, s, 
H15), 6.20 (1H, dd, J = 15.2, 10.8 Hz, H6), 5.91 (1H, dd, J = 15.2, 0.9 Hz, H7), 5.90 (1H, d, J = 
15.3 Hz, H2), 4.13 (1H, d, J = 8.0 Hz, H13), 3.73 (3H, s, CO2Me), 3.38 (1H, dd, J = 9.3, 2.2 Hz, 
H11), 3.37 (1H, s, H9a), 3.27 (1H, dd, J = 7.7, 3.7 Hz, H9), 2.50 (1H, m, H8), 1.96 (1H, m, H10), 
1.75 (1H, m, H12), 1.67 (3H, d, J = 0.9 Hz, Me14), 1.08 (3H, d, J = 6.7 Hz, Me8), 0.93 (3H, d, J 
= 6.8 Hz, Me12), 0.83 (3H, d, J = 7.1 Hz, Me10); 13C NMR (125 MHz, CDCl3): δC 169.4, 150.2, 
146.7, 144.5, 143.2, 130.7, 129.6, 120.4, 87.1, 80.7, 79.4, 74.1, 59.0, 52.0, 41.9, 40.3, 38.9, 19.5, 
17.9, 12.1, 7.8; FT-IR (Thin film): νmax 3387 (br), 2919, 2850, 1717, 1616, 1458, 1378, 1260, 























1H NMR 13C NMR 
Natural Mult. J (Hz) 195 Mult. J (Hz) Δ Natural 195 Δ 
1 N.A.   N.A.   N.A. 174.1 169.4 -4.7 
2 5.90 d 15.3 5.90 d 15.3 0 127.6 120.4 -7.2 
3 7.10 dd 15,1, 11.1 7.41 dd 15.1, 11.3 0.31 142.7 146.7 4.0 
4 6.27 dd 15.0, 11.0 6.34 dd 15.0, 11.3 0.07 130.7 129.6 -1.1 
5 6.45 dd 15.0, 10.7 6.71 dd 15.0, 10.8 0.26 139.8 143.2 3.4 
6 6.17 dd 15.3, 10.7 6.20 dd 15.2, 10.8 0.03 130.9 130.7 -0.2 
7 5.87 dd 15.1, 8.7 5.91 dd 15.2, 0.9 0.04 142.8 144.5 1.7 
8 2.53 m  2.50 m  -0.03 41.5 41.9 0.4 
Me8 1.07 d 6.7 1.08 d 6.7 0.01 17.2 17.9 0.7 
9 3.27 dd 6.7, 4.6 3.27 dd 7.7, 3.7 0 88.3 87.1 -1.2 
OMe9 3.38 s  3.37 s  -0.01 59.6 59 -0.6 
10 2.02-
1.22 
m  1.96 m  N.A. 40.1 40.3 0.2 
Me10 0.85 d 7.0 0.83 d 7.1 -0.02 13 12.1 -0.9 
11 3.57 dd 9.6, 2.0 3.38 dd 9.3, 2.2 -0.19 75.5 74.1 -1.4 
12 2.02-1.22 m  1.75 m  N.A. 38.5 38.9 0.4 
Me12 0.93 d 
No J 
value 0.93 d 6.8 0 7.6 7.8 0.2 
13 3.99 d 7.3 4.13 d 8.0 0.14 82.1 80.7 -1.4 
14 N.A.   N.A.   N.A. 137.4 150.2 12.8 
Me14 1.69 s  1.67 d 0.9 -0.02 14 19.5 5.5 
15 5.95 s  6.31 s  0.36 131.7 79.4 -52.3 
 




NaH (60 wt% in oil dispersion, 101 mg, 2.53 mmol) was washed with hexane (2 × 3 mL), 
suspended in Et2O (3 mL) and cooled to 0 °C. A solution of vinyl iodide 114 (100 mg, 0.505 
mmol) in Et2O (2 mL) was added via cannula (2 x 1 mL wash) and the mixture was stirred at rt 
for 30 min before being cooled to −78 °C. SnBu3Cl (205 μL, 0.758 mmol) was added followed by 
dropwise addition of t-BuLi (1.7 M in pentanes, 2.10 mL, 2.53 mmol). The reaction mixture was 
stirred for 15 minutes before quenching with NH4Cl (5 mL) and warmed to rt. The layers were 









were dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (Et3N washed silica gel, 5% → 20% EtOAc/PE 40-60) gave the title compound 
as a colourless oil (109 mg, 0.303 mmol, 60%). 
 
Rf: 0.18 (5% EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3): δH 5.80 (1H, s, H15), 4.08 (2H, s, 
H13), 1.78 (3H, s, Me14), 1.49 (6H, m, SnBu3), 1.31 (6H, m, SnBu3), 0.94-0.87 (15H, m, SnBu3); 
13C NMR (100 MHz, CDCl3): δC 152.8, 120.3, 68.5, 28.8, 27.0, 13.3, 9.7; FT-IR (Thin film): 
νmax 3267 (br), 2956, 2922, 2872, 2856, 1620, 1464, 1376, 1292, 1133, 1072, 1009, 961, 863, 840, 
796; HRMS (ES+) calc. for C16H34OSn–C4H9 [M–Bu]+
 





A solution of Pd(PPh3)4 (5.5 mg, 4.8 μmol), CuTC (9.0 mg, 47.6 μmol) and [NBu4][Ph2PO2] 
(21.9 mg, 47.6 μmol) was prepared in degassed DMF (0.2 mL) and cooled to 0 °C. A degassed 
solution of vinyl iodide 174 (12.0 mg, 23.8 μmol) and vinyl stannane 201 (9.0 mg, 25.0 μmol) in 
DMF (0.2 mL) was added via cannula (2 x 0.1 mL wash) and the reaction mixture was stirred at 
0 °C in the dark for 2 h. H2O (2 mL) and Et2O (2 mL) were added and the layers were separated. 
The aqueous phase was extracted with Et2O (3 x 5 mL) and the combined organic extracts were 
washed with water (2 x 4 mL) dried (Na2SO4), concentrated in vacuo and purified by flash 
column chromatography (30% → 50% EtOAc/PE 40-60) to give the title compound as a 
colourless oil (7.9 mg, 17.7 μmol, 74%). 
 
Rf: 0.20 (50% EtOAc/PE 40-60); 1H NMR (500 MHz, d4-MeOD): δH 7.25 (2H, d, J = 8.7 Hz, 
ArH), 6.89 (2H, d, J = 8.7 Hz, ArH), 5.87 (1H, s, H15), 5.10 (1H, d, J = 10.2 Hz, H17), 4.42 (1H, 
d, J = 11.4 Hz, OCH2Ar), 4.41 (1H, ddd, J = 11.6, 7.7, 3.7 Hz, H19), 4.39 (1H, d, J = 11.4 Hz, 
OCH2Ar), 4.23 (1H, s, H22), 3.96 (2H, s, H13) 3.78 (3H, s, ArOMe), 3.50 (1H, dd, J = 9.8, 5.6 
Hz, H25a), 3.47 (1H, dd, J = 9.7, 5.1 Hz, H25b), 2.75-2.66 (1H, m, H18), 2.31-2.23 (1H, m, H24), 
1.94 (1H, dd, J = 14.5, 3.8 Hz, H20a), 1.79 (1H, d, J = 14.5, 11.9 Hz, H20b), 1.75 (3H, s, Me14), 
1.71 (1H, s, Me16), 1.07 (3H, d, J = 6.6 Hz, H18), 1.00 (3H, d, J = 7.1 Hz, Me24); 13C NMR 
(125 MHz, d4-MeOD): δC 176.6, 160.8, 136.5, 135.2, 131.6, 131.1, 130.6, 129.6, 114.8, 82.6, 

















3444 (br), 2933, 1730, 1613, 1514, 1455, 1380, 1247, 1174, 1103, 1033, 819; HRMS (ES+) calc. 
for C25H36O7Na [M+Na]+
 
471.2353, found 471.2348; [α]D
20 = +8.0 (c 0.20, CHCl3). 
 
Atom 
1H NMR 13C NMR 
Natural Mult. J (Hz) 202 Mult. J (Hz) Δ Natural 202 Δ 
13 3.99 d 7.3 3.96 s  -0.03 82.1 69 -13.1 
14 N.A.   N.A.   N.A. 137.4 136.5 -0.9 
Me14 1.69 s  1.75 s  0.06 14 15.5 1.5 
15 5.95 s  5.87 s  -0.08 131.7 129.6 -2.1 
16 N.A.   N.A.   N.A. 135.4 135.2 -0.2 
Me16 1.82 s  1.71 s  -0.11 17.9 17.6 -0.3 
17 5.16 d 9.8 5.10 d 10.2 -0.06 131.6 131.1 -0.5 
18 2.81 m  2.70 m  -0.11 39.3 39.2 -0.1 
Me18 1.10 d 6.7 1.07 d 6.6 -0.03 17.2 17.1 -0.1 
19 4.42 ddd 11.3, 7.5, 
3.5 
4.41 ddd 11.6, 7.7, 
3.7 
-0.01 82.8 82.6 -0.2 
20a 2.02-1.22 m  1.94 dd 14.5, 13.8 N.A. 32.2 33.9 1.7 
20b 2.02-1.22 m  1.79 dd 14.5, 11.9 N.A. 76.4 75.4  
21 N.A.   N.A.   N.A. 72.5 73.2 -1.0 
22 4.27 s  4.23 s  -0.04 177 176.6 0.7 
23 N.A.   N.A.   N.A. 39.3 40 -0.4 
24 2.02-1.22 m  2.27 m  N.A. 13.1 11.9 0.7 
Me24 0.96 d 6.7 1.00 d 7.1 0.04 13.1 11.9 -1.2 
25a 2.02-1.22 m  3.50 dd 9.8, 5.6 N.A. 28.0 73.0 45.0 
25b 1.00 m  3.47 dd 9.7, 5.1 N.A.    
 





NaH (60 wt% in oil dispersion, 17.9 mg, 447 μmol) was washed with hexane (2 × 1 mL) and 
cooled to 0 °C. A solution of vinyl iodide 144 (55.0 mg, 89.5 μmol) in Et2O (0.5 mL) was added 











−78 °C. SnBu3Cl (194 μL, 716 μmol) was added followed by dropwise addition of t-BuLi (1.6 M 
in pentanes, 560 μL, 895 μmol). The reaction mixture was stirred for 15 minutes before 
quenching with pH 7 buffer (1 mL) and immediately warmed to rt. The layers were separated and 
the aqueous phase extracted with Et2O (4 × 1 mL), the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column chromatography (Et3N 
washed silica gel, 0% → 5% EtOAc/PE 40-60) gave the title compound as a colourless oil (42.9 
mg, 55.1 μmol, 62%) contaminated with proto-destannylated 204. Ent-203 was prepared in an 
analogous fashion from ent-144 (27 mg, 43.9 μmol) as a colourless oil (ca. 15.0 mg, 25.7 μmol, 
59%) contaminated with ent-204. 
 
Rf: 0.21 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 5.78 (1H, s, H15), 4.08 (1H, d, 
J = 4.9 Hz, H13), 3.67-3.60 (3H, m, H7a, H7b, H9), 3.48 (1H, dd, J = 8.0, 2.0 Hz, H11), 3.36 (3H, 
s, OMe9), 2.11-2.02 (1H, m, H8), 2.00-1.90 (2H, m, H12), 1.69 (3H, s, Me14), 1.54-1.44 (6H, m, 
SnBu3), 1.37-1.26 (6H, m, SnBu3) 1.01-0.84 (42H, m, OSiCH2CH3 x2, Me8, Me10, Me12, SnBu3 
x2) 0.63 (6H, q, J = 7.7 Hz, OSiCH2CH3), 0.60-0.53 (6H, m, OSiCH2CH3); 13C NMR (125 MHz, 
CDCl3): δC 155.4, 123.6, 83.1, 80.1, 78.0, 67.7, 58.8, 40.2, 38.2, 37.6, 29.4, 27.5, 20.9, 15.9, 13.8, 
10.9, 10.8, 10.1, 7.4, 7.2, 5.9, 5.2; FT-IR (Thin film): νmax 3444 (br), 2933, 1730, 1613, 1514, 
1455, 1380, 1247, 1174, 1103, 1033, 819; HRMS (ES+) Calc. for C38H82O4Si2SnH [M+H]+
 
779.4859, found 779.4861; 203 [α]D
20  = +8.0 (c 0.20, CHCl3), ent-203 [α]D







A solution of Pd(PPh3)4 (8.1 mg, 4.8 μmol), CuTC (13.4 mg, 70.5 μmol) and [NBu4][Ph2PO2] 
(32.4 mg, 70.5 μmol) was prepared in degassed DMF (100 μL) and cooled to 0 °C. A degassed 
solution of vinyl iodide 102 (23.0 mg, 35.2 μmol) and vinyl stannane 203 (27.4 mg, 35.2 μmol) in 
DMF (100 μL) was added via cannula (2 x 100 μL wash) and the reaction mixture was stirred at 
0 °C in the dark for 2 h. H2O (2 mL) and Et2O (2 mL) were added and the layers were separated. 
The aqueous phase was extracted with Et2O (3 x 2 mL) and the combined organic extracts were 



















column chromatography (30% → 50% EtOAc/PE 40-60) to give the title compound as a 
colourless oil (27.8 mg, 27.5 μmol, 78%). 
 
Rf: 0.10 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 5.80 (1H, s, H15), 5.00 (1H, d, 
J = 9.8 Hz, H17), 4.33 (1H, ddd, J = 11.2, 7.7, 3.2 Hz, H19), 4.23 (1H, s, H22), 3.96 (1H, d, J = 
5.9 Hz, H13), 3.69 (1H, dd, J = 5.4, 3.1 Hz, H11), 3.66-3.58 (2H, m, H7a, H7b), 3.39 (1H, dd, J = 
8.3, 2.3 Hz, H9), 3.36-3.33 (1H, obs m, OH), 3.34 (3H, s, OMe9), 2.65 (1H, m, H18), 2.56 (1H, 
ddd, J = 17.3, 11.6, 5.2 Hz, H26a), 2.31 (1H, ddd, J = 17.5, 11.2, 4.1 Hz, H26b), 2.15 (3H, s, 
H28), 2.07-1.89 (4H, m, H8, H10, H12, H24), 1.87 (1H, dd, J = 13.9, 3.4 Hz, H20a), 1.74 (3H, s, 
Me16), 1.66 (3H, s, Me14), 1.60 (1H, m, H25a), 1.46 (1H, dd, J = 13.4, 11.4 Hz, H20b), 1.19 (1H, 
m, H25b), 1.08 (3H, d, J = 6.6 Hz, Me18), 1.01-0.85 (48H, m, Me8, Me10, Me12, Me24, 
OSiCH2CH3 x4), 0.78-0.69 (6H, m, OSiCH2CH3), 0.67-0.53 (18H, m, OSiCH2CH3 x3); 13C 
NMR (125 MHz, CDCl3): δC 208.3, 172.8, 137.4, 133.8, 130.2, 130.1, 83.1, 80.8, 79.9, 79.8, 
73.2, 67.3, 59.0, 58.9, 42.4, 50.1, 39.4, 38.1, 37.7, 37.0, 32.8, 30.2, 25.8, 17.6, 17.2, 15.2, 14.3, 
12.8, 11.02, 11.00, 7.35, 7.33, 7.22, 7.09, 6.75, 5.89, 5.33, 5.14; FT-IR (Thin film): νmax 3478 
(br), 2959, 2913, 2877, 1751, 1720, 1459, 1411, 1376, 1239, 1147, 1080, 1008, 964, 902, 830, 
737; HRMS (ES+) Calc. for C54H108O9Si4H [M+H]+
 
1013.7143, found 1013.7143; [α]D
20 = +11.6 






A solution of Pd(PPh3)4 (6.0 mg, 5.1 μmol), CuTC (9.8 mg, 51.4 μmol) and [NBu4][Ph2PO2] 
(23.6 mg, 51.4 μmol) was prepared in degassed DMF (100 μL) and cooled to 0 °C. A degassed 
solution of vinyl iodide 102 (13.0 mg, 25.7 μmol) and vinyl stannane ent-203 (15.0 mg, 25.7 
μmol) in DMF (100 μL) was added via cannula (1 x 100 μL wash) and the reaction mixture was 
stirred at 0 °C in the dark for 2 h. H2O (1 mL) and Et2O (1 mL) were added and the layers were 
separated. The aqueous phase was extracted with Et2O (3 x 1 mL) and the combined organic 
extracts were washed with water (2 x 1 mL) dried (Na2SO4), concentrated in vacuo and purified 
by flash column chromatography (10% EtOAc/PE 40-60) to give the title compound as a 




















Rf: 0.10 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 5.82 (1H, s, H15), 4.99 (1H, d, 
J = 9.4 Hz, H17), 4.33 (1H, ddd, J = 11.3, 7.7, 3.5 Hz, H19), 4.23 (1H, s, H22), 3.99 (1H, d, J = 
5.4 Hz, H13), 3.68 (1H, dd, J = 5.9, 2.8 Hz, H11), 3.64-3.59 (2H, m, H7a, H7b), 3.43-3.38 (1H, 
m, H9), 3.35 (3H, s, OMe9), 2.66 (1H, m, H18), 2.57 (1H, ddd, J = 17.5, 11.5, 5.3 Hz, H26a), 
2.31 (1H, ddd, J = 17.4, 11.1, 4.0 Hz, H26b), 2.15 (3H, s, H28), 2.10-1.89 (4H, m, H8, H10, H12, 
H24), 1.87 (1H, dd, J = 14.0, 3.2 Hz, H20a), 1.74 (3H, s, Me16), 1.65 (3H, s, Me14), 1.63-1.54 
(1H, m, H25a), 1.46 (1H, dd, J = 13.8, 12.0 Hz, H20b), 1.18 (1H, m, H25b), 1.09 (3H, d, J = 6.8 
Hz, Me18), 1.00-0.85 (48H, m, Me8, Me10, Me12, Me24 and OSiCH2CH3 x4), 0.81-0.69 (6H, m, 
OSiCH2CH3), 0.69-0.53  (18H, m, OSiCH2CH3 x3); 13C NMR (125 MHz, CDCl3): δC 208.3, 
172.9, 137.5, 133.8, 129.82, 129.78, 82.9, 80.9, 79.8, 79.5, 76.9, 73.2, 67.2, 59.0, 42.5, 40.1, 39.0, 
38.0, 37.7, 37.1, 32.7, 30.2, 25.8, 17.7, 17.1, 15.4, 14.6, 12.8, 11.0, 10.9, 7.4, 7.3, 7.2, 7.1, 6.8, 
5.9, 5.3, 5.2; FT-IR (Thin film): νmax 3671 (br), 2955, 2912, 2878, 1752, 1721, 1459, 1414, 1379, 









A flask was charged with Pd(PPh3)2Cl2 (15.0 mg, 20.8 μmol), Li2CO3 (76.8 mg, 1.04 mmol), 
vinyl iodide 101 (150 mg, 208 μmol) and (Me3Sn)2 (216 μL, 1.04 mmol) in THF (7 mL) and 
heated to 40 ˚C for 1 h. Upon complete reaction, the reaction mixture was cooled to rt, filtered 
through Celite® and concentrated in vacuo. The crude product was purified by flash column 
chromatography (0 ® 2% EtOAc/PE 40-60) to give the title compound as a colourless oil (111 
mg, 0.146 mmol, 70%). Ent-211 was prepared in an analogous fashion from ent-101 (255 mg, 
354 μmol) to give a colourless oil (329 mg, 456 μmol, 70%). 
 
Rf: 0.35 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.31 (1H, d, J = 15.1, 11.6 Hz, 
H3), 6.53 (1H, d, J = 14.8, 10.5 Hz, H5), 6.23 (1H, d, J = 14.9, 11.3 Hz, H4), 6.13 (1H, d, J = 
15.4, 10.6 Hz, H6), 5.97 (1H, d, J = 15.2, 7.5 Hz, H7), 5.85 (1H, d, J = 15.1 Hz, H2), 5.75 (1H, s, 
H15), 3.95 (1H, d, J = 7.3 Hz, H13), 3.74 (3H, s, CO2Me), 3.73 (1H, t, J = 3.8 Hz, H9), 3.30 (3H, 
s, OMe9), 3.08 (1H, dd, J = 7.3, 4.2 Hz, H11), 2.52-2.44 (1H, m, H8), 1.97-1.86 (2H, m, H12, 
H10), 1.70 (3H, s, Me14), 1.04 (3H, d, J = 6.9 Hz, Me8), 0.98-0.89 (24H, m, Me10, Me12, 













CDCl3): δC 167.6, 155.9, 145.0, 144.6, 144.2, 128.7, 128.2, 125.9, 119.7, 86.7, 81.9, 74.2, 60.0, 
51.5, 40.9, 39.6, 39.5, 19.2, 14.9, 14.1, 11.0, 7.2, 7.0, 5.8, 5.0, -9.1; FT-IR (Thin film): νmax 2953, 
2877, 2913, 1721, 1618, 1458, 1261, 1241, 1133, 1097, 1005, 726; HRMS (ES+) Calc. for 
C36H70O5Si2SnH [M+H]+
 
759.3863, found 759.3859; 211 [α]D
20 = –12.4 (c 0.88, CHCl3), ent-211 
[α]D







To a stirred suspension of alcohol 207 (20 mg, 19.7 μmol) and NaHCO3 (16.6 mg, 197 μmol) in 
CH2Cl2 (200 μL) was added Dess–Martin periodinane (25.1 mg, 59.2 μmol). After 1 h, the 
reaction was diluted with CH2Cl2 (1 mL) and quenched with NaHCO3 (1 mL) and Na2S2O3 (1 mL) 
and stirring continued for another 30 min until a clear phase boundary was observed. The layers 
were separated and the aqueous phase extracted with CH2Cl2 (3 x 1 mL). The combined organic 
phases were dried (MgSO4), filtered and concentrated in vacuo. The crude product was rapidly 
filtered through a short plug of silica, eluting with 20% Et2O/PE 40-60 and used without further 
purification. 
 
LDA (237 μL, 118 μmol, 0.5 M in THF) was added to a solution of phosphonate 104 (31.0 mg, 
118 μmol) in THF (100 μL) at –78 °C to give a bright yellow-orange solution. The reaction was 
stirred for 30 min and then a solution of the crude aldehyde in THF (100 μL) was added via 
cannula (1 x 100 μL wash). The reaction was stirred at –78 ˚C for 30 min, and then at –40 ˚C for 
30 min before quenching with NH4Cl (1 mL). The layers were separated and the aqueous phase 
extracted with Et2O (3 x 1 mL). The combined organic phases were dried (MgSO4), filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography (5% 
EtOAc/PE 40-60) to give the title compound as a colourless oil (329 mg, 0.456 mmol, 52%). 
 
Rf: 0.45 (25% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δ 7.30 (1H, dd, J = 15.4, 11.4 Hz, 
H3), 6.52 (1H, dd, J = 14.8, 10.7 Hz, H5), 6.21 (1H, dd, J = 15.0, 11.2 Hz, H4), 6.13 (1H, dd, J = 





















s, H15), 5.02 (1H, d, J = 9.8 Hz, H17), 4.32 (1H, ddd, J = 11.3, 8.3, 3.3 Hz, H19), 4.24 (1H, s, 
H22), 3.89 (1H, d, J = 7.6 Hz, H13), 3.74 (3H, s, CO2Me), 3.76-3.73 (1H, obs m, H11), 3.28 (3H, 
s, OMe9), 3.07 (1H, dd, J = 7.6, 3.9 Hz, H9), 2.65 (1H, m, H18), 2.56 (1H, ddd, J = 17.4, 11.7, 
5.5 Hz, H26a), 2.49 (1H, m , H8), 2.30 (1H, ddd, J = 17.3, 11.3, 3.9 Hz, H26b), 2.15 (3H, s, H28), 
2.00-1.93 (2H, m, H12, H24), 1.93-1.87 (2H, m, H10, H20a), 1.74 (3H, s, Me16), 1.66 (3H, s, 
Me14), 1.60-1.55 (1H, obs m, H25a), 1.45 (1H, dd, J = 13.7, 11.8 Hz, H20b), 1.17 (1H, dd, J = 
12.3, 4.7 Hz, H25b), 1.09 (3H, d, J = 6.5 Hz, Me18), 1.04 (3H, d, J = 7.0 Hz, Me8), 1.00-0.87 
(42H, m, Me10, Me12, OSiCH2CH3 x4), 0.86 (3H, d, J = 6.9 Hz, Me24), 0.81-0.67 (6H, m, 
OSiCH2CH3), 0.67-0.52 (18H, m, OSiCH2CH3 x3); 13C NMR (125 MHz, CDCl3): δ 208.2, 172.8, 
167.8, 145.1, 144.7, 141.4, 137.8, 133.5, 130.5, 130.2, 128.9, 128.3, 119.9, 86.8, 80.84, 80.79, 
79.8, 74.1, 73.2, 60.1, 51.6, 42.5, 41.1, 39.7, 39.5, 38.3, 37.0, 33.1, 30.2, 25.8, 17.7, 17.4, 14.8, 
14.1, 13.8, 12.8, 11.2, 7.35, 7.34, 7.2, 7.1, 6.8, 5.8, 5.3, 5.1; FT-IR (Thin film): νmax 2954, 2877, 
1747, 1720, 1618, 1457, 1414, 1378, 1260, 1143, 1093, 1005, 802, 725; HRMS (ES+) Calc. for 
C61H114O10Si4H [M+H]+
 
1119.7562, found 1119.7571; [α]D








Ester 100 was prepared in an analogous fashion to 99 from 208 (15.0 mg, 14.8 μmol) to give a 
colourless oil (9.1 mg, 8.1 μmol, 55%). 
 
Method B 
A solution of Pd(PPh3)4 (34.3 mg, 29.2 µmol) and CuTC (55.7 mg, 292 µmol) was prepared in 
degassed DMF (1 mL) and cooled to 0 °C. A degassed solution of vinyl iodide ent-102 (95 mg, 
146 µmol) and vinyl stannane 211 (111 mg, 146 µmol) in DMF (1 mL) was added via cannula (2 
x 0.1 mL wash) and the reaction mixture was stirred at 0 °C in the dark for 5 h. H2O (10 mL) and 
Et2O (10 mL) were added and the layers were separated. The aqueous phase was extracted with 






















(Na2SO4), concentrated in vacuo and purified by flash column chromatography (2% ® 10% 
EtOAc/PE 40-60) to give the title compound as a colourless oil (114 mg, 102 µmol, 70%). 
 
Rf: 0.20 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.30 (1H, dd, J = 15.3, 11.4 
Hz, H3), 6.53 (1H, dd, J = 14.9, 10.6 Hz, H5), 6.22 (1H, dd, J = 15.0, 11.3 Hz, H4), 6.13 (1H, dd, 
J = 15.3, 10.8 Hz, H6), 6.00 (1H, dd, J = 15.4, 7.3 Hz, H7), 5.85 (1H, d, J = 15.4 Hz, H2), 5.82 
(1H, s, H15), 5.00 (1H, d, J = 9.4 Hz, H17), 4.31 (1H, ddd, J = 11.5, 8.0, 3.2 Hz, H19), 4.23 (1H, 
s, H22), 3.92 (1H, d, J = 6.8 Hz, H13), 3.74 (3H, s, CO2Me), 3.73 (1H, dd, J = 7.7, 3.8 Hz, H11), 
3.27 (3H, s, OMe9), 3.10 (1H, dd, J = 7.8, 3.6 Hz, H9), 2.64 (1H, m, H18), 2.55 (1H, ddd, J = 
17.1, 11.3, 5.1 Hz, H26a), 2.49 (1H, m , H8), 2.30 (1H, ddd, J = 17.2, 11.3, 4.1 Hz, H26b), 2.14 
(3H, s, H28), 2.00-1.89 (3H, m, H10, H12, H24), 1.86 (1H, dd, J = 14.2, 3.3 Hz, H20a), 1.76 (3H, 
s, Me16), 1.65 (3H, s, Me14), 1.60-1.55 (1H, obs m, H25a), 1.45 (1H, dd, J = 13.6, 11.9 Hz, 
H20b), 1.16 (1H, dd, J = 12.3, 5.0 Hz, H25b), 1.10 (3H, d, J = 6.6 Hz, Me18), 1.03 (3H, d, J = 
6.6 Hz, Me8), 1.00-0.87 (42H, m, Me10, Me12, OSiCH2CH3 x4), 0.85 (3H, d, J = 6.9 Hz, Me24), 
0.80-0.68 (6H, m, OSiCH2CH3), 0.68-0.53 (18H, m, OSiCH2CH3 x3); 13C NMR (125 MHz, 
CDCl3): δC 208.1, 172.8, 167.8, 145.1, 144.9, 141.4, 137.7, 133.8, 130.38, 130.37, 128.8, 128.3, 
119.8, 86.5, 80.8, 80.4, 79.8, 75.0, 73.2, 60.0, 51.6, 42.5, 40.7, 39.7, 39.5, 38.2, 37.0, 33.0, 30.2, 
25.8, 17.6, 17.2, 15.2, 14.0, 13.8, 12.8, 11.1, 7.35, 7.34, 7.2, 7.1, 6.8, 5.9, 5.3, 5.2; FT-IR (Thin 
film): νmax 2952, 2877, 1752, 1720, 1618, 1463, 1378, 1241, 1147, 1006, 831, 727; HRMS (ES+) 
Calc. for C61H114O10Si4NH4 [M+NH4]+
 
1136.7827, found 1136.7823; [α]D








NaBH4 (6.8 mg, 179 µmol) was added to a stirring solution of ketone ent-100 (40.0 mg, 35.7 
µmol) in MeOH (1 mL) at 0 °C. The reaction was stirred at 0 °C for 30 min before quenching 
with a solution of NH4Cl (1 mL) and diluting with Et2O (3 mL). The layers were separated, and 
the aqueous phase was extracted with Et2O (3 x 1 mL). The combined organic phases were dried 




















EtOAc/PE 40-60) afforded the title compound as a colourless oil (36.8 mg, 32.8 µmol, 92%) as a 
3:2 epimeric mixture at C27. 
 
Rf 0.14 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.30 (1H, dd, J = 15.4, 11.1 Hz, 
H3), 6.53 (1H, dd, J = 15.0, 10.5 Hz, H5), 6.22 (1H, dd, J = 14.9, 11.2 Hz, H4), 6.13 (1H, dd, J = 
14.9, 10.6 Hz, H6), 6.00 (1H, dd, J = 15.0, 7.2 Hz, H7), 5.85 (1H, d, J = 15.2 Hz, H2), 5.82 (1H, 
s, H15), 5.02 (1H, d, J = 8.5 Hz, H17), 4.34 (1H, ddd, J = 11.3, 7.5, 3.0 Hz, H19), 4.23 (1H, s, 
H22; minor epimer 4.21, s), 3.92 (d, J = 6.9 Hz, H13), 3.80-3.70 (5H, m, H11, H27, CO2Me), 
3.27 (3H, s, OMe9), 3.10 (dd, J = 7.7, 3.7 Hz, H9), 2.67 (1H, m, H18), 2.49 (1H, m, H8), 2.02-
1.92 (2H, m, H12, H24), 1.92-1.83 (2H, m, H10, H20a), 1.76 (3H, s, Me16), 1.65 (3H, s, Me14), 
1.60-1.38 (3H, m, H20b, H25a, H26a), 1.28 (1H, m, H26b), 1.19 (3H, d, J = 6.4 Hz, H28; minor 
epimer 1.21, d J = 6.5 Hz), 1.09 (3H, d, J = 6.7 Hz, Me18), 1.04 (3H, d, J = 6.7 Hz, Me8), 1.01-
0.81 (47H, m, Me10, Me12, Me24, H25b, OSiCH2CH3 x4), 0.80-0.72 (6H, m, OSiCH2CH3), 
0.68-0.53 (18H, m, OSiCH2CH3 x3); 13C NMR (125 MHz, CDCl3): δC 173.0, 167.8, 145.1, 144.8, 
141.4, 137.7, 133.9, 130.4, 130.3, 128.8, 128.3, 119.9, 86.5, 80.8 (minor 80.9), 80.4, 79.9, 75.0, 
73.2 (minor 73.2), 68.5 (minor 68.9), 60.0, 51.6, 40.7, 39.7, 39.5, 38.0, 38.0, 37.5, 32.6, 28.3 
(minor 28.9), 23.9 (minor 24.2), 17.6, 17.2, 15.2, 14.0, 13.8, 13.0 (minor 12.9), 7.4, 7.3, 7.1, 6.8, 
5.7, 5.4, 5.2; FT-IR (Thin film): νmax 3502 (br), 2955, 2932, 2877, 1748, 1721, 1618, 1458, 1241, 
1147, 1115, 1006, 728; HRMS (ES+) Calc. for C61H116O10Si4NH4 [M+NH4]+ 1138.7984, found 







A solution of alcohol 22a (37 mg, 33.0 µmol) in CH2Cl2 (200 µL) was added to a suspension of 
Me3OBF4 (48.5 mg, 143 µmol), Proton Sponge® (106 mg, 494 µmol) and crushed 4 Å molecular 
sieves (ca. 28 mg) in CH2Cl2 (200 µL). The resulting suspension was stirred for 3 h at rt before 
quenching with NaHCO3 (1 mL). The layers were separated and the aqueous phase was extracted 
with CH2Cl2 (3 x 1 mL). The combined organic extracts were dried (MgSO4) and concentrated in 
vacuo. Purification by flash column chromatography (5% EtOAc/PE 40-60) afforded methyl 






















Rf 0.21 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.30 (1H, dd, J = 15.0, 11.1 Hz, 
H3), 6.53 (1H, dd, J = 14.8, 10.5 Hz, H5), 6.22 (1H, dd, J = 14.8, 11.4 Hz, H4), 6.13 (1H, dd, J = 
15.3, 10.6 Hz, H6), 5.99 (1H, dd, J = 15.2, 7.2 Hz, H7; minor epimer 6.00, dd, J = 15.4, 7.2 Hz), 
5.84 (1H, d, J = 15.2 Hz, H2), 5.82 (1H, s, H15), 5.02 (1H, dq, J = 9.6, 1.7 Hz, H17), 4.35 (1H, 
ddd, J = 11.2, 7.7, 3.4 Hz, H19), 4.21 (1H, s, H22), 3.93 (1H, d, J = 7.2 Hz, H13), 3.74-3.71 (4H, 
m, H11, CO2Me), 3.29 (3H, s, OMe27; minor epimer 3.30, s), 3.27 (3H, s, OMe9), 3.27-3.20 (1H, 
m, H27), 3.10 (1H, m, H9), 2.68 (1H, m, H18), 2.49 (1H, m, H8), 2.00-1.92 (2H, m, H12, H24), 
1.94-1.86 (2H, m, H10, H20a), 1.76 (3H, s, Me16), 1.66 (3H, s, Me14), 1.57-1.51 (1H, m, H26a), 
1.45-1.36 (2H, m, H20b, H25a), 1.13 (3H, d, J = 5.7 Hz, H28; minor epimer 1.12, d, J = 6.0 Hz), 
1.09 (3H, d, J = 6.7 Hz, Me18), 1.04 (3H, d, J = 6.7 Hz, Me8), 1.01-0.86 (46H, m, Me10, Me12, 
Me24, H25b, OSiCH2CH3 x4), 0.80-0.74 (6H, m, OSiCH2CH3), 0.68-0.53 (18H, m, OSiCH2CH3 
x3); 13C NMR (125 MHz, CDCl3): δC 173.0, 167.8, 145.0, 144.9 (minor 144.8), 141.4, 137.6, 
133.9, 130.4 (minor 130.4), 130.3, 128.8, 128.3, 119.9, 86.5 (minor 86.5), 80.9 (minor 80.8), 80.4 
(minor 80.4), 79.9 (minor 79.9), 73.2, 59.9, 56.1, 51.6, 40.7 (minor 40.6), 39.7 (minor 39.7), 39.5, 
38.0, 37.6, 35.5, 34.5, 32.7 (minor 32.6), 29.9, 28.4, 27.6, 19.2, 17.6, 17.2, 15.2 (minor 15.2), 
14.0, 13.8 (minor 13.8), 12.9 (minor 12.9), 11.1, 7.4, 7.3, 7.1, 6.8, 5.9, 5.4 (minor 5.4), 5.2, 5.0; 
FT-IR (Thin film): νmax 2954, 2876, 1749, 1720, 1617, 1458, 1378, 1260, 1239, 1145, 1089, 
1005, 973, 803, 725; HRMS (ES+) Calc. for C62H118O10Si4H [M+H]+ 1135.7875, found 
1135.7880; [α]D






To a solution of TES ether 215 (10 mg, 8.8 µmol) in THF was added a solution of TASF (12.2 
mg, 44.1 µmol) in DMF (300 µL) at 0 °C. The light pink solution was stirred at 0 °C for 30 min, 
before quenching with NH4Cl (1 mL) and diluting with EtOAc (1 mL). The aqueous phase was 
extracted with EtOAc (5 × 0.5 mL), dried (MgSO4), concentrated in vacuo and the crude 
immediately redissolved in THF (300  L) and stirred at 0 °C. A solution of HFpy/py (1:3, 300 
µL) was added and the solution was stirred at 0 °C for 3 h. The reaction was quenched by slow 
addition of sat. NaHCO3 (1 mL), the layers separated and the aqueous phase extracted with 



















in vacuo. Purification by flash column chromatography (80% EtOAc/PE 40-60) afforded the title 
compound as a colourless oil (4.0 mg, 5.89 µmol, 67% over two steps). 
  
Rf 0.39 (80% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 7.31 (1H, dd, J = 15.4, 11.3 Hz, 
H3), 6.61 (1H, dd, J = 14.8, 10.6 Hz, H5), 6.33 (1H, dd, J = 14.6, 11.5 Hz, H4), 6.21 (1H, dd, J = 
15.3, 10.7 Hz, H6), 5.99 (1H, dd, J = 15.3, 8.8 Hz, H7), 5.95 (1H, s, H15), 5.90 (1H, d, J = 15.4 
Hz, H2), 5.15 (1H, d, J = 9.6, H17), 4.42 (1H, ddd, J = 11.4, 7.4, 3.9 Hz, H19), 4.24 (1H, s, H22), 
3.99 (1H, d, J = 7.4 Hz, H13), 3.72 (3H, s, CO2Me) 3.55 (1H, d, J = 9.6 Hz, H11), 3.38 (3H, s, 
OMe9), 3.33 (1H, m, H27), 3.31 (3H, s, OMe27), 3.28 (1H, dd, J = 6.6, 4.4 Hz, H9), 2.78 (1H, m, 
H18), 2.58 (1H, m, H8), 2.00-1.89 (3H, m, H10, H20a, H24), 1.84-1.75 (4H, m, H12, Me16), 
1.73-1.64 (4H, m, Me14, H20b), 1.62-1.43 (3H, m, H25a, H26a, H26b), 1.13 (3H, d, J = 6.1 Hz, 
H28), 1.12 (3H, d, J = 6.8 Hz, Me18), 1.08 (3H, d, J = 6.7 Hz, Me8), 0.97-0.90 (7H, m, Me12, 
Me24, H25b), 0.85 (3H, d, J = 7.1 Hz, Me10); 13C NMR (125 MHz, CDCl3): δC 176.9, 169.3, 
146.6, 145.1, 143.0, 137.4, 135.3, 131.6, 131.3, 130.5, 129.4, 120.5, 88.1, 82.7, 82.0, 78.5 (minor 
78.2), 76.3, 75.7, 72.5, 59.5, 56.2 (minor 56.3), 52.0, 41.5, 40.0, 39.2, 39.2 (minor 39.1), 38.4, 
35.8 (minor 36.1), 32.1, 28.7, 19.3 (minor 19.4), 17.9, 17.1, 17.0 (minor 17.1), 14.1, 13.0, 13.0, 
7.5; FT-IR (Thin film): νmax 3394 (br), 2960, 2935, 1719, 1615, 1456, 1437, 1379, 1304, 1232, 
1137, 1105, 1008, 971; HRMS (ES+) Calc. for C38H62O10NH4 [M+NH4]+ 696.4681, found 
696.4682; [α]D




8,10,12,14,16-pentamethylnonadeca-2,4,6,14,16-pentaenoic acid (221) 
 
Ba(OH)2•8H2O (4.7 mg, 14.8 µmol) was added to a stirred solution of tetraol 219 (2.0 mg, 2.95 
µmol) in methanol (70 µL). The resulting pale-yellow suspension was stirred at rt for 24 h before 
quenching with 1 M HCl (1 mL) and partitioning with EtOAc (1 mL). The aqueous phase was 
extracted with EtOAc (5 × 0.5 mL), dried (Na2SO4), concentrated in vacuo and purified by flash 
column chromatography (1% AcOH in 10% MeOH/CH2Cl2) to the title compound as an 
amorphous white solid (0.98 mg, 1.48 µmol, 50%). 
 
Rf 0.30 (10% MeOH/CH2Cl2); 1H NMR (500 MHz, d4-MeOD): δH 7.26 (1H, dd, J = 14.9, 11.4 




















J = 15.1, 10.6 Hz, H6), 5.96 (1H, dd, J = 15.0, 8.7 Hz, H7), 5.86 (1H, d, J = 15.2 Hz, H2), 5.95 
(1H, s, H15), 5.15 (1H, d, J = 10.0, H17), 4.42 (1H, ddd, J = 11.3, 7.3, 3.7 Hz, H19), 4.24 (1H, s, 
H22), 4.00 (1H, d, J = 7.0 Hz, H13), 3.61 (1H, dd, J = 9.5, 1.5 Hz, H11), 3.39 (3H, s, OMe9), 
3.31 (3H, s, OMe27), 3.34-3.30 (1H, m, H27), 3.28 (1H, dd, J = 6.4, 4.4 Hz, H9), 2.79 (1H, m, 
H18), 2.56 (1H, m, H8), 2.00-1.91 (3H, m, H10, H20a, H24a), 1.83-1.77 (4H, m, H12, Me16), 
1.73-1.66 (4H, m, Me14, H20b), 1.62-1.41 (3H, m, H25a, H26a, H26b), 1.13 (3H, d, J = 6.1 Hz, 
H28), 1.12 (3H, d, J = 7.0 Hz, Me18), 1.08 (3H, d, J = 6.4 Hz, Me8), 0.95-0.90 (7H, m, Me12, 
Me24, H25b), 0.85 (3H, d, J = 7.1 Hz, Me10); 13C NMR (125 MHz, d4-MeOD): δC 177.0, 174.9 
(br), 142.6, 142.1, 139.4, 137.4, 135.4, 131.3, 131.2, 130.9, 130.8, 128.1 (br), 88.7, 82.8, 81.9, 
78.5 (minor 78.2), 76.3, 76.1, 72.5, 59.8, 56.2 (minor 56.3), 41.4, 40.0, 39.2 (minor 39.1), 39.2 
(minor 39.1), 38.3, 35.8 (minor 36.1), 32.1, 28.7 (minor 28.6), 19.3 (minor 19.4), 17.9, 17.1, 16.8, 
14.3, 13.1, 13.0 (minor 13.0), 7.3; FT-IR (Thin film): νmax 3654 (br), 2957, 2925, 1723, 1697, 
1684, 1615, 1458, 1379, 1258, 1232, 1155, 1092, 1010, 667; HRMS (ES+) Calc. for 
C37H60O10Na [M+Na]+ 687.4073, found 687.4079; [α]D
20   +23.0 (c 0.1, CHCl3). 





1H NMR 13C NMR 
Natural Mult. J (Hz) 220 Mult. J (Hz) Δ 221 Mult. J (Hz) Δ Natural 220 Δ 221 Δ 
1 N.A.   N.A.    N.A.    174.1  0.0 174.9 0.8 
2 5.90 d 15.3 5.89 d 15.4 -0.01 5.86 d 15.2 -0.04 127.6 128.2 0.6 128.1 0.5 
3 7.10 dd 15,1, 11.1 7.13 dd 15.3, 11.1 0.03 7.26 dd 14.9, 11.4 0.16 142.7 143.2 0.5 142.1 -0.6 
4 6.27 dd 15.0, 11.0 6.27 dd 14.9, 11.2 0.00 6.32 dd 14.7, 11.5 0.05 130.7 130.8 0.1 130.8 0.1 
5 6.45 dd 15.0, 10.7 6.47 dd 14.6, 10.7 0.02 6.57 dd 14.4, 10.4 0.12 139.8 140.1 0.3 139.4 -0.4 
6 6.17 dd 15.3, 10.7 6.18 dd 15.0, 10.7 0.01 6.21 dd 15.1, 10.6 0.04 130.9 130.5 -0.4 130.9 0.0 
7 5.87 dd 15.1, 8.7 5.89 dd 15.0, 8.8 0.02 5.96 d 15.0, 8.7 0.09 142.8 143 0.2 142.6 -0.2 
8 2.53 m  2.54 m  -0.01 2.56 m  0.01 41.5 41.5 0.0 41.4 -0.1 
Me8 1.07 d 6.7 1.07 d 6.7 0.00 1.08 d 6.4 0.01 17.2 17.2 0.0 16.8 -0.4 
9 3.27 dd 6.7, 4.6 3.28 dd 6.4, 4.5 0.01 3.28 dd 6.4, 4.4 0.01 88.3 88.3 0.0 88.7 0.4 
OMe9 3.38 s  3.39 s  0.00 3.39 s  0.00 59.6 59.6 0.0 59.8 0.2 
10 2.02-1.22 m  1.98 m  0.00 1.98 m  0.00 40.1 40.1 0.0 40.0 -0.1 
Me10 0.85 d 7.0 0.85 d 7.1 0.00 0.85 d 7.1 0.00 13.0 13.1 0.1 13.0 0.0 
11 3.57 dd 9.6, 2.0 3.57 dd 9.8, 2.0 0.00 3.61 dd 9.5, 1.5 0.04 75.5 75.5 0.0 76.1 0.6 
12 2.02-1.22 m  1.80 m  0.00 1.81 m  0.00 38.5 38.5 0.0 38.3 -0.2 
Me12 0.93 d No J value 0.93 d 6.7 0.00 0.92 d 7.0 -0.01 7.6 7.5 -0.1 7.3 -0.3 
13 3.99 d 7.3 3.99 d 7.2 0.00 4.00 d 7.0 0.01 82.1 82.1 0.0 81.9 -0.2 
14 N.A.   N.A.    N.A.    137.4 137.3 -0.1 137.4 0.0 
Me14 1.69 s  1.68 s  -0.01 1.68 s  -0.01 14.0 13.9 -0.1 14.3 0.3 
15 5.95 s  5.95 s  0.00 5.96 s  0.00 131.7 131.7 0.0 131.3 -0.4 
16 N.A.   N.A.    N.A.    135.4 135.4 0.0 135.4 0.0 





Me16 1.82 s  1.82 s  0.00 1.80 s  -0.02 17.9 17.8 -0.1 17.9 0.0 
17 5.16 d 9.8 5.16 d 9.6 0.00 5.15 d 10.0 -0.01 131.6 131.6 0.0 131.2 -0.4 
18 2.81 m  2.81 m  0.00 2.79 m  -0.02 39.3 39.2 -0.1 39.2 -0.1 
Me18 1.10 d 6.7 1.10 d 6.7 0.00 1.12 d 7.0 0.02 17.2 17.2 0.0 17.1 -0.1 
19 4.42 ddd 11.3, 7.5, 3.5 4.42 ddd 
11.1, 7.3, 
3.5 0.00 4.42 ddd 
11.3, 7.3, 
3.7 0.00 82.8 82.8 0.0 82.8 0.0 
20a 2.02-1.22 m  1.97 m  0.00 1.95 m  0.00 32.2 32.1 -0.1 32.1 -0.1 
20b 2.02-1.22 m  1.67 m  0.00 1.65 m  0.00      
21 N.A.   N.A.    N.A.    76.4 76.4 0.0 76.3 -0.1 
22 4.27 s  4.26 s  -0.01 4.24 s  -0.03 72.5 72.5 0.0 72.5 0.0 
23 N.A.   N.A.   -0.01 N.A.    177.0 177 0.0 177.0 0.0 
24 2.02-1.22 m  1.93 m  0.00 1.93 m  0.00 39.3 39.2 -0.1 39.2 -0.1 
Me24 0.96 d 6.7 0.95 d 6.8 -0.01 0.94 d 7.0 -0.02 13.1 13.1 0.0 13.1 0.0 
25a 2.02-1.22 m  1.57 m  0.00 1.57 m  0.00 28.0 28.7 0.7 28.7 0.7 
25b 1.00 m  0.96 m  -0.04 0.97 m  -0.03      
26a 2.02-1.22 m  1.50 m  0.00 1.54 m  0.00 40.8 35.9 -4.9 35.8 -5.0 
26b 2.02-1.22 m  1.44 m  0.00 1.47 m  0.00      
27 3.33 m  3.31 m  -0.02 3.32 m  -0.01 79.1 78.5 -0.6 78.5 -0.6 
OMe27 3.33 s  3.32 s  -0.01 3.31 s  -0.02 56.5 56.3 -0.2 56.2 -0.3 
28 2.02-1.22 m  1.12 d 6.0 0.00 1.13 d 6.1 0.00 40.8 19.3 -21.5 19.3 -21.5 
 
Table 12: NMR correlation table of 13,18-syn acid 22071 and 13,18-anti salt 221 against natural hemicalide 








In a 5 mm NMR tube, Na2CO3 (ca. 5 mg) was added to a solution of the free acid 221 in d4-
MeOD (500 μL). The mixture was vigorously shaken for ca. 30 seconds to afford the title 
compound as a solution in d4-MeOD. 
 
1H NMR (500 MHz, d4-MeOD): δH 7.02 (1H, dd, J = 15.3, 11.2 Hz, H3), 6.43 (1H, dd, J = 
14.8, 10.6 Hz, H5), 6.25 (1H, dd, J = 14.9, 10.6 Hz, H4), 6.16 (1H, dd, J = 15.2, 10.7 Hz, H6), 
5.91 (1H, d, J = 15.3 Hz, H2), 5.85 (1H, dd, J = 15.2, 8.6 Hz, H7), 5.96 (1H, s, H15), 5.15 
(1H, d, J = 9.8, H17), 4.42 (1H, ddd, J = 11.4, 7.3, 4.0 Hz, H19), 4.25 (1H, s, H22), 4.02 (1H, 
d, J = 6.6 Hz, H13), 3.61 (1H, dd, J = 9.5, 1.8 Hz, H11), 3.39 (3H, s, OMe9), 3.33 (1H, m, 
H27), 3.31 (3H, s, OMe27), 3.26 (1H, dd, J = 5.6, 4.8 Hz, H9), 2.80 (1H, m, H18), 2.53 (1H, 
m, H8), 2.00-1.91 (3H, m, H10, H20a, H24a), 1.83-1.77 (4H, m, H12, Me16), 1.73-1.64 (4H, 
m, Me14, H20b), 1.62-1.43 (3H, m, H25a, H26a, H26b), 1.13 (3H, d, J = 6.1 Hz, H28), 1.11 
(3H, d, J = 6.6 Hz, Me18), 1.07 (3H, d, J = 6.7 Hz, Me8), 0.96-0.89 (7H, m, Me12, Me24, 
H25b), 0.85 (3H, d, J = 7.0 Hz, Me10); 13C NMR (125 MHz, d4-MeOD): δC 177.0, 175.9, 
161.5 (CO32–), 142.0, 141.0, 138.7, 137.4, 135.3, 131.2, 131.2, 131.0, 131.0, 129.7, 88.7 
(minor 88.8), 82.8 (minor 82.8), 81.9, 78.5, 76.4 (minor 76.3), 76.2, 72.5, 59.8 (minor 59.8), 
56.2 (minor 56.3), 41.4, 40.1, 39.2, 39.2 (minor 39.1), 38.3, 35.9 (minor 36.1), 32.1, 28.7 
























1H NMR 13C NMR 
Natural Mult. J (Hz) 222 Mult. J (Hz) Δ 223 Mult. J (Hz) Δ Natural 222 Δ 223 Δ 
1 N.A.   N.A.    N.A.    174.1 175.9 1.8 175.9 1.8 
2 5.90 d 15.3 5.90 d 15.4 0.00 5.91 d 15.3 0.01 127.6 129.7 2.1 129.7 2.1 
3 7.10 dd 15,1, 11.1 7.02 dd 15.3, 11.3 -0.08 7.02 dd 15.3, 11.2 -0.08 142.7 142 -0.7 141 -1.7 
4 6.27 dd 15.0, 11.0 6.24 dd 15.1, 11.2 -0.03 6.25 dd 14.9, 10.6 -0.02 130.7 131 0.3 131 0.3 
5 6.45 dd 15.0, 10.7 6.41 dd 15.0, 10.8 -0.04 6.43 dd 14.8, 10.6 -0.02 139.8 138.6 -1.2 138.7 -1.1 
6 6.17 dd 15.3, 10.7 6.16 dd 15.2, 10.8 -0.01 6.16 dd 15.2, 10.7 -0.01 130.9 131.1 0.2 131 0.1 
7 5.87 dd 15.1, 8.7 5.83 dd 15.2, 8.8 -0.04 5.85 d 15.2, 8.6 -0.02 142.8 141 -1.8 142 -0.8 
8 2.53 m  2.53 m  -0.02 2.53 m  -0.02 41.5 41.5 0.0 41.4 -0.1 
Me8 1.07 d 6.7 1.07 d 6.7 0.00 1.07 d 6.7 0.00 17.2 17.2 0.0 16.8 -0.4 
9 3.27 dd 6.7, 4.6 3.27 dd 6.3, 4.6 0.00 3.26 dd 5.6, 4.8 -0.01 88.3 88.5 0.2 88.7 0.4 
OMe9 3.38 s  3.39 s  0.00 3.39 s  0.00 59.6 59.6 0.0 59.8 0.2 
10 2.02-1.22 m  1.98 m  0.00 1.98 m  0.00 40.1 40.1 0.0 40.1 0.0 
Me10 0.85 d 7.0 0.85 d 7.0 0.00 0.85 d 7.0 0.00 13.0 13.1 0.1 13.1 0.1 
11 3.57 dd 9.6, 2.0 3.59 dd 9.6, 2.2 0.02 3.61 dd 9.5, 1.8 0.04 75.5 75.7 0.2 76.2 0.7 
12 2.02-1.22 m  1.80 m  0.00 1.82 m  0.00 38.5 38.4 -0.1 38.3 -0.2 
Me12 0.93 d No J value 0.92 d 6.8 -0.01 0.91 d 6.9 -0.02 7.6 7.5 -0.1 7.3 -0.3 
13 3.99 d 7.3 4.00 d 7.3 0.01 4.02 d 6.6 0.03 82.1 82 -0.1 81.9 -0.2 
14 N.A.   N.A.    N.A.    137.4 137.4 0.0 137.4 0.0 
Me14 1.69 s  1.69 s  0.00 1.69 s  0.00 14.0 14 0.0 14.3 0.3 
15 5.95 S  5.95 s  0.00 5.96 s  0.01 131.7 131.6 -0.1 131.2 -0.5 




16 N.A.   N.A.    N.A.    135.4 135.5 0.1 135.3 -0.1 
Me16 1.82 s  1.82 s  0.00 1.8 s  -0.02 17.9 17.9 0.0 17.9 0.0 
17 5.16 d 9.8 5.15 d 9.9 -0.01 5.15 d 9.8 -0.01 131.6 131.5 -0.1 131.2 -0.4 
18 2.81 m  2.81 m  0.00 2.8 m  -0.01 39.3 39.2 -0.1 39.2 -0.1 
Me18 1.10 d 6.7 1.10 d 6.7 0.00 1.11 d 6.6 0.01 17.2 17.1 -0.1 17.1 -0.1 
19 4.42 ddd 11.3, 7.5, 3.5 4.42 ddd 
11.4, 7.6, 
3.9 0.00 4.42 ddd 
11.4, 7.3, 
4.0 0.00 82.8 83 0.2 82.8 0.0 
20a 2.02-1.22 m  1.97 m  0.00 1.95 m  0.00 32.2 32.1 -0.1 32.1 -0.1 
20b 2.02-1.22 m  1.68 m  0.00 1.67 m  0.00      
21 N.A.   N.A.    N.A.    76.4 76.4 0.0 76.4 0.0 
22 4.27 s  4.26 s  -0.01 4.25 s  -0.02 72.5 72.5 0.0 72.5 0.0 
23 N.A.   N.A.    N.A.    177.0 177 0.0 177 0.0 
24 2.02-1.22 m  1.94 m  0.00 1.94 m  0.00 39.3 39.2 -0.1 39.2 -0.1 
Me24 0.96 d 6.7 0.95 d 6.9 -0.01 0.94 d 6.9 -0.02 13.1 13.1 0.0 13.1 0.0 
25a 2.02-1.22 m  1.57 m  0.00 1.56 m  0.00 28.0 28.7 0.7 28.7 0.7 
25b 1.00 m  0.96 m  -0.04 0.97 m  -0.03      
26a 2.02-1.22 m  1.51 m  0.00 1.53 m  0.00 40.8 35.9 -4.9 35.9 -4.9 
26b 2.02-1.22 m  1.43 m  0.00 1.46 m  0.00      
27 3.33 m  3.32 m  -0.01 3.33 m  0.00 79.1 78.6 -0.5 78.5 -0.6 
OMe27 3.33 s  3.31 s  -0.02 3.31 s  -0.02 56.5 56.3 -0.2 56.2 -0.3 
28 2.02-1.22 m  1.13 d 6.2 0.00 1.13 d 6.1 0.00 40.8 19.3 -21.5 19.3 -21.5 
 
Table 13: NMR correlation table of 13,18-syn salt 22271 and 13,18-anti salt 223 against natural hemicalide





5.7 Experimental Procedures for the C27-C35 Fragment 
 
(±)-ethyl 3-hydroxy-4-methylpent-4-enoate (224) 
 
To a stirred solution of i-Pr2NH (14.6, 102.5 mmol) in THF (85 mL) at 0 ˚C was added n-
BuLi (72.3 mL, 86.7 mmol, 1.2 M in hexanes). The resulting pale yellow solution was stirred 
at 0 ˚C for 15 min then cooled to −78 ˚C. Ethyl acetate (10.0 mL, 102.5 mmol) was added 
dropwise. The reaction mixture was stirred at −78 ˚C for 1 h before adding methacrolein (6.5 
mL, 78.8 mmol) and stirring continued for another 2 h. The reaction was quenched after 1.5 h 
with NH4Cl (30 mL) and warmed to rt. The mixture was diluted with Et2O (30 mL) and the 
layers were separated. The aqueous layer was extracted with Et2O (3 x 50 mL) and the 
combined organic extracts were washed with brine (20 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography (10% 
Et2O/PE 30-40) to give ester 19 as a colourless oil (11.6 g, 73.3 mmol, 93%). 
 
Rf 0.40 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 5.03 (1H, s, H34a), 4.88 
(1H, s, H34b), 4.47 (1H, ddd, J = 8.3, 4.1, 4.1 Hz, H32), 4.18 (2H, q, J = 7.0 Hz, OCH2CH3), 
2.92 (1H, d, J = 4.0 Hz, OH), 2.59 (1H, dd, J = 16.2, 4.1 Hz, H31a), 2.54 (1H, dd, J = 16.1, 
8.5 Hz, H31b), 1.76 (3H, s, Me33), 1.28 (3H, t, J = 7.3 Hz, OCH2CH3); 13C NMR (125 MHz, 
CDCl3): δC 172.8, 145.6, 111.6, 71.7, 61.0, 40.2, 18.4, 14.3. 
 
Data in agreement with that presented by Yamashita.149 
 
(±)-ethyl 3-((tert-butyldimethylsilyl)oxy)-4-methylpent-4-enoate (225) 
 
Alcohol 224 (2.00 g, 12.6 mmol), Et3N (2.65 mL, 19.0 mmol) and DMAP (2.32 g, 19.0 
mmol) were dissolved in CH2Cl2 (120 mL) at rt and stirred until a clear homogenous solution 
was obtained, followed by the addition of TBSCl (2.29 g, 15.2 mmol). The reaction was 
stirred for 3 h and carefully quenched with NH4Cl (30 mL). The layers were separated and 
the aqueous layer extracted with CH2Cl2 (3 x 30 mL). The combined organic extracts were 















product was purified by flash column chromatography (5% Et2O/PE 30-40) to give the title 
compound as a colourless oil (3.02 g, 11.1 mmol, 88%). 
 
Rf 0.58 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 4.95 (1H, s, H34a), 4.79 
(1H, s, H34b), 4.55 (1H, dd, J = 8.9, 4.4 Hz, H32), 4.11 (2H, m, OCH2CH3), 2.53 (1H, dd, J 
= 14.3, 8.8 Hz, H31a), 2.41 (1H, dd, J = 14.1, 4.5 Hz, H31b), 1.71 (3H, s, Me33), 1.26 (1H, 
dd, J = 7.2, 7.2 Hz, OCH2CH3), 0.86 (9H, s, OSit-BuMe2), 0.04 (3H, s, OSit-BuMe2), 0.01 
(3H, s, OSit-BuMe2); 13C NMR (125 MHz, CDCl3): δC 171.6, 146.8, 111.7, 74.0, 60.5, 42.7, 
25.8, 18.2, 17.1, 14.3, –4.7, –5.2; HRMS (ES+) Calc. for C14H28O3SiH [M+H]+ 273.1886, 
found 273.1890. 
 




Ester 225 (1.80 g, 6.61 mmol) was dissolved in CH2Cl2 (33 mL) and cooled to –78 ˚C. 
DIBAL (7.28 mL, 1 M in hexanes, 7.28 mmol) was added dropwise at this temperature and 
stirring continued for 1 h. Upon complete reaction, the reaction was quenched with MeOH 
(10 mL) and warmed to rt. Rochelle’s salt (30 mL) was added while stirring vigorously for 2 
h. The layers were separated and the aqueous layer extracted with CH2Cl2 (3 x 20 mL). The 
combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography (5% Et2O/PE 30-40) to give the title 
compound as a colourless oil (1.40 g, 6.13 mmol, 93%). 
 
Rf 0.57 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 9.76 (1H, dd, J = 2.9, 2.3 
Hz, H30), 5.00 (1H, s, H34a), 4.85 (1H, s, H34b), 4.57 (1H, dd, J = 7.8, 4.3 Hz, H32), 2.64 
(1H, ddd, J = 15.5, 7.8, 3.0 Hz, H31a), 2.46 (1H, ddd, J = 15.5, 4.4, 2.2 Hz, H31b), 1.71 (3H, 
s, Me33), 0.87 (9H, s, OSit-BuMe2), 0.06 (3H, s, OSit-BuMe2), 0.03 (3H, s, OSit-BuMe2); 
13C NMR (125 MHz, CDCl3): δC 202.0, 146.3, 111.8, 72.3, 49.9, 25.8, 18.2, 17.6,–4.6, –5.1. 
 















A flame-dried flask was charged with Et2O (90 mL) and Et3N (13.5 mL, 97.2 mmol) then 
cooled to 0 ˚C. TMSOTf (16.0 mL, 88.3) was added dropwise over 10 min and stirring 
continued for 30 min, during which time a red-brown oily precipitate formed. The red-brown 
phase was discarded and the remaining ethereal phase washed with NaHCO3 (40 mL). The 
aqueous phase was extracted with Et2O (2 x 20 mL) and the combined ethereal extracts dried 
(Na2SO4), filtered, and concentrated in vacuo to ca. 20 mL. The crude product was 
fractionally distilled through a 150 mm Vigreux column to afford the silyl enol ether as a 
colourless oil (9.78 g, 75.0 mmol, 85%). 
 
Aldehyde 226 (1.40 g, 6.13 mmol) and silyl enol ether (2.79 mL, 18.4 mmol) were dissolved 
in CH2Cl2 (61 mL) and cooled to –78 ˚C. BF3•Et2O (1.13 mL, 9.19 mmol) was added 
dropwise and the reaction stirred for 20 min before quenching with NaHCO3 (30 mL). The 
layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 20 mL). The 
combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (10% Et2O/PE 30-40) to give 
the title compound as a colourless oil (1.37 g, 4.78 mmol, 78%, d.r. 5:1). 
 
Major isomer: Rf 0.30 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 5.00 (1H, m, 
H34a), 4.85 (1H, m, H34b), 4.34 (1H, m, H32), 4.24 (1H, m, H30), 3.45 (1H, d, J = 2.4 Hz, 
OH), 2.60 (1H, dd, J = 17.0, 8.0 Hz, H29a), 2.54 (1H, dd, J = 16.9, 4.4 Hz, H29b), 2.17 (3H, 
s, H27), 1.69 (3H, s, Me33), 1.61 (2H, m, H31), 0.90 (6H, s, OSit-BuMe2), 0.083 (3H, s, 
OSit-BuMe2), 0.032 (3H, s, OSit-BuMe2); 13C NMR (125 MHz, CDCl3): δC 209.2, 146.8, 
111.1, 74.0, 64.7, 50.8, 41.8, 30.9, 26.0, 25.9, 18.4, –4.7, –5.2; FT-IR (Thin film): νmax 3524 
(br), 2956, 2929, 2858, 1712, 1472, 1361, 1251, 1163, 1079, 1004, 961, 898, 836, 776, 667; 



















MeOH (535 μL, 13.2 mmol) was added to LiBH4 (3.00 mL, 4M in THF, 12.0) in THF (9 mL) 
at 0 ˚C and stirred at rt for 1.5 h. The resulting solution of LiBH3OMe (ca. 1 M in THF) was 
used immediately. 
 
A flame-dried flask was charged with Cy2BCl (386 μL, 2.20 mmol), Et3N (408 μL, 2.93 
mmol) in THF (10 mL) at 0 °C. A solution of ketone 227 (210 mg, 0.733 mmol) in THF (1 
mL) was added via cannula (2 x 1 mL wash) and the reaction mixture stirred for 30 min 
before cooling to –78 ˚C. LiBH3OMe (5.86 mL, 1 M in THF, 5.86 mmol) was added and 
stirring continued at –78 ˚C for 1 h and allowed to warm slowly to 0 ˚C over 4 h. The 
reaction was quenched with pH 7 buffer (3 mL), MeOH (3 mL) and H2O2 (30% aq. 1 mL) 
and stirred at rt for 1 h. The reaction was partitioned between H2O (5 mL) and Et2O (10 mL) 
and the layers were separated. The aqueous layer was extracted with Et2O (3 x 10 mL) and 
the combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (10% EtOAc/PE 40-60) to give 
the title compound as a colourless oil (173 mg, 0.601 mmol, 82%, d.r. 5:1). 
 
Major isomer: Rf 0.18 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 5.05 (1H, s, 
H34a), 4.91 (1H, s, H34b), 4.35 (1H, dd, J = 4.6, 4.6, Hz, H32), 4.10-4.00 (2H, m, H30, H28), 
1.70-1.65 (2H, m, H31), 1.67 (3H, s, Me33), 1.57-1.52 (1H, m, H29a), 1.42 (1H, ddd, J = 
14.1, 2.4, 2.4, Hz, H29b), 1.16 (3H, d, J = 6.4 Hz, H27), 0.90 (9H, s, OSit-BuMe2), 0.09 (3H, 
s, OSit-BuMe2), 0.04 (3H, s, OSit-BuMe2); 13C NMR (125 MHz, CDCl3): δC 145.9, 111.5, 
75.0, 70.0, 68.6, 45.4, 41.6, 25.9, 23.9, 19.0, 18.3, –4.8, –5.3; FT-IR (Thin film): νmax 3348 
(br), 2930, 2857, 1452, 1407, 1320, 1251, 1137, 1071, 1004, 965, 897, 836, 776; HRMS 




















To a solution of diol 237 (10 mg, 34.7 μmol) in 2,2-dimethoxypropane (500 μL) was added 
PPTS (1 crystal) at rt. The reaction mixture was stirred for 16 h and then concentrated in 
vacuo. The residue was purified by flash column chromatography flash column 
chromatography (5% Et2O/PE 30-40) to give the title compound as a colourless oil (10.8 mg, 
33.0 μmol, 95%, d.r. 5:1). 
 
Major isomer: Rf 0.67 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 4.88 (1H, s, 
H34a), 4.73 (1H, s, H34b), 4.25 (1H, dd, J = 9.3, 3.3 Hz, H32), 4.01-3.94 (2H, m, H30, H28), 
1.67 (3H, s, Me33), 1.58-1.48 (2H, m, H31), 1,48-1.6 (1H, m, H29a), 1.44 (3H, s Me), 1.39 
(3H, s, Me), 1.15 (3H, d, J = 6.1 Hz, H27), 1.13-1.07 (1H, m, H29b), 0.89 (9H, s, OSit-
BuMe2), 0.04 (3H, s, OSit-BuMe2), 0.00 (3H, s, OSit-BuMe2); 13C NMR (125 MHz, CDCl3): 




NaH (528 mg, 60 wt% suspension in mineral oil, 13.2 mmol) was suspended in THF (10 mL) 
cooled to 0 °C. A solution of diol 236 (380 mg, 1.32 mmol) in THF (1 mL) was added via 
cannula (2 x 1 mL wash) and the reaction mixture stirred for 30 min before adding MeI (820 
μL, 13.2 mmol). The reaction was stirred at rt for 1 h before quenching with NH4Cl (10 mL). 
The mixture was diluted with Et2O (10 mL) and the layers were separated. The aqueous layer 
was extracted with Et2O (3 x 5 mL) and the combined organic extracts were dried (MgSO4), 
filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (5% Et2O/PE 30-40) to give the title compound as a colourless oil (389 mg, 
1.23 mmol, 93%, d.r. 5:1). 
 
Major isomer: Rf 0.72 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 4.89 (1H, m, 
H34a), 4.75 (1H, m, H34b), 4.21 (1H, dd, J = 6.3, 6.3, Hz, H32), 3.45 (1H, m, H30), 3.40 
(1H, m, H28), 3.33 (3H, s, OMe), 3.31 (3H, s, OMe), 1.69 (3H, s, Me33), 1.59 (4H, m, H31a, 















OSit-BuMe2), 0.00 (3H, s, OSit-BuMe2); 13C NMR (125 MHz, CDCl3): δC 148.2, 111.0, 75.0, 
74.1, 73.6, 56.4, 56.1, 42.3, 41.7, 26.0, 19.6, 18.3, 17.1, –4.4, –5.0; FT-IR (Thin film): νmax 
2960, 2930, 1470, 1375, 1251, 1085, 897, 835, 775; HRMS (ES+) Calc. for C17H36O3SiH 




A solution of EtCHO (457 μL, 6.28 mmol) in THF (7 mL) was cooled to 0 ˚C and SmI2 (1.05 
mL, 0.1 M in THF, 0.105 mmol) was added dropwise. The reaction mixture was stirred for 
10 min before cooling to –20 ˚C, A solution of ketone 227 (300 mg, 1.05 mmol) in THF (1 
mL) was added via cannula (2 x 1 mL wash) at this temperature and stirring was continued 
for 2 h. The reaction was quenched with NaHCO3 (4 mL) and the layers were separated. The 
aqueous layer was extracted with Et2O (3 x 5 mL) and the combined organic extracts were 
dried (Na2SO4), filtered and concentrated in vacuo. 
 
The crude product was suspended in MeOH (7 mL) and K2CO3 (290 mg, 2.10 mmol) was 
added. The reaction mixture was stirred for 5 h and quenched with NH4Cl (2 mL). The 
solution was extracted with CH2Cl2 (4 x 5 mL) and the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography flash column chromatography (10% EtOAc/PE 40-60) to give the 
title compound as a colourless oil (270 mg, 0.935 mmol, 89% over two steps, d.r. 5:1). 
 
Major isomer: Rf 0.18 (20% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 5.07 (1H, s, 
H34a), 4.92 (1H, s, H34b), 4.37 (1H, dd, J = 4.4, 4.4 Hz, H32), 4.18 (1H, m, H30), 4.12 (1H, 
m, H28), 3.74 (1H, s, OH), 2.95 (1H, s, OH), 1.81 (1H, ddd, J = 14.4, 10.1, 4.4 Hz, H31a), 
1.64 (1H, ddd, J = 14.4, 4.8, 2.0 Hz, H31b), 1.67 (3H, s, Me33), 1.65 (1H, ddd, J = 14.4, 4.7, 
1.9 HX), 1.56 (2H, ddd, J = 7.0, 4.3, 2.6 Hz, H29); 13C NMR (125 MHz, CDCl3): δC 145.8, 
111.5, 75.1, 66.6, 65.3, 44.6, 40.6, 25.9, 23.6, 19.2, 18.3, –4.8, –5.3; FT-IR (Thin film): νmax 
3351 (br), 2953, 2930, 2859, 1463, 1374, 1252, 1072, 1004, 967, 938, 836, 776, 668; HRMS 
















To a solution of diol 240 (10 mg, 34.7 μmol) in 2,2-dimethoxypropane (500 μL) was added 
PPTS (1 crystal) at rt. The reaction mixture was stirred for 16 h and then concentrated in 
vacuo. The residue was purified by flash column chromatography flash column 
chromatography (5% Et2O/PE 30-40) to give the title compound as a colourless oil (10.9 mg, 
33.3 μmol, 96%, d.r. 5:1). 
 
Major isomer: Rf 0.67 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 4.88 (1H, s, 
H34a), 4.74 (1H, s, H34b), 4.20 (1H, dd, J = 6.3, 6.3 Hz, H32), 4.00-3.88 (2H, m, H30, H28), 
1.68 (3H, s, Me33), 1.62 (2H, dd, J = 6.3, 6.3 Hz, H31), 1.60-1.55 (2H, m, H29), 1.36 (3H, s, 
Me), 1.35 (3H, s, Me), 1.18 (3H, d, J = 6.3 Hz, H27), 0.88 (9H, s, OSit-BuMe2), 0.05 (3H, s, 
OSit-BuMe2), 0.00 (3H, s, OSit-BuMe2); 13C NMR (125 MHz, CDCl3): δC 148.3, 111.1, 




NaH (332 mg, 60 wt% suspension in mineral oil, 8.32 mmol) was suspended in THF (2 mL) 
cooled to 0 °C. A solution of diol 238 (120 mg, 0.416 mmol) in THF (1 mL) was added via 
cannula (2 x 0.5 mL wash) and the reaction mixture stirred for 30 min before adding MeI 
(518 μL, 8.32 mmol). The reaction was stirred at rt for 1 h before quenching with NH4Cl (2 
mL). The mixture was diluted with Et2O (2 mL) and the layers were separated. The aqueous 
layer was extracted with Et2O (3 x 1 mL) and the combined organic extracts were dried 
(MgSO4), filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (5% Et2O/PE 30-40) to give the title compound as a colourless oil (118 mg, 
0.374 mmol, 90%, d.r. 5:1). 
 
Major isomer: Rf 0.72 (10% EtOAc/PE 40-60); 1H NMR (500 MHz, CDCl3): δH 4.90 (1H, m, 
H34a), 4.74 (1H, m, H34b), 4.23 (1H, dd, J = 8.8, 3.7 Hz, H32), 3.47 (1H, m, H30), 3.36 (1H, 
m, H28), 3.31 (3H, s, OMe), 3.30 (3H, s, OMe), 1.89 (1H, ddd, J = 14.0, 7.4, 5.3 Hz, H29a), 















(1H, ddd, J = 14.1, 7.0, 5.4 Hz, H29b), 1.15 (3H, d, J = 6.1 Hz, H27), 0.89 (9H, s, OSit-
BuMe2), 0.06 (3H, s, OSit-BuMe2), 0.00 (3H, s, OSit-BuMe2); 13C NMR (125 MHz, CDCl3): 
δC 148.4, 110.8, 74.8, 74.1, 73.4, 56.2, 55.8, 42.1, 40.6, 26.0, 19.5, 18.3, 17.2, –4.4, –5.0; FT-
IR (Thin film): νmax 2974, 2928, 1452, 1381, 1251, 1066, 897, 836, 775, 667; HRMS (ES+) 
Calc. for C17H36O3SiH [M+H]+ 317.2512, found 317.2510. 
 
  





CHAPTER SIX: SELECTED SPECTRA 
 
methyl (2E,4E,6E,8S,9R,10R,11R,12S,13R,14E)-15-iodo-9-methoxy-8,10,12,14-tetramethyl-
11,13-bis((triethylsilyl)oxy)pentadeca-2,4,6,14-tetraenoate (101) .............................. 1H, 13C 
Methyl (2E,4E,6E,8S,9R,10S,11S,12S,13R,14E)-11,13-dihydroxy-15-iodo-9-methoxy-
8,10,12,14-tetramethylpentadeca-2,4,6,14-tetraenoate (195) ...................................... 1H, 13C 
methyl (2E,4E,6E,8S,9R,10R,11R,12S,13R,14E)-9-methoxy-8,10,12,14-tetramethyl-11,13-
bis((triethylsilyl)oxy)-15-(trimethylstannyl)pentadeca-2,4,6,14-tetraenoate (211) ..... 1H, 13C 
(3S,4R,6R)-3,4-dihydroxy-6-((R,E)-4-iodopent-3-en-2-yl)-4-((S)-1-((4-
methoxybenzyl)oxy)propan-2-yl)tetrahydro-2H-pyran-2-one (174) ............. 1H, 13C, NOESY 
(3S,4R,6R)-6-((R,E)-4-iodopent-3-en-2-yl)-4-((S)-5-oxohexan-2-yl)-3,4-
bis((triethylsilyl)oxy)tetrahydro-2H-pyran-2-one (102) .............................................. 1H, 13C 
(3S,4R,6R)-6-((2R,3E,5E,7S,8R,9S,10S,11S,12R)-13-hydroxy-11-methoxy-4,6,8,10,12-
pentamethyl-7,9-bis((triethylsilyl)oxy)trideca-3,5-dien-2-yl)-4-((S)-5-oxohexan-2-yl)-3,4-
bis((triethylsilyl)oxy)tetrahydro-2H-pyran-2-one (207) .............................................. 1H, 13C 
(3S,4R,6R)-6-((2R,3E,5E,7R,8S,9R,10R,11R,12S)-13-hydroxy-11-methoxy-4,6,8,10,12-
pentamethyl-7,9-bis((triethylsilyl)oxy)trideca-3,5-dien-2-yl)-4-((S)-5-oxohexan-2-yl)-3,4-
















(215) ............................................................................................................................. 1H, 13C 






8,10,12,14,16-pentamethylnonadeca-2,4,6,14,16-pentaenoate (219) .......................... 1H, 13C 
(2E,4E,6E,8R,9S,10R,11R,12R,13S,14E,16E,18S)-18-((2S,4S,5R)-4,5-dihydroxy-4-((2R)-5-
methoxyhexan-2-yl)-6-oxotetrahydro-2H-pyran-2-yl)-11,13-dihydroxy-9-methoxy-
8,10,12,14,16-pentamethylnonadeca-2,4,6,14,16-pentaenoic acid (221) .................... 1H, 13C 
sodium (2E,4E,6E,8R,9S,10R,11R,12R,13S,14E,16E,18S)-18-((2S,4S,5R)-4,5-dihydroxy-4-
((2R)-5-methoxyhexan-2-yl)-6-oxotetrahydro-2H-pyran-2-yl)-11,13-dihydroxy-9-methoxy-
8,10,12,14,16-pentamethylnonadeca-2,4,6,14,16-pentaenoate (223) .......................... 1H, 13C 
(±)-(4S,6S)-6-((tert-butyldimethylsilyl)oxy)-4-hydroxy-7-methyloct-7-en-2-one (227) 
...................................................................................................................................... 1H, 13C 
(±)-(2R,4R,6S)-6-((tert-butyldimethylsilyl)oxy)-7-methyloct-7-ene-2,4-diol (236) ... 1H, 13C 
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